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Delirium is a severe neuropsychiatric syndrome, characterised by the acute onset of 
inattention, altered level of arousal, and other mental status abnormalities. Delirium is 
extremely common in acute stroke, affecting at least 1 in 5 such patients admitted to hospital. 
It is a serious complication of stroke, being associated with higher mortality, longer length of 
hospital stay and higher dependency at discharge. The pathophysiology of delirium is not 
completely understood, and there are no specific treatments. This thesis investigated the role 
of cortisol in the development of delirium after stroke and also investigated the role of 
delirium and of cortisol in the development of cognitive impairment in the 12 months after 
stroke. The thesis specifically investigated whether levels of cortisol in saliva are elevated in 
delirium and also whether there is a loss of the normal diurnal rhythm in delirium, evidenced 
by elevated afternoon salivary cortisol levels and reduced morning level to afternoon level 
ratio. The thesis also investigated whether cortisol levels are persistently elevated in the year 
after stroke in those who developed delirium and whether cortisol levels are associated with 
cognitive decline. Finally it investigated whether acute and/or chronic changes seen on 
Computed Tomography (CT) brain scans taken around the time of stroke onset are associated 
with the development of delirium after stroke 
 
A longitudinal cohort study was conducted in 95 participants aged 60 years or over, who 
were admitted to hospital with a clinically confirmed stroke. Participants gave informed 
consent, or proxy consent was obtained if they lacked capacity to consent. At baseline 
participants underwent brief cognitive testing and were then assessed for the presence of 
delirium, using DSM IV criteria, at regular intervals during the first two weeks after stroke. 
At each assessment a saliva sample was collected in the morning and in the afternoon, to 
measure cortisol. Participants were then visited at 1 month, 4 months and 12 months after 
stroke onset, at which point they were assessed for the presence of delirium, further saliva 
samples were taken and a cognitive test battery was completed.   
 
26 (27%) participants developed delirium during the course of the study period.  The study 
found elevated salivary cortisol levels in those with delirium at up to 4 months after stroke, 
but at 12 months there was no difference between the delirium and no delirium group. A loss 
of the diurnal rhythm was seen in those who developed delirium at 5 days after stroke, but the 
diurnal variation had returned to a normal pattern at follow-up. However, in a multivariate 
analysis, controlling for age, sex, stroke severity (NIHSS), current illness burden (APACHE 
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II), chronic illness burden (CCI) and prior cognitive impairment (IQCODE), neither median 
salivary cortisol levels in the first two weeks after stroke, nor the ratio of morning to 
afternoon cortisol levels were independent predictors of delirium diagnosis, although median 
9am cortisol approached significance (OR=0.95, 95% confidence interval (CI) 0.89-1.01, 
p=0.08). In a random effects logistic regression analysis, the probability of developing 
delirium decreased over time from stroke onset and increased per unit increase in salivary 
cortisol (nmol/L), however this effect was not statistically significant (OR 1.02, CI 0.84-1.19 
P=0.70 for morning cortisol and OR 1.05, CI 0.82-1.25 p=0.46 for afternoon cortisol). Global 
cognition, measured by the MoCA, was significantly poorer in the delirium group at each 
time point throughout the 12 months after stroke. However, there was a trend towards 
improvement in MoCA scores in the whole cohort throughout the 12 month follow-up, with 
the exception of those who developed the most severe delirium. The presence of delirium at 
any point during the 12 month follow-up did not affect the rate of change of the MoCA 
scores over the 12 months after stroke. The presence of brain atrophy identified on admission 
CT brain scans was independently associated with delirium (OR 3.7, CI 1.15-11.88, p=0.02), 
however the presence of a visible acute or chronic stroke lesion and the presence of white 
matter lesions were not. Finally, those who developed delirium had a worse functional 
outcome, longer length of hospital stay and were more likely to require institutional care or a 
package of care at home, compared with those who did not develop delirium. 
This thesis has contributed to our understanding of the mechanisms and phenomenology of 
delirium after stroke, and has also highlighted areas for further research which will be 













Delirium, or “acute confusional state” is common after stroke and has serious adverse 
consequences including longer length of stay in hospital, a higher risk of being discharged to 
an institution (rather than home) and a higher risk of death. The underlying mechanisms 
which cause delirium are not well understood and consequently there are currently no 
specific treatments available. The studies presented in this thesis investigated whether the 
stress hormone cortisol is found in higher levels in those with delirium after a stroke, when 
compared to those without delirium after stroke. The studies also investigated the duration of 
delirium, by following participants up over the course of a year, and investigated whether 
cortisol levels remained high over that year in those who had delirium. The studies also 
investigated the relationship between cognitive function and delirium over the course of a 
year, and whether higher cortisol levels were found in those with poorer cognitive function. 
Finally, the relationship between brain changes, (such as reduction in brain volume, termed 
“brain atrophy”) seen on a brain scan taken at the time of admission (a Computed 
Tomography, or CT scan) and their relationship to who went on to develop delirium was 
investigated.  
 
A study, involving 95 participants aged over 60 who had been admitted to hospital following 
a stroke, was conducted. Participants, or if they were not capable, their next of kin, gave 
informed consent to take part in the study. Brain CT scans, taken at the time of admission as 
part of clinical care, were assessed for changes, including reduction in brain volume, blood, 
areas of stroke damage and changes to the white matter of the brain. Participants were 
assessed on alternate days in the week after their stroke and at regular intervals thereafter, to 
see if they had developed delirium. Of the 95 participants, 26 (27%) developed delirium at 
some point during the study. A small sample of saliva was collected in the morning and 
afternoon on each assessment day, and levels of cortisol in the saliva were subsequently 
measured. Participants underwent brief testing of their memory and thinking at the time of 
recruitment, and an informant completed a questionnaire about the participant’s memory in 
the period prior to their stroke.  Participants were visited at 1 month, 4 months and 12 months 
after their stroke and were tested for delirium, underwent more detailed memory testing and 




The study found that those who developed delirium did have slightly higher levels of cortisol 
than those without delirium, but once factors such as age and how severe the stroke was were 
accounted for, there was no difference in cortisol levels between the two groups. Those who 
had delirium were more likely to have cognitive impairment at follow-up, but taking the 
cohort as a whole, there was an improvement in cognitive function between the time of 
recruitment to the study and the 1 year follow-up, which is probably due to recovery from 
delirium and recovery from the acute effects of the stroke. Those who developed delirium 
were more likely to have volume loss of their brain, detected by CT scanning, but there were 
no differences between those with and without delirium when the other brain changes 
previously described were looked at. The studies have improved our understanding of the 
possible underlying mechanisms of delirium after stroke, and have improved our 
understanding of the natural history and characteristics of delirium after stroke. Finally, 
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Chapter 1: General Introduction 
  
1.1 Stroke 
In this section stroke will be defined and its epidemiology and pathophysiology will be 
described. The diagnosis of stroke and subsequent classification of stroke types and stroke 
severity will also be discussed.  
 
1.1.1 Stroke definition 
 
A stroke is defined as rapidly developing clinical signs of focal (at times global) disturbance 
of cerebral function, lasting more than 24 hours or leading to death with no apparent cause 
other than that of vascular origin (Hatano, 1976). 
  
1.1.2 Stroke epidemiology 
Approximately 152 000 strokes occur in the United Kingdom (UK) annually, and the 
incidence of stroke is between 115-150 per 100 000 of the population (The Stroke 
Association, 2015). Over the last 15 years both the incidence of stroke and the overall 
mortality from stroke has fallen consistently, which has been attributed to better control of 
risk factors both before and after incident stroke, and also improved treatments for acute 
stroke (e.g. thrombolysis) (Lee et al., 2011b).  Age is the most important risk factor, with the 
risk doubling with every decade after the age of 55, and 1 in 5 women and 1 in 6 men having 
had a stroke by the age of 75 (The Stroke Association, 2015). Other major risk factors include 
social deprivation, race (those of black and South Asian origin having a higher risk than 
white Europeans), hypertension, smoking cigarettes, hypercholesterolaemia, diabetes and 
atrial fibrillation. There are currently 1.2 million stroke survivors living in the UK, many of 
whom have been left with significant physical disabilities, fatigue and cognitive impairment 
(The Stroke Association, 2015). Minimising cognitive changes after stroke has recently been 
identified as the top priority for stroke survivors, their carers and clinicians (Pollock et al., 
2014). Finally, stroke confers significant mortality, with 1 in 8 strokes being fatal within the 





1.1.3 Stroke pathophysiology  
The main pathological stroke types are ischaemic, primary intracerebral haemorrhage and 
subarachnoid haemorrhage, with ischaemic strokes accounting for 80% of all strokes in the 
UK (The Stroke Association, 2015). Ischaemic stroke may be divided into subtypes base on 
pathophysiology, using the TOAST classification system (Adams et al., 1993). This includes 
five categories: 1. Large-artery atherosclerosis, 2. Cardioembolism. 3. Small-vessel occlusion 
4. Stroke of other determined aetiology (for example vasculopathies or haematological 
conditions) and 5. Stroke of undetermined aetiology. The net result of an ischaemic stroke, 
regardless of the aetiology, is ischaemia, and if reperfusion does not occur, infarction of brain 
tissue in the affected territories. 
 Haemorrhagic strokes are caused by blood vessel rupture, which leads to compression of 
brain tissue from the expanding haematoma. Haemorrhage usually occurs as a result of 
hypertensive vascular disease, arteriovenous malformation rupture or aneurysm rupture, 
although there are several other causes such as cerebral amyloid angiopathy, vascular 
tumours and infection (Weatherall, 1996). Cerebral amyloid angiopathy (CAA) is a frequent 
pathological finding in the elderly human brain, and is an accumulation of beta-amyloid in 
the walls of cortical blood vessels (Reijmer, 2015). Whilst CAA is generally thought to be a 
cause of haemorrhagic stroke, it is also known to be a risk factor for vascular cognitive 
impairment (Greenberg et al., 2004).  
 
1.1.4 Stroke diagnosis 
The diagnosis of stroke is a clinical one, relying on the history of an acute neurological event, 
along with clinical signs of neurological deficit, and with no apparent cause other than a 
vascular event. Neuroimaging (usually Computed Tomography, CT) is essential in 
distinguishing ischaemic from haemorrhagic stroke, and for excluding other underlying 
pathology which may mimic a stroke, such as a brain tumour. However, it is important to 
note that signs of ischaemia are often absent from a CT brain scan in the acute setting, 
particularly when scans are performed very early after symptom onset, but this does not 
preclude the diagnosis of stroke (providing no other pathology which may mimic a stroke is 
seen on neuroimaging) in the context of a salient history and examination. Neuroimaging in 
acute stroke will be discussed in more detail in section 1.5. 
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It is useful to categorize (or classify) the type of stroke a patient has had in clinical practice, 
and also for clinical research, in order that epidemiological studies can be performed to gain 
information about specific types of stroke, such as prognosis, and also in order that new 
treatments can be targeted and tested on patients who have had specific types of stroke.   
 
 
1.1.5 Stroke classification  
 
One conventional  system for classifying stroke type used in clinical practice in the UK is the 
Oxford Community Stroke Project (OCSP) classification system (Bamford et al., 1991). This 
classification system was developed to create subgroups with patterns of characteristics 
which would be useful in both clinical practice and also in clinical research, but which do not 
require a detailed assessment of the pathophysiological mechanism underlying the particular 
stroke in order to allow classification. The OCSP classification system was chosen for this 
study, as it is widely used on stroke units in Scotland and also has been widely used in 
clinical research into delirium after stroke, thus allowing comparison between this study and 
those preceding it. The four subgroups are outlined in Table 1.1 in a simplified form. These 
subgroups broadly correspond to anatomical territories in terms of affected vasculature, 
however it is important to remember that the classification is based purely on clinical 
findings, and this does not always exactly match neuroimaging findings. In general, a Total 
Anterior Circulation Stroke (TACS) is a stroke affecting the territories supplied by the deep 
and superficial territories of the Middle Cerebral Artery (MCA), a Partial Anterior 
Circulation Stroke (PACS) affects the territories supplied by either the upper or the lower 
division of the MCA as well as individual branch occlusions and a Lacunar Stroke (LACS) 
usually relates to a lacune in the pons or basal ganglia. Posterior Circulation Strokes (POCS) 
are more difficult to categorise in terms of vasculature because of variable vascular anatomy 
and extensive collateral channels, consequently posterior strokes refer to those affecting the 
brainstem, cerebellum or occipital lobes (Bamford et al., 1991).  
This classification allows predictions to be made about prognosis following stroke. A TACS 
has the poorest prognosis, with 60% dead at 1 year, 36% dependant and 4% independent. The 





Table 1.1 Clinical features and prognosis for stroke by OCSP classification type  
Stroke Subtype 
 
Clinical Features Prognosis at 1 year (%) 
Total Anterior Circulation 
Stroke (TACS) 
New higher cerebral 
dysfunction* and 
Homonymous hemianopia and 





Partial Anterior Circulation 
Stroke (PACS) 
Higher cerebral dysfunction 
alone or 
2 out of 3 of features of TACS 
or 





Lacunar Stroke (LACS) Pure motor stroke or 
Pure sensory stroke or 





Posterior (POCS) Ipsilateral cranial nerve palsy 
with contralateral motor 
and/or sensory deficit 
Bilateral motor and/or sensory 
deficit 



















1.1.6 Stroke severity  
There are several scales used to measure stroke severity, both for research and clinical 
purposes. Examples include the Scandinavian Stroke Scale (SSS) (Scandinavian Stroke Study 
Group, 1985), the National Institutes of Health Stroke Scale (NIHSS) (Brott et al., 1989) and 
the Canadian Neurological Scale (Cote et al., 1986). The NIHSS was chosen for this study as 
it is already routinely used in clinical practice on the Acute Stroke Unit in Edinburgh, it has 
been used in many previous stroke studies, and is relatively simple to score (with brief 
training). It is known to correlate with infarct size and long-term prognosis and predict 
discharge disposition (Siegler and Martin-Schild, 2015). The maximum score on this scale is 
42 (with a higher score indicating a more severe stroke). A score of 1-4 is conventionally 
accepted to represent a minor stroke, 5-15 a moderate stroke, 16-20 a moderate to severe 
stroke and 21-42 a severe stroke (Brott et al., 1989). There are, however, some limitations to 
this method of rating stroke severity. For example a posterior circulation stroke resulting in 
significant vertigo may be rated as a minor stroke using this scale, and yet have a very 
significant effect on functional status and quality of life.     
 
1.1.7 Summary 
In summary, stroke is common and is associated with several adverse outcomes including 
significant physical disability, fatigue and cognitive impairment. Stroke has several 
pathophysiological sub-types, some of which may co-exist and diagnosis of a stroke is made 
based on clinical findings, although neuroimaging may help to confirm the diagnosis and 
distinguish haemorrhagic from ischaemic stroke. Finally stroke may be classified according 
to the clinical features found, using the OCSP system and also according to the severity as 
rated by a validated scale, such as the NIHSS. Both the OCSP classification and NIHSS score 








In this section delirium will be defined and its core feature of inattention will be explored. 
The epidemiology and pathophysiology of delirium will then be described, and the diagnosis 
of delirium will then be discussed. Finally, delirium in the context of acute stroke will be 
discussed.  
1.2.1 Delirium definition 
Delirium, previously often commonly referred to as an “acute confusional state,” is an acute 
and severe neuropsychiatric condition, characterised by its core feature of inattention. 
Inattention refers to disturbed consciousness and a reduced ability to focus, shift or sustain 
attention (American Psychiatric Association, 2000). Other cognitive features are also 
commonly seen including altered alertness, mood disturbance, disturbed sleep-wake cycle, 
and psychotic features such as delusions and hallucinations (Inouye et al., 2014).  
 
1.2.2 Attention 
As inattention is the core feature of delirium, I will discuss attention in general terms here. 
Attention is a complex part of cognition. During wakefulness, we are constantly encountering 
a multitude of external stimuli from the environment via all of our sensory organs, as well as 
being attentive to internal stimuli in the form of constant thoughts, ideas and memories. 
Despite these stimuli, we are able to perform a number of goal driven tasks, such as driving a 
car or solving complex problems, meaning that attentional processes allow us to focus on 
specific stimuli whilst holding other stimuli at bay, at least temporarily. Attention has been 
classified in various ways in the literature. Hodges (Hodges, 2007) provides a useful 4 
component classification system outlined below: 
1. Arousal. Describes the general state of wakefulness and responsivity. 
2. Sustained attention. The capacity to maintain attentional activity over prolonged 
periods of time. 
3. Divided attention. The ability to respond to more than one task at once 
4. Selective attention. The ability to highlight or focus on one stimulus whilst 






The maintenance of attention depends on the interaction of two neural systems: 
1. The ascending reticular activating system (ARAS) 
2. Cortical regulation, involving limbic, parietal and prefrontal cortical regions. 
 
The ARAS is said to provide ‘bottom up’ modulation of cortical regions and the cortex is said 
to provide ‘top down’ regulation via the thalamus (Hodges, 2007). In addition to these two 
systems of regulation, there are local processes, which operate in specialized domain specific 
regions, and modulate responsivity to sounds, tactile stimuli, faces, motion, words and 
memories.  
Functional imaging studies have provided useful information as to the specific areas of the 
cortex involved in attention. For example, the parietal cortex has been found to be active 
during tasks requiring sustained and selected attention, and the prefrontal cortex is active in 
tasks requiring divided attention. Disorders of attention can, therefore, arise from a wide 
range of pathological processes involving any of the structures and pathways previously 
described. This may be in the form of structural damage, or be due to pharmacological agents 
or metabolic disorders (Hodges, 2007).  
 
1.2.3 Delirium epidemiology 
Delirium affects approximately 12 % of all hospitalised patients (MacLullich, 2013), and 
around 25% of those hospitalised following an acute stroke (Shi et al., 2012). In surgical units 
delirium is even more common, with an incidence of more than 40% reported after hip 
fracture (Freter et al., 2015) and around 28% after cardiac surgery (although rates varied 
widely depending on the type of surgery participants underwent) (Tse et al., 2015). Delirium 
is also commonly seen in Intensive Care Unit (ICU) patients, with an incidence of up to 80% 
reported in the literature (Girard et al., 2008). The differences in incidence rates between the 
various clinical settings are likely due to the variations in the patient populations found in 
each setting (for example those in an elective orthopaedic ward are likely to be younger and 
fitter than those on a Medicine of the Elderly ward), as well as the differences in the 
pathophysiological insult conferred by the condition for which the patient is hospitalised, and 
the variability in the underlying vulnerability conferred by comorbid disease. Incident rates 
for each individual setting vary between studies and this is likely due to a number of 
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methodological factors, including the country in which the study is conducted, method and 
frequency of assessment for delirium and the demographics of the study population.  
Risk factors for delirium vary depending upon the clinical setting, although there are some 
common themes throughout. A recent systematic review of delirium incidence and risk 
factors for older adults in acute medical units found that dementia, illness severity, 
catheterisation, low albumin, visual impairment and length of stay were all associated with 
the development of delirium (Ahmed et al., 2014). Following hip fracture, prior cognitive 
impairment has been shown to be the strongest risk factor for developing delirium (Freter et 
al., 2015) and in the ICU setting age, dementia, illness severity and emergency surgery or 
trauma prior to admission have been shown to be associated with delirium (Zaal et al., 2015). 
Risk factors associated with delirium after stroke are discussed in detail in section 1.2.6.  
 
1.2.4 Delirium pathophysiology 
The pathophysiology of delirium remains incompletely understood. Several possible 
mechanisms have been postulated, which for clarity have been divided into seven main 
categories below (Maldonado, 2013). These mechanisms are mainly complimentary rather 
than competing, and it is probable that some, if not all of these mechanisms play a part in the 
pathogenesis of delirium. It is not known whether delirium after stroke is caused by the same 
pathophysiological mechanisms as delirium in other conditions (such as during the time of an 
infection), but as the features of delirium are uniform, as defined by Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (DSM IV), irrespective of the precipitant to 
delirium, it is assumed that one or more of these mechanisms are as likely to be as pertinent 
to post-stroke delirium as they are to all other forms of delirium. One exception to this may 
be thalamic strokes, which may specifically affect attention (by the mechanisms described in 
the “attention” section), however these are relatively rare (Saez de Ocariz et al., 1996).  
Neurotransmitters 
Several neurotransmitters have been investigated with respect to their putative role in 
delirium pathophysiology. The most commonly described changes seen in delirium are a 
reduction in acetylcholine (ACh) (Flacker, 1998, Saez de Ocariz et al., 1996), and an increase 
in dopamine (Maldonado, 2013), in both blood and cerebrospinal fluid (CSF) (Hall, 2011). 
Acetylcholine is required for selective attention activities, and low levels of Ach have been 
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found in serum in those with delirium (Flacker, 1998). Furthermore, high levels of 
acetylcholinesterase, the main enzyme involved in the metabolism of Ach, have been found 
in CSF in those with delirium (Hall, 2011). Finally, medications with anticholinergic activity 
have been found to frequently precipitate delirium (Tune LE, 1999). High levels of dopamine 
metabolites have also been found in those with delirium, and it is hypothesised that dopamine 
may at least in part, be responsible for some of the behavioural changes commonly described, 
as dopamine has a role in attention, memory and perception (Trzepacz, 2000). Indeed, 
evidence of increased dopaminergic signalling has been found in the CSF of delirium patients 
with psychotic features (Ramirez-Bermudez, 2008). 
Other neurotransmitters have also been implicated, for example, Serotonin is a monoamine 
neurotransmitter which has a role in cognition, mood and wakefulness, and it has been 
hypothesised that increased serotonergic activity can lead to delirium (Flacker, 1999). This 
hypothesis is supported by evidence of elevated 5-hydroxyindoleacetic acid (a metabolite of 
serotonin) in the CSF of those with delirium (Koponen, 1994) Finally, GABA is thought to 
be the main inhibitory neurotransmitter in the human CNS and GABA has been found to be 
elevated in some types of delirium and reduced in others (Maldonado, 2013).  
Inflammation 
The inflammation hypothesis is based on the premise that an acute stimulus, such as an 
infection, causes a cascade of pro-inflammatory cytokines, which cause neuronal and 
synaptic dysfunction. Many inflammatory cytokines, such as CRP, Interleukin- 6 (IL-6), IL-8 
and Tumour Necrosis Factor have been found to be elevated in both blood and CSF in  
delirium when compared with controls, even after controlling for factors such as infection (de 
Rooij, 2007, Hall, 2011). The mechanism by which a minor infection, such as a urinary tract 
infection, without apparent systemic upset is able to precipitate delirium remains unclear.   
Neuronal Ageing 
Several age-related cerebral changes are hypothesised to contribute to the increased risk of 
delirium with age. These include neurone loss, reduced blood flow to the brain, and reduced 
vascular density in the brain. Pathological processes seen more commonly in ageing, such as 
those associated with Alzheimer’s dementia, probably also increase the vulnerability of the 
brain to delirium, with CNS cells being chronically activated to produce an exaggerated 




An acute insult such as infection may lead to tissue hypoperfusion, hypoxia and subsequent 
tissue damage. This in turn results in increased energy expenditure and reduced cerebral 
oxidative metabolism. The longer-term result of this may be damage to cerebral tissue and 
consequent longer-term cognitive decline (Maldonado, 2013).  
Loss of Circadian Rhythm 
Disruption of the normal twenty-four hour circadian rhythm may lead to disturbances in sleep 
architecture. Sleep deprivation has long been associated with delirium (Lipowski, 1987), and 
it has been shown that sleep debt can lead to poorer attention and reduced critical thinking. 
Whether loss of the normal circadian rhythm is a cause of delirium per se, or whether it 
simply aggravates or perpetuates delirium is not clear. Melatonin, with its sleep-wake cycle 
regulatory effects, actions as a free radical scavenger, as well as its anti-inflammatory 
properties and actions to reduce the affinity of glucocorticoid receptors, has been 
hypothesised as a potential treatment or preventative measure for delirium. A recent large 
randomised trial of melatonin after hip fracture did not shown any benefit in prevention of 
delirium (de Jonghe, 2014), however a recent systematic review and meta-analysis of all 
trials of melatonin (incorporating 4 randomised controlled trials, with a total n of 669) for 
delirium prevention found that there was a reduction in delirium incidence in patients 
admitted to medical wards, but not in those admitted to surgical wards, in the treatment 
groups (Chen et al., 2015). Further larger studies are across a range of hospital settings are 
now required to unpick the relationship between melatonin supplementation and delirium 
prevention.  
Network Disconnectivity  
This hypothesis is based on the premise that factors such as drugs, inflammation or infection 
affect neurotransmitter pathways and may cause them to fail or partially fail. Furthermore, 
the failure of any one pathway because of an acute insult will also affect the other 
neurotransmitter pathways, as they are intrinsically linked. Those subjects who do not have 
robust pathway (or “network”) connectivity due to ageing or cognitive impairment or reduced 





Aberrant Stress Response 
The role of the stress response in delirium pathophysiology is the main focus of this thesis, 
and as such a detailed description of the hypothesis is given in sections 1.4.4 and 5.1. In brief, 
it is hypothesised that an acute physiological stressor (such as infection) triggers and then 
sustains high circulating levels of cortisol, which has physiological benefits in the short term 
including mobilisation of glucose from the liver and adipose tissue and suppression of the 
inflammatory responses. However, if the stress response is not suppressed in the normal way 
by a negative feedback mechanism, and circulating cortisol levels remain high, this may have 
deleterious effects in the brain, particularly in the hippocampus, which lead to delirium 
(MacLullich et al., 2008). 
 
1.2.5 Delirium Diagnosis 
The current gold standard for the diagnosis of delirium is based on the criteria set out in the 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), which are 
reproduced in table 1.2. Delirium can be divided into two main subtypes; hyperactive 
delirium, when inattention manifests itself as over activity and hypervigilance, and 
hypoactive delirium, when drowsiness and reduced frequency of movements are commonly 
seen (Inouye et al., 2014) In practice, fluctuation between these two states in an individual 















Table 1.2 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 
criteria for the diagnosis of delirium 
Criteria Description 
1 Disturbance of consciousness with reduced 
ability to focus, sustain or shift attention 
2 A change in cognition or the development of 
a perceptual disturbance that is not better 
accounted for by a pre-existing, established 
or evolving dementia 
3 The disturbance develops over a short 
period of time (usually hours to days) and 
tends to fluctuate during the course of the 
day 
4 There is evidence from the history, physical 
examination or laboratory finding that the 
disturbance is caused by the direct 




The diagnosis of delirium is made using DSM-IV criteria as previously stated. Several 
screening tests, based around these diagnostic criteria, have been developed for use in a 
clinical setting to assess the features of delirium. The screening tests selected for this study 
(the Confusion Assessment Method for the Intensive Care Unit, the Delirium Rating Scale-
Revised-98, Digit Span Forwards and Backwards and the Edinburgh Delirium Test Box Mark 
2) which will be discussed in more detail in the methods chapter (section 4.4.5), were 
specifically chosen as they can be used on participants who are unable to verbalise (for 
example in those who are aphasic after a stroke).  
 
1.2.6 Post-stroke delirium 
 According to a recent systematic review (Shi et al., 2012), approximately 25% of patients on 
the acute stroke unit will have delirium at some point during their hospital stay. The 
incidence of delirium found in the studies included in this review ranged from  10% to 48%, 
however this broad range is probably accounted for by methodological differences in the 
studies (frequency and method of delirium assessment), as well as changes in the way stroke 
care is provided (such as development of dedicated stroke units) (Shi et al., 2012). This is 
important, because delirium after stroke, as well as delirium associated with other illnesses 
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such as sepsis, is associated with multiple adverse outcomes, including longer-term cognitive 
impairment, longer length of stay, higher mortality and higher risk of institutionalisation 
(Sheng et al., 2006, Witlox et al., 2010, McManus et al., 2007, MacLullich et al., 2009). 
However, the mechanisms of post-stroke delirium remain poorly understood.  It is recognised 
that, as in the non-stroke population, risk factors for delirium after stroke include infection 
and prior cognitive impairment, as well as factors specific to stroke such as increasing stroke 
severity (Oldenbeuving, 2013). Anterior circulation strokes are also associated with delirium 
(Oldenbeuving, 2011), but conflicting results have been found as to whether right or left 
hemisphere strokes confer the greater risk (Oldenbeuving et al., 2014, Henon et al., 1999).   
 Stroke as a cause or precipitant of delirium has been rather neglected from a research point 
of view, perhaps because it has been seen as a direct brain insult, which may at times be 
difficult to distinguish from delirium. It is recognised that stroke, particularly stroke affecting 
the thalamus, can cause attentional deficits and reduced conscious level (Kraft, 2015) . 
However, it is important to recognise that this is a distinct entity from delirium, with its 
fluctuating course and attentional and cognitive deficits which occur acutely and are a change 
from the patient’s new baseline following stroke. This is an important point- this distinction 
is crucial if we are to recognise delirium in the stroke population and understand its 
pathophysiology in more detail. It is, of course, possible that those with a large thalamic 
stroke (or indeed a large TACS) may develop delirium around the time of stroke onset, and 
this would be difficult to distinguish from the stroke itself, but as previously discussed the 
incidence of thalamic stroke is low overall, and a pragmatic approach of looking for new 
changes following stroke and assessing all of the features of delirium in a detailed way 
ensures that the incidence is not over-estimated.  
 
1.2.7 Summary 
In summary, delirium is a common finding in patients post-stroke in hospital, and is 
associated with adverse outcomes. Delirium has two motor subtypes, hypoactive and 
hyperactive (and the two may co-exist, in that there may be rapid fluctuation between them). 
The diagnosis of delirium is based on clinical findings using the framework of the DSM-IV 
criteria, along with other screening tools to assess features in more detail. The 
pathophysiology of post-stroke delirium is incompletely understood, and several possible 
mechanisms have been investigated. One plausible pathophysiological mechanism is that of 
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the “aberrant stress response” which precipitates and then maintains delirium, and it is this 




















1.3 Cognitive impairment after stroke 
One of the adverse outcomes associated with post-stroke delirium is cognitive impairment 
(van Rijsbergen et al., 2011). Indeed those who have an episode of delirium in the acute 
phase post-stroke, have between a five and seven fold increased risk of having dementia 
when assessed two years later (when pre-morbid cognitive impairment is controlled for using 
the IQCODE)(van Rijsbergen, 2011).   Long-term cognitive impairment after stroke and its 
association with delirium in the acute phase after stroke will be explored in this thesis, and 
therefore cognitive impairment after stroke will be described in general terms in the 
following section. 
 
1.3.1 Cognitive impairment definition 
 
Cognitive impairment, as defined by the DSM-5 criteria (American Psychiatric Association, 
2013) , may be divided into minor (sometimes called mild) or major cognitive impairment 
(often referred to as dementia -for the purposes of this thesis the two terms will be used 
interchangeably).  
A minor cognitive impairment is defined by the following: 
1. Evidence of modest cognitive decline from a previous level of performance and a 
decline in neurocognitive performance in the range of one or two standard deviations 
below appropriate norms on formal testing. 
2. The cognitive deficits are insufficient to interfere with independence, but greater 
effort, compensatory strategies or accommodation may be needed to maintain 
independence. 
3. The cognitive deficits do not occur exclusively in the context of delirium 
4. The cognitive deficits are not primarily attributable to another mental disorder (such 
as depression)  
A major cognitive impairment is defined by the following: 
1. Evidence of a substantial cognitive decline in one or more domains and a decline in 
neurocognitive performance in the range of two or more standard deviations below 
appropriate norms on formal testing. 
2. The cognitive deficits are sufficient to interfere with independence (requires 
assistance with activities of daily living). 
3. The cognitive deficits do not occur exclusively in the context of delirium 
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4. The cognitive deficits are not primarily attributable to another mental disorder (such 
as depression)  
 
 
1.3.2 Cognitive impairment epidemiology 
 
Stroke and cognitive impairment are interrelated because they share similar risk factors and 
after stroke around 10% of patients without pre-stroke cognitive problems will develop 
cognitive impairment (Pendlebury, 2009).The overall incidence of post-stroke cognitive 
impairment at 6 months is approximately 20%, rising to approximately 22 % at 1 year 
(Pendlebury, 2012b) (the overall incidence of dementia in the over 65’s in the UK is around 
3%) (Prince, 2014). Cognitive impairment is an important long-term consequence of stroke, 
and is strongly associated with significant functional deficits (Mok et al., 2004) and new 
institutionalisation (Pasquini et al., 2007).  
 
 
1.3.3 Cognitive impairment pathophysiology 
 
The mechanisms of cognitive impairment after stroke are incompletely understood. The 
stroke lesion causes damage to a focal area of brain, however the effects seen on cognition 
tend to be more global. It has been hypothesised that this may in part be due to the strategic 
location of the infarct, for example affecting the thalamus, which might result in a more 
global cognitive decline, and that both single and multiple lesions may interrupt intracerebral 
circuits, for example by disrupting white matter connectivity (Pendlebury, 2012a). It is likely 
that both large vessel disease (atherosclerosis and other arteriopathies) and small vessel 
pathology (such as arteriosclerosis, amyloid angiopathy and other intracerebral 
vasculopathies) play a part in the pathophysiology of vascular cognitive impairment. Large 
vessel disease probably contributes to white matter pathology and causes impaired cerebral 
blood flow (even in the absence of an infarct), although the clinical significance of this is 
uncertain (Iemolo et al., 2009). Small vessel disease leads to cerebral tissue damage, usually 
lacunar infarcts and white matter changes (Iemolo et al., 2009). 
 
Pathological studies have demonstrated that cerebrovascular disease contributes to the 
majority of cases of late onset dementia (including those diagnosed in life with Alzheimer’s 
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dementia) ( Savva and Stephan, 2010). Indeed, for dementia of any cause, vascular lesions 
have been shown to have a higher attributable risk than amyloid-beta plaques and 
neurofibrillary tangles combined (Matthews et al., 2009). Cerebrovascular disease and 
neurodegenerative pathology (such as that found in Alzheimer’s Disease) frequently co-exist 
in the elderly, and the presence of both pathologies lowers the threshold for dementia 
(Snowdon, 1997). It is not clear whether stroke disease unmasks previous subclinical 
degenerative pathology, or works synergistically to accelerate degeneration and development 
of a clinical cognitive impairment. It should also be noted that vascular changes such as 
hypoperfusion may underlie the pathological changes seen in Alzheimer’s disease (such as 
amyloid-beta plaques) (Pendlebury, 2012a). Determining the relative contributions of 
vascular and degenerative pathology to cognitive decline post-stroke is difficult, partly 
because several of the features are overlapping (for example, atrophy of the temporal lobes). 
Glucocorticoid excess may also have a role to play in the pathophysiology of cognitive 
impairment, and this hypothesis is discussed in detail in section 1.4.3. 
 
Those with brain atrophy are known to be at higher risk of developing a major cognitive 
impairment after stroke (Area Under Curve (AUC) = 0.71, 95% CI 0.64-0.77), and those with 
white matter lesions (WMLs) may also be at higher risk (AUC = 0.59 CI 0.59-0.65)(Saini et 
al., 2014),(Pendlebury, 2012a). These two specific pathological changes are discussed in 
depth in the neuroimaging section of this chapter (section 1.5). 
 
 
1.3.4 Diagnosis of cognitive impairment 
The clinical diagnosis of a cognitive impairment after stroke relies on the history (ideally 
given by an informant, such as the closest relative) of the person’s ability to live 
independently as well as formal testing of cognition using one of the published tests. The 
cognitive tests most commonly employed for this purpose in the hospital setting in the UK 
are the Mini-Mental State Examination (MMSE) (Folstein et al., 1975), The Addenbrook’s 
Cognitive Examination-Revised (ACE-R) (Mioshi et al., 2006) and the Montreal Cognitive 
Assessment (MoCA) (Nasreddine, 2005). More detailed neuropsychological tests are also 
available, which can test specific domains in more detail. The MoCA was selected as the 
main multi-domain cognitive test for this study, because it takes only 10 minutes to 
administer (in contrast to the ACE-R which takes around 20 minutes), and has been shown to 
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pick up more cognitive deficits than the MMSE in patients with stroke, and in particular the 
MoCA is able to demonstrate deficits in executive function and attention, which the MMSE 
is not (Pendlebury, 2010). More detailed neuropsychological tests were also performed as 
part of the study during follow up visits and these are described in detail in the General 
Methods chapter (section 4.6). Previous cognitive ability is also relevant and crystallised 
intelligence (and hence pre-morbid intelligence in those with cognitive decline) was therefore 
measured using the National Adult Reading Test (NART Nelson, 1991), which is also 
described in more detail in section 4.6.1. Finally an informant history was taken about the 
participants ability to live independently, and at the time of recruitment an informant 
completed the Informant Questionnaire on Cognitive Decline in the Elderly  IQCODE (Jorm, 
1995a) to screen for undiagnosed pre-existing dementia (section 4.6.2). 
 
1.3.5 Classification (including severity) of cognitive impairment after stroke 
In the DSM-5 criteria, the term “dementia” has been replaced by the term “major 
neurocognitive impairment.” However this change has not reached clinical practice nor 
research publications to date and for the purpose of this thesis the two will be used 
interchangeably. The distinction between mild and major cognitive impairment are outlined 
in the definition section (section 1.3.1). Those with either a mild or major cognitive 
impairment with clinical and/or radiological cerebrovascular disease may be diagnosed with a 
vascular cognitive impairment, however Alzheimer’s dementia pathology and vascular 
pathology frequently co-exist and it may be difficult to determine which patients have a 
single pathological process and which do not. Roman and colleagues, as long ago as 1993, 
published the NINDS-AIREN criteria for diagnosis of vascular dementia, which have been 
used extensively in clinical research (Roman et al., 1993). These criteria state that probable 
vascular dementia requires the presence of dementia along with the presence of 
cerebrovascular disease (focal neurological signs and evidence of recent cerebrovascular 
disease on brain imaging and a link between the two). The link between the two requires 
either a temporal relationship (onset of cognitive impairment within 3 months of the 
cerebrovascular disease), or a “classical clinical course,” meaning an abrupt onset and 
stepwise course. The diagnosis of probable vascular dementia can be made if brain imaging 
criteria are not met or if the temporal relationship between cerebrovascular disease and 
dementia is not clear (Roman et al., 1993). A minor vascular cognitive impairment must fit 
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In summary, cognitive impairment is common after stroke and is a major concern for stroke 
survivors and their carers. Vascular cognitive impairment can be sub-divided into minor and 
major categories. The pathophysiology of vascular cognitive impairment frequently co-exists 
with other pathology such as that seen in Alzheimer’s dementia. The diagnosis is made based 
on informant history (and participant history if possible) along with clinical examination and 
cognitive testing. Delirium is associated with cognitive impairment after stroke, in that those 
who develop delirium are more likely to have developed cognitive impairment at 2 years 
post-stroke (van Rijsbergen et al., 2011).  Conversely, those with pre-existing  cognitive 















As this thesis will be examining the associations between delirium after stroke and cortisol, I 
will discuss glucocorticoids (cortisol in humans, corticosterone in rodents) in general and 
then in relation to stroke specifically in the following section. A systematic review of the 
literature in relation to cortisol and stroke follows the introduction section (chapter 2). 
 
1.4.1 Physiology 
Glucocorticoids are hormones produced by the adrenal cortex in response to physical or 
psychological stress. The release of these hormones is under the control of the hypothalamic-
pituitary-adrenal axis (HPA axis), which has a negative feedback mechanism. A schematic 
diagram of the HPA axis is shown below (Figure 1.1). Cortisol is transported in the blood 
bound to corticosteroid-binding globulin, a high affinity transporter, which is saturable. 
Serum albumin acts as an additional transporter, but has low affinity for cortisol. Free cortisol 
can be detected in saliva, and salivary cortisol levels have been shown to correlate with serum 
levels in healthy elderly adults (Reid et al., 1992).  Glucocorticoid receptors are found in 
almost every cell in the body. Cortisol inhibits glucose uptake by peripheral tissues, which is 
thought to be in order to spare glucose for the brain, and stimulates gluconeogenesis, 
proteolysis and lipolysis. It also inhibits inflammatory pathways (Weatherall, 1996). 
 
The HPA pathway is entrained on the circadian cycle, producing fluctuations which are 
cyclical, occurring every 24 hours. More specifically, the HPA axis exhibits diurnal variation, 
with a characteristic peak of cortisol being produced in the early morning and a nadir 
occurring in the late afternoon. This corresponds to the daily activity-rest cycle, and alteration 
of activity patterns (for example working at night) results in a slow, but corresponding, re-
phasing of the HPA axis (Herbert et al., 2006). The circadian secretion of 
adrenocorticotrophic hormone (ACTH) from the pituitary is controlled by the 
suprachiasmatic nuclei, via a self-sustaining transcriptional/translational feedback loop, and 
is synchronised by input from photoreceptive retinal ganglion cells that project directly into 
the suprachiasmatic nuclei (Herbert et al., 2006). In addition to these diurnal fluctuations in 
cortisol, several stressors (both internal and external), via effects on the HPA axis, may cause 
a rise in cortisol levels. For example, cortisol is released in response to physiological stress 
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and hypoglycaemia (Weatherall, 1996) and elevated cortisol levels have also associated with 
psychologically stressful life events (Herane Vives et al., 2015).  
An exaggerated response to physiological and psychological stressors, leading to higher 
levels of circulating cortisol, has been shown to be associated with several diseases including 
Alzheimer’s disease and depression (Lupien et al., 1999). A meta-analysis of studies 
comparing healthy older volunteers, with younger healthy volunteers found that the elderly 
had an exaggerated cortisol response to physiological, psychological or pharmacological 
challenge (Otte, 2005). The study also found that the effect of age on cortisol response was 
greater in women than men, and the authors hypothesise that this may be related to the 
decrease in oestrogen in post-menopausal women, in some way attenuating the cortisol 
response (males do not undergo such a dramatic change in sex hormone levels with ageing) 
(Otte, 2005). In a cross-sectional study of 745 elderly participants, Johar and colleagues 
found that frailty is associated with a blunted diurnal cortisol pattern (evidenced by lower 
morning and higher evening cortisol levels) (Johar et al., 2014). However, the number of 
participants who were frail in the study (as defined by the study protocol) was low, at only 25 
(3.4%), and participants were required to be able to walk, in order that gait speed be 
measured, meaning that the frailest, with poor mobility, were excluded. The dampening of 
diurnal variation in cortisol and the loss of negative feedback, resulting in persistent 
activation of the HPA axis with stress, has been hypothesised to be caused by age-related 
adaptations of both the central nervous system and endocrine system (Ferrari and Magri, 
2008). For example, the suprachiasmatic nuclei have been shown to shrink with ageing and 
age related impairment of the zona reticularis of the adrenal cortex has also been 
































1.4.2 Glucocorticoids and stroke 
Stroke is linked with an increase in the activity of the HPA axis, resulting in elevated 
circulating levels of cortisol (Fassbender et al., 1994, Feibel et al.,1977, Olsson et al., 1992). 
In general there is considerable individual variability in the degree and duration of cortisol 
elevation. Increased variability and a tendency towards dysregulation (resulting in 
abnormally prolonged HPA axis activation) is seen with ageing and especially in the presence 
of neurodegenerative disease (MacLullich et al., 2005). More prolonged HPA axis activation 
after a stroke may also occur for reasons specific to stroke. These reasons include cytokine 
release following neuronal injury, and that the stroke lesion itself may destroy HPA 
inhibitory areas of the brain in the frontal or medial temporal lobes (Mitchell, 1997). In order 
to explore the relationship between the HPA axis and stroke I have performed a systematic 



























1.4.3 Glucocorticoids, the brain and cognition 
The primary source of glucocorticoids in the brain is from the blood (Herbert et al., 2006). 
Glucocorticoids are primarily bound to corticosteroid-binding globulin (CBG) in blood, and 
CBG is the major limiting factor in diffusion across the blood brain barrier (BBB). 
Glucocorticoids themselves are relatively lipid soluble, and as such are able to diffuse across 
the BBB when unbound (Herbert et al., 2006). As CBG has limited binding capacity, any 
sudden rises in blood cortisol may lead to disproportionate rises in cerebrospinal fluid 
cortisol. P-glycoprotein transporters in the brain play a role in exporting cortisol across the 
BBB back into the blood, but are not thought to play a role in importing cortisol from the 
blood to the brain (Mason et al., 2010). Once cortisol enters the brain it is regulated by 11β-
hydroxysteroid dehydrogenase activity (11β-HSD). This enzyme has two isoforms- 11β-
HSD1 and 11 β-HSD2, which work in opposing directions, with 11β-HSD1 generating 
cortisol from its inactive 11-keto precursor (cortisone in humans), and 11 β-HSD2 
inactivating cortisol (Mason et al., 2010). The 11β-HSD1 isoform is widespread in the human 
brain as well as in liver and adipose tissue, whereas the 11 β-HSD2 isoform is scarcely 
expressed in the human brain, being predominantly found in epithelial cells of the colon, 
kidney and salivary glands (Herbert et al., 2006).      
Glucocorticoids have important effects on the brain, such as alteration of neuronal 
excitability throughout the diurnal cycle and modification of structural and neurochemical 
features of the brain following a stressor (Lupien et al., 1997). Corticosteroid hormones act 
via intracellular receptors that mediate slow genomic actions, however corticosteroids also 
have more rapid effects, which are thought to be mediated by actions on membranes and 
neurotransmitters (Lupien et al., 1997). There are two types of corticosteroid receptors in the 
human brain, Type 1 (or mineralocorticoid), which have a high affinity for cortisol and 
aldosterone, and Type 2 (or glucocorticoid) which have a lower affinity for aldosterone. 
When levels of circulating corticosteroids are low (such as after adrenalectomy), there is an 
increase in the number and also the affinity of the corticosteroid receptors (up-regulation), 
and conversely, when levels of corticosteroids are high (such as in Cushing’s disease) there is 
a decrease in the number and affinity of the receptors (down-regulation). Corticosteroids have 
both immediate and delayed actions on neurones. The immediate action is to rapidly depress 
the firing activity of the neurones and the delayed action is to reduce the ability of neurones 
to respond to subsequent acute stimuli, and this effect can last for hours or even days (Lupien 
et al., 1997).  Mineralocorticoid receptors are particularly prevalent in the limbic system, and 
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glucocorticoid receptors are widely expressed in most brain regions. The hippocampal 
formation, which has a key role in new learning and immediate memory, is known to contain 
the highest concentration of glucocorticoid binding sites in the entire brain (Starkman et al., 
1992). Interestingly, prolonged exposure to high (non-basal) levels of corticosterone has been 
shown to be associated with hippocampal atrophy in rodents (Murray et al., 2008) and in 
humans with Cushing’s disease (where cortisol levels are pathologically high), the 
hippocampal formation volume is negatively correlated with plasma cortisol levels and those 
with smaller hippocampal formation volumes have poorer verbal learning and verbal recall 
scores, even after correcting for prior cognitive ability (Starkman et al., 1992). Following 
successful treatment for Cushing’s disease (leading to physiological cortisol levels being 
restored) the hippocampal formation volume has been found to increase by up to 10%. 
However, this study included only 22 participants, and although 18/22 showed an increase in 
hippocampal formation volume (with the remaining 4 showing no change) larger studies will 
be required to confirm this finding (Starkman et al., 1999). Declarative memory (voluntary or 
conscious recollection of previous information), in which the hippocampus plays a key role, 
is particularly affected by corticosteroids, adding weight to the hypothesis that the 
hippocampus is central to understanding the effects of corticosteroids on memory 
(Newcomer, 1994).   
 
 
In rodent animal models and in humans, corticosteroids have been shown to have beneficial 
effects on memory at basal levels (Lupien et al., 2007). However, higher levels of 
corticosteroids have been found to have detrimental effects in a dose dependant fashion, and 
as such the relationship between corticosteroids and memory has been described as a U 
shaped curve (Lupien et al., 1997). There is a large literature describing the association 
between dysregulation of the HPA axis, resulting in elevated cortisol and chronic cognitive 
dysfunction and dementia (Herbert et al., 2006) (MacLullich et al., 2005). For example, in a 
cross-sectional study of 967 older community-dwelling adults, elevated cortisol levels were 
associated with poorer cognitive function (Lee et al., 2007), and in patients with Alzheimer’s 
disease higher cortisol levels are associated with faster cognitive decline (Csernansky et al., 






1.4.4 Glucocorticoids and delirium 
 
One of the fundamental hypotheses as to the pathophysiological mechanisms of delirium, that 
explains the clinical features of delirium and its association with physiological stress, is that it 
is triggered and then sustained by high circulating levels of cortisol (MacLullich et al., 2008). 
This hypothesis is supported by convergent evidence from basic science and clinical research. 
The phenomenon of “steroid psychosis,” that is the development of significant changes in 
behavior and mood following the administration of corticosteroid medication, has been the 
subject of research and debate for many decades. There has been particular interest in how 
corticosteroids may regulate behavior, and how additional exogenous steroids may therefore 
interrupt this mechanism, resulting in the observed psychosis. Animal studies of the 
phenomenon include those conducted by Wolkowitz, who administered corticosteroid or 
placebo to rats and found that those given corticosteroids had significant increases in caudate 
homovanillic acid, a dopamine metabolite (Wolkowitz, 1994). Changes in behavior which 
correspond to dopamine activity, such as increased locomotion, were also observed 
(Wolkowitz, 1994). Interestingly, Lithium pre-treatment of the rats was found to prevent the 
occurrence of both the biochemical and behavioral effects of corticosteroids (Wolkowitz, 
1994). The same group also performed a number of human studies, and found that 
administration of Dexamethasone to healthy volunteers resulted in elevated plasma 
homovanillic acid levels. A second study in which 12 healthy volunteers were given a 5 day 
course of placebo, followed by 5 days of oral Prednisolone (80mg) and then 7 days of 
placebo (using a double-blind methodology), found that Prednisolone was associated with 
diverse and fluctuating behavioral changes, including depression and anger, in 75% of 
participants. Both study groups underwent cognitive testing during the period of 
corticosteroid administration. Neither Dexamethasone nor Prednisolone were associated with 
altered attention per se, but were associated with errors of commission, which refers to the 
inability to filter out distractors during testing (Wolkowitz, 1994). 
 
 
1.4.4.1 Clinical studies of glucocorticoids and delirium 
 
There is mounting direct evidence from clinical studies linking glucocorticoids with delirium 





 Kudoh and co-workers (Kudoh, 2005) found that elderly patients (age range 70-90) who 
developed post-operative delirium had higher post-operative cortisol levels, although despite 
controlling for surgery duration, age and anaesthesia length, they did not control for post-
operative illness severity. Kazmierski and colleagues investigated 113 participants 
undergoing coronary artery bypass grafting (CABG) surgery, and found that raised peri-
operative plasma cortisol levels were associated with the development of delirium, although 
only 2 plasma levels were measured, one in the morning prior to surgery and one on the 
morning following surgery (Kazmierski et al., 2013). Mu and colleagues also investigated the 
relationship between plasma cortisol levels and delirium in a cohort of 243 participants 
undergoing elective CABG surgery. They also found an independent association between 
elevated cortisol and post-operative delirium, after controlling for other confounders such as 
age and illness severity (Mu et al., 2010). A meta-analysis of studies investigating the 
predisposing and precipitating factors associated with delirium after cardiac surgery (and 
which included the 2 studies discussed here) concluded that elevated cortisol is one of the 
most established precipitating factors of delirium after cardiac surgery (Lin et al., 2012). 
Bisschop et al investigated the associations between plasma cortisol and delirium in a cohort 
of 143 participants following hip fracture and found a trend towards higher cortisol levels in 
those who developed delirium, but this was not statistically significant in multivariate 
analysis (Bisschop et al., 2011). More recently Hall et al investigated a cohort of 104 
participants with hip fracture, and found an association between morning cortisol levels and 
delirium after adjusting for age, illness severity, prior cognitive impairment and co-
morbidities (Hall et al., 2015). 
 
Medical and ICU studies 
O’Keeffe and Devlin (O' Keeffe, 1994) studied the relationship between delirium and the 
dexamethasone suppression test in 16 elderly patients with lower respiratory tract infection. 
Seven of the nine patients with delirium, and only one of the seven non-delirious patients, 
were non-suppressors. Colkeson et al investigated the relationship between serum cortisol 
and delirium in 52 patients presenting with an acute coronary syndrome (ACS) and found an 
independent association with elevated cortisol and delirium, after controlling for age, sex and 
severity of the ACS, however dementia and co-morbid disease were not controlled for 
(Colkesen et al., 2013). A significant correlation between delirium severity (measured by the 
DRS) and cortisol levels was also demonstrated.  In a critical care setting, Nguyen et al 
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(Nguyen et al., 2014) investigated the relationship between plasma cortisol and delirium in 
those with sepsis (n=128). Delirium (or brain dysfunction, as it was termed in this study) 
before sedation was defined as a positive CAM-ICU or a Glasgow Coma Scale of ≤13, and 
after withdrawal of sedation was defined as a positive CAM-ICU. Delirium was diagnosed in 
84% of participants after sedation withdrawal (104/128). Cortisol was measured only in the 
morning rather than diurnally, and so no information about the diurnal cortisol variability is 
available from this study. The authors found an independent association between elevated 
cortisol and the development of delirium after controlling for confounders (Nguyen et al., 
2014).    
 
Stroke studies 
There is some specific evidence directly linking HPA axis dysregulation with delirium in 
stroke patients.  Two studies have reported that non-suppression to dexamethasone is 
associated with a higher risk of delirium (n = 99)(Gustafson Y, 1993, Olsson et al., 1992) and 
one study has reported higher cortisol levels in those with delirium (n = 88) (Marklund et al., 
2004).  These studies are discussed in more detail in section 5.1. 
 
1.4.5 Summary  
In summary, glucocorticoids have important functions throughout the body, including the 
brain, and play a central role in the stress response. Abnormally high levels of cortisol have 
been linked with cognitive impairment, and this may be due to its detrimental effects on the 
hippocampus. Delirium has been shown to be associated with higher cortisol levels in a 
variety of clinical scenarios, including after hip fracture and following surgery. Three small 
studies have found an association between cortisol after stroke and delirium, but all are 












Neuroimaging is performed on nearly all stroke patients and neuroimaging analysis is an 
important area of investigation into the pathophysiology of delirium. As image analysis will 




1.5.1 Imaging modality 
 
The majority of stroke patients undergo brain imaging, usually with computed tomography 
(CT) around the time of admission (within 24 hours of stroke onset), as recommended in the 
current national Scottish Intercollegiate Guidelines Network (SIGN) guidelines 
(www.sign.ac.uk). Magnetic Resonance Imaging (MRI) is not routinely available for all 
stroke patients and is particularly problematic in this patient group, because of the time 
required to complete the scan and also because MRI can be distressing and noisy for patients 
to tolerate. Furthermore MRI may not reveal hyperacute haemorrhage correctly, and up to 
one fifth of patients are not able to undergo MRI scanning, either because they are too unwell 
or because they have an intracerebral or intraocular metallic foreign body or a pacemaker 
(Wardlaw, 2004). In the context of an acute stroke, CT brain scanning is used to detect acute 
areas of hypo or hyperattenuation which indicate an ischaemic or haemorrhagic stroke 
respectively.  The scan will, however, detect other changes in the brain which may or may 
not be related to the acute stroke. For example changes to the white matter (in regions other 
than that of the acute stroke, often referred to as white matter lesions (WMLs)) are frequently 
seen in stroke patients (Leys, 1999) as is brain volume loss (often referred to as brain 
atrophy), which may be global or localised to specific regions. These two specific changes 
(The presence of WMLs and brain atrophy) are of particular interest as they have both (either 
in combination or individually) been associated with deterioration in cognitive ability (Leys, 






1.5.2 White Matter Lesions 
White matter lesions (WMLs) are patchy or confluent periventricular and subcortical areas of 
lower density on CT scans (they can be seen as high signal intensity areas on MRI). The 
aetiology of WMLs remains obscure, but they are assumed to be of vascular origin (Kalaria, 
2012). The pathogenesis of WMLs includes reactive gliosis, shrinkage of oligodendrocytes, 
ischaemic demyelination and transient oedema, which are thought to result from vascular 
insufficiency and a chronic hypoxic state (Kalaria, 2012).  Shrinkage of oligodendrocytes 
seems to lead to eventual cell death with consequent loss of numbers of these cells in the 
white matter (Ihara et al., 2010). Mild ischaemic injury is known to activate myelin repair, 
however prolonged ischaemia is thought to damage oligodendrocyte precursor cells with a 
net result of unsuccessful remyelination (Simpson et al., 2007).  WMLs are associated with 
cerebrovascular risk factors, particularly hypertension and advancing age (Salat et al., 2005). 
WMLs and stroke are closely associated, with WMLs being a risk factor for first ever and for 
recurrent stroke (Grueter and Schulz, 2012). This can probably, at least partially, be 
explained by their shared risk factors such as hypertension. WMLs have been found to be 
present in up to 40% of those with a diagnosis of Alzheimer’s dementia and are also a 
common pathological change seen in vascular dementia (Leys, 1999). It is postulated that 
changes to the white matter is a mechanism of age related cognitive decline. One possible 
mechanism by which this may come about has been termed “cortical disconnection,” a term 
first described by Geschwind in 1965(Geschwind, 2010) but which has gained credence 
following the results of several functional neuroimaging studies which have confirmed loss of 
white matter connectivity associated with advancing age (D'Esposito, 1999, O'Sullivan et al., 
2001). The cortical disconnection theory is based on the concept that loss of white matter 
fibres leads to the loss of functional integration of neurocognitive networks, which in turn 
leads to the clinical picture of cognitive impairment (O'Sullivan et al., 2001).  Finally, WMLs 










1.5.3 Brain Atrophy  
 
Global (or whole brain) atrophy has been related to increased risk of dementia in several 
neuroimaging studies (Erten-Lyons et al., 2006). Global brain atrophy, characterised by 
narrowing of the gyri, widening of the sulci and enlargement of the ventricles, is a common 
finding on CT or MRI in the elderly (Appleman, 2010). The extent and rate of total brain 
atrophy and ventricular enlargement are associated with development of dementia, 
independent of hippocampal atrophy (Appleman, 2010).  However, it is important to note that 
there is a life-long association between whole brain size and general cognitive ability, and so 
when investigating the contribution of global or regional brain atrophy to overall cognitive 
status, it is important that prior maximum brain size (estimated using intracranial area) and 
peak cognitive ability are taken account of (Shenkin, 2009).   
 Risk factors for brain atrophy are similar to those associated with WMLs, namely age and 
hypertension, but also diabetes and cigarette smoking, reflecting once again the presumed 
vascular origin of the pathology (Appleman, 2010).  
 
 Medial temporal lobe atrophy, and in particular hippocampal atrophy, is closely related to 
memory impairment and is a predictor of Alzheimer’s dementia (hippocampal atrophy 
corrected for intracranial volume, to account for prior brain volume) (Ikram et al., 2010), 
even in those who are currently not symptomatic. Hippocampal neurones are extremely 
vulnerable to hypoxia which may be caused by systemic vascular disease. However, it is not 
clear whether hypoxia is the sole underlying mechanism for development of cerebral atrophy 
per se, or whether other mechanisms may be involved (Kalaria, 2012). It is now clear, from 
neuroimaging studies and from The Nun Study (Snowdon, 1997) that medial temporal lobe 
atrophy is not restricted to Alzheimer’s disease, and also that there is considerable 
pathological overlap between vascular cognitive impairment and Alzheimer’s disease.   
 
 
1.5.4 White Matter Lesions, Brain Atrophy and Delirium 
 
Currently, there are very few neuroimaging studies in delirium. A systematic review in 2008 
identified twelve neuroimaging (CT, MRI, Single Proton Emission Computed Tomography 
(SPECT)) studies that had studied a total of 194 patients with delirium and 570 controls (only 
four of these studies included stroke patients)(Soiza et al., 2008). Though delirium appeared 
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to be more common in patients with white matter lesions, the studies were very small, and did 
not control for confounding factors. To my knowledge just two published studies have 
investigated neuroimaging features after stroke in relation to delirium risk. Henon and 
colleagues recruited 202 participants and found that those with delirium had greater degrees 
of cortical atrophy and white matter lesions ((WMLs), 120 had a computed tomography (CT) 
scan and 82 had a Magnetic Resonance Imaging (MRI) scan), but there was no correction for 
age.(Henon et al., 1999)  Oldenbeuving and colleagues reported that in 484 stroke 
participants, brain atrophy on CT scan (13 brain regions rated and scored combined to give an 
overall brain atrophy score) was associated with an increased risk of delirium in the first 
week after stroke, but did not re-assess participants after the first week, unless they were 
diagnosed with delirium (Oldenbeuving, 2011).  
 
 
1.5.5 Stroke Lesion and Delirium  
 
Few studies have investigated the relationship between the stroke lesion (type, site and size) 
and delirium. Those that did reported conflicting results. For example, Gustafson and 
colleagues (Gustafson Y, 1993) studied 83 participants after stroke and found that delirium 
was associated with haemorrhagic stroke and left sided lesions, however Oldenbeuving and 
colleagues (Oldenbeuving, 2011) studied 484 participants and found an association between 
right hemisphere lesions and delirium. Henon and colleagues (Henon et al., 1999) examined 
the relationship between old infarcts seen on neuroimaging and silent infarcts and found no 




In summary, neuroimaging offers the potential to improve our understanding of the 
pathophysiological processes underpinning the development of delirium after stroke. Both 
acute (in the form of any visible acute stroke lesions) and chronic (in the form of any old 
stroke lesions, WMLs and brain atrophy) changes can be assessed from clinical CT brain 
scans. CT scanning has the advantage of being suitable for almost all stroke patients, ensuring 
that bias is not introduced by relying on MRI (which is most suitable for those with less 
severe strokes). Previous studies, presented in this section, support the need for further work 
in this area to elucidate whether white matter lesions, stroke lesions, and other factors such as 
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brain atrophy, seen on clinical CT imaging, are associated with the development of delirium. 
The findings from such studies may be useful, in conjunction with clinical measures, in 
aiding clinicians to predict who is particularly at risk of delirium. This may be especially 
useful for predicting those likely to develop hypoactive delirium which is may be under-
recognised. Strategies to reduce the risk of delirium in the most vulnerable can then be 




























1.6 Aims, objectives and hypotheses of this thesis 
 
The main aim of this thesis is to investigate the role of hypothalamic-pituitary-adrenal (HPA) 
axis dysregulation (resulting in elevated cortisol levels) in delirium and long-term cognitive 
impairment after stroke. 
 
 
My key objectives are to determine: 
 
1. Whether delirium after stroke is associated with dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axis 
2. Whether dysregulation of the HPA axis in the week after stroke predicts cognitive 
decline up to one year 
3. Whether delirium after stroke is associated with the development of cognitive decline 
up to one year  
4. Whether features detectable on baseline clinical Computed Tomography (CT) scans 
(e.g. global atrophy, white matter lesions) can predict the development of delirium 
following stroke.  
 
My core hypotheses are: 
 
1. Delirium after stroke is associated with dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis as indexed by elevated morning and afternoon cortisol levels, and 
reduced morning: afternoon cortisol ratios.  
2. Dysregulation of the HPA axis as indexed by elevated morning and afternoon cortisol 
levels, and reduced morning: afternoon cortisol ratios in the first week after stroke 
predicts cognitive decline at up to 12 months. 
3. Delirium after stroke is associated with decrements in cognitive function over one 
year.  
4. Baseline pathology detected on admission CT brain scans, namely global cerebral 
atrophy, white matter lesions and visible acute stroke lesions, predict the development 




Chapter 2: Glucocorticoids and stroke- a systematic 
review of the literature 
 
The following systematic review has been published in The Journal of Neurology (Barugh et 
al., 2014)(see appendix 9 for permission to use publication in this thesis). The review has 
been updated for this thesis. All of the literature searches, data extraction and drafting of the 
manuscript was performed by AJB. Paul Gray also extracted data and all of the authors 





Although several studies have investigated what happens to cortisol after stroke, 
(Franceschini et al., 2001, Mitchell, 1997, Olsson, 1999) there are no systematic reviews. It is 
important to know whether HPA axis activation, or indeed downregulation, is associated with 
adverse outcomes in patients with stroke because treatments which impact on the HPA axis, 
and consequently on cortisol, may affect outcomes (such as morbidity (in particular 
delirium), and mortality).  
 
This systematic review has three main goals.  The first is to document comprehensively the 
evidence on cortisol levels and changes over time following stroke. The second is to 
determine if there are any associations between cortisol levels and stroke severity. The third 
is to determine if there are associations between cortisol levels and stroke outcomes-
specifically dependency (defined as the degree of functional impairment, measured by, for 
example, the Modified Rankin Scale (mRS), Barthel Index (BI), Katz Index (KI) or the 











Searches were conducted, by a single author (AJB), in MEDLINE (from 1966) and EMBASE 
(from 1980) in April 2013 and PsychINFO in July 2013 and updated in May 2015. Searches 
used the keywords “stroke” and “cortisol” and their synonyms and were not limited by 
language (appendix 1). Well-validated search strings, including more than 50 terms, were 
used to perform the search. Where possible, translations of papers were obtained (possible for 
one Chinese, one Russian and two Spanish papers, not possible for one Polish, one Bosnian 
and one Serbian paper). Results were exported to EndNote X4 and duplicates removed.  
Every title and abstract was read and full texts for all potentially relevant papers were 
obtained. Inclusion and exclusion criteria were then applied. Reference lists of the included 
papers and relevant review articles were scrutinized for further references. 
 
 
2.2.1 Inclusion criteria 
 
1. Full text publication in peer-reviewed journal; 2. Recruited 10 or more participants after 
stroke (ischaemic, haemorrhagic or subarachnoid hemorrhage (SAH)), older than 18 years; 3. 
Reported cortisol levels (measured in blood, saliva, cerebrospinal fluid (CSF) or urine) at 
least once in the first year following stroke. 
 
2.2.2 Exclusion criteria 
 
1. Published only in abstract form; 2. Contained no primary data (for example reviews, 
editorials); 3. Dissertations or case reports; 4. Did not report data for stroke participants 
separately from other participants. 
 
2.2.3 Quality Assessment 
 
 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
statement was used to assess quality (von Elm et al., 2008). This consists of 22 items, with 
each item scoring 1 point, thus the maximum score is 22 points. One author (AJB) rated all of 





2.2.4 Data Extraction 
 
Data were extracted using standardized data collection forms. Data concerning study design, 
participant characteristics and outcome measures was extracted. Two authors (AJB and Paul 
Gray) independently extracted data for included studies. Any uncertainties were discussed 
with a third reviewer (Gillian Mead).  
 
2.2.5 Data Synthesis 
 
The data lacked homogeneity, in particular with respect to the timing and method of cortisol 
measurement, and so were not suitable for meta-analysis. Results were tabulated and 






11 601 titles and abstracts were scrutinized, and 106 full texts were retrieved (Figure 2.1). 
Fifty-three studies recruiting 2665 participants (median 36, range 10-281) met the inclusion 
criteria. The mean participant age range was from 47 years (absolute range 25-69)(Poll et al., 
2010) to 80 years (absolute range 75-92)(O'Neill et al., 1991). The proportion of males 
ranged from 13% (Weant et al., 2008) to 92% (Harney et al., 1993). Twenty-nine studies used 
a longitudinal methodology and the remaining 24 were cross-sectional studies. Fifty-one of 
the studies recruited participants from hospital (Szczudlik et al., 2004, Jenkins et al., 1969, 
Anne et al., 2007, Bendel et al., 2008, Christensen et al., 2004b, Christensen et al., 2004a, 
Davalos et al., 1996, Espiner et al., 2002, Fassbender et al., 1994, Gustafson Y, 1993, Harney 
et al., 1993, Johansson et al., 2000, Marklund et al., 2004, Michalaki et al., 2010, Neidert et 
al., 2011, O'Neill et al., 1991, Poll et al., 2010, Reding et al., 1985, Schwartz et al., 2004, 
Slowik et al., 2002, Theodoropoulou et al., 2006, Urra et al., 2009, Zierath et al., 2011, 
Ahmed et al., 2004, Dimopoulou et al., 2005, Dziedzic et al., 2012, Elwan et al., 1990, Harms 
et al., 2011, Korsic et al., 1990, Lueken et al., 2009, Mangieri et al., 2003, Olsson et al., 1989, 
Olsson et al., 1992, Parenti et al., 2011, Selakovic et al., 2002, Olsson, 1990, Weant et al., 
2008, Murros et al., 1993, Feibel et al., 1977, Zhao et al., 1989, Lanterna, 2013, Back, 2015, 
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Tu, 2013, Terroni, 2015, Wahab, 2015), and two studies did not specify source of participants 
(Giordano et al., 2005, Burd and Sergeeva, 1981). Finally, twelve of the studies recruited 
only first ever stroke (Anne et al., 2007, Bendel et al., 2008, Harney et al., 1993, Murros et 
al., 1993, Slowik et al., 2002, Theodoropoulou et al., 2006, Ahmed et al., 2004, Szczudlik et 
al., 2004, Lueken et al., 2009, O'Neill et al., 1991, Dziedzic et al., 2012, Terroni, 2015), eight 
studies recruited both first ever and recurrent strokes (Christensen et al., 2004a, Christensen 
et al., 2004b, Davalos et al., 1994, Gustafson Y, 1993, Neidert et al., 2011, Urra et al., 2009, 
Zierath et al., 2011, Harms et al., 2011) and the remaining twenty-eight studies did not 
specify this (Olsson, 1990, Dimopoulou et al., 2005, Espiner et al., 2002, Fassbender et al., 
1994, Feibel et al., 1977, Giordano et al., 2005, Jenkins et al., 1969, Johansson et al., 2000, 
Marklund et al., 2004, Michalaki et al., 2010, Poll et al., 2010, Reding et al., 1985, Schwarz 
et al., 2003, Elwan et al., 1990, Korsic et al., 1990, Mangieri et al., 2003, Olsson et al., 1989, 
Olsson et al., 1992, Parenti et al., 2011, Selakovic et al., 2002, Weant et al., 2008, Zhao et al., 
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dead at 6 months 
 
400±200 if 
alive at 6 months 
Mean cortisol on day 2 
and 7 significantly 
correlated to stroke 
severity, mRS and 
mortality  
Severity r =  0.44 
 
mRS r = 0.37 
 
Mortality RR= 5.4 








790±300 Serum cortisol not 











Blood 550 Serum cortisol 
associated with stroke 
severity and positive 
correlation with higher 
mRS and mortality 
Severity r =  0.45 
 
mRS r =  0.18 
 











High free urinary 
cortisol predicted poor 
outcome, independent of 
age, sex and nutritional 
status at admission 
NR 18 
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Cortisol not correlated 
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340 BI 
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32 52 Subarachnoid 
haemorrhage 
Blood Figures not 
stated 
No data NR 12 
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depression at 1 week 
Depression r = 0.49 17 
Huttner 2013 
Germany 
20 68 Cerebral 
haemorrhage 
Blood 483 No data NR 19 
Jenkins 1969 
UK 
18 52 Subarachnoid 
haemorrhage 
Blood 535 No data NR 12 
Johansson 2000 
Sweden 
12 74 Cerebral 
infarction 
Blood 500 Cortisol levels 
correlated significantly 
to the severity of paresis  
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High morning cortisol 
levels are associated 
with ECG abnormalities 
ECG abnormality  
(day 2) OR = 2.56 
ECG abnormality  
(day 4) OR = 1.08 
14 
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Lanterna 2013 
Italy 
26 54 Subarachnoid 
haemorrhage 
Blood 610 Low cortisol levels 






31 57 Cerebral 
Infarction 
Saliva Not applicable 
 
No relationship between 
cortisol levels and 
aphasia severity 
Aphasia  r = 0.26 17 
Marklund 2004 
Sweden 
88 71 Cerebral 
infarction 
Blood 450 High cortisol levels 
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Murros 1993 
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101 61 Cerebral 
infarction 
Blood 590 Cortisol levels 
correlated significantly 
to the severity of paresis 
(on day 1 and at 3 
months) and to the mRS 
Severity r = 0.41 
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Blood 480 Cortisol levels 
correlated positively 
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Functional outcome 
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22 47 Subarachnoid 
haemorrhage 
Blood 540 Abnormal cortisol 
(elevated baseline and 
loss of diurnal rhythm) 
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GCS , longer ICU stay  
and less favorable 
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GCS r =  -0.56 
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Blood Figures not 
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Cortisol correlated with 
stroke severity (-0.42) , 
and associated with 
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Blood 230 No correlation between 
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46 74 Cerebral 
infarction and 
haemorrhage 
Blood Figures not 
stated 
Cortisol was positively 
correlated with the 
NIHSS score (0.31) 
NIHSS 0.31 19 
Zetterling 
(Zetterling et 
al., 2011) 2011 
Sweden 
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correlated with stroke 
severity (0.72) 
Severity 0.72 21 
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Cross-sectional Cohort Studies (listed alphabetically) 
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sova et al., 2009) 
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Bulgaria 
33 58 Cerebral 
infarction 
Blood 484 No data NR 18 
Back 2014 
Denmark 
16 70 Cerebral 
infarction 
Blood 213 No data NR 16 
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Dimopoulou 2005 
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Finklestein 1982 
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al., 2009) 2009 
Germany 
32 57 Cerebral 
infarction 
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2.3.1 Measurement of cortisol 
 
Of the 53 included studies, 45 (n=2430) measured cortisol in blood (table 1). Thirteen 
studies (n=512) used either the dexamethasone suppression test (DST) or short 
synacthen test (SST) (which included a random, pre-test, measure of blood cortisol), 
18 (n=1419) measured cortisol in blood in the early morning and 13 (n=532) 
measured diurnal cortisol levels. The remaining eight measured salivary (n=182), 
urinary (=94) and/or cerebrospinal fluid (CSF) (n=53) cortisol. There was variability 
in time from stroke to first sample being taken (median 1 day, interquartile range 
(IQR) 1-3 days, range 0-111 days).  
 
2.3.2 Cortisol levels and changes over time following stroke 
 
Cortisol after stroke 
Cortisol levels in blood (n=2242) at baseline (i.e. at the time of recruitment) following 
admission to hospital ranged from 200 nmol/L (Anne, Juha et al. 2007) to 1120 
nmol/L (Zhao, Liu et al. 1989). The majority of studies (28 studies, n =1562) found 
that cortisol levels were high (outwith the reference range) within the first week after 
stroke onset. Eight studies compared baseline cortisol levels to those in controls. The 
majority of controls were healthy age-matched individuals; one study included both 
healthy controls and controls admitted with non-stroke acute medical conditions 
(Olsson, Astrom et al. 1989). Three of these studies found no significant difference 
(n=187) (Olsson, Marklund et al. 1992, Gustafson Y 1993, Marklund, Peltonen et al. 
2004), four (n=163) (Zhao, Liu et al. 1989),(Burd and Sergeeva 1981, Olsson, Astrom 
et al. 1989, Atanassova, Terzieva et al. 2009) found significantly higher cortisol in 
stroke patients and one study (n=25) found that male, but not female, stroke patients 
had significantly higher cortisol compared to controls (Elwan, Abdallah et al. 1990).  
 
Changes in cortisol over time 
Thirteen studies (n=567) measured cortisol at two or more time points on different 
(non-consecutive) days and reported changes over time. Five studies (n= 264) 
reported that cortisol fell (Davalos, Ricart et al. 1996, Espiner, Leikis et al. 2002, 
Marklund, Peltonen et al. 2004, Giordano, Aimaretti et al. 2005, Poll, Bostrom et al. 
2010), with two of these (n=106) (Espiner, Leikis et al. 2002, Marklund, Peltonen et 
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al. 2004) reporting cortisol levels within the reference range at follow up (4 days and 
2 weeks respectively) in all participants. One study (n=22) reported low (below the 
reference range) serum cortisol in all subjects after stroke for the duration of the study 
period (nine days on average)(Schwartz, Carlucci et al. 2004). Two studies found 
persistent elevation of cortisol over the duration of their study period, one of which 
studied participants up to day five after stroke (n= 23) and one up to one month after 
stroke (n= 111) (Fassbender, Schmidt et al. 1994, Zierath, Tanzi et al. 2011). One 
study reported a peak of cortisol at day 5, with troughs at day 1-2 and day 8 
(n=26)(Lanterna 2013). Four studies (n=121) reported that cortisol was within the 
normal reference range over the entire study period (ranging from seven days to three 
months).  
 
Dexamethasone Suppression Test (DST) after stroke 
Nine studies (n=347) used the DST (median day of first test; day 5 post stroke, IQR 
2.8-5.8 days); all reported non-suppression of cortisol in stroke participants (Jenkins, 
Buckell et al. 1969, Finklestein, Benowitz et al. 1982, Reding, Orto et al. 1985, 
Olsson, Astrom et al. 1989, Olsson 1990, Olsson, Marklund et al. 1992, Gustafson Y 
1993, Harney, Fulton et al. 1993, Terroni 2015). This persisted over time in the three 
studies that repeated the test (median day of second test day 17.5 post stroke, IQR 3.5-
28 days). 
 
Diurnal variation in cortisol after stroke  
Eleven studies (nine using blood and two using saliva) analyzed diurnal variation in 
cortisol. Six studies measured cortisol twice during a 24 hour period (morning and 
evening) and the remainder took measurements four times during a 24 hour period 
(generally early morning, mid-morning, early evening and just before bed). Five 
(n=196) found that diurnal variation was lost in those with more severe strokes (as 
determined by a validated scoring scale, for example the Scandinavian Stroke Scale) 
but preserved in those with more minor strokes (Murros, Fogelholm et al. 1993, 
Szczudlik, Dziedzic et al. 2004, Anne, Juha et al. 2007, Atanassova, Terzieva et al. 
2009, Poll, Bostrom et al. 2010). Two studies (n=82) (Johansson, Ahren et al. 2000, 
Slowik, Turaj et al. 2002) found that diurnal variation was lost in those with high 
baseline cortisol, but did not assess whether this was associated with stroke severity. 
One study found enhanced diurnal variation in those diagnosed with anhedonia 
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(n=36) (Terroni 2015). One study (n=22) (Schwarz, Schwab et al. 2003) found that 
diurnal variation was lost between days one and seven after stroke, and one study 
found that over half (17/22) of their participants had an abnormal diurnal variation in 
the first week after stroke, but at one month this change persisted in only two 
participants(Jenkins, Buckell et al. 1969). Finally, one study which recruited only 
those with mild stroke (n=17) (Theodoropoulou, Metallinos et al. 2006) found that 
diurnal variation was preserved in all participants. 
 
2.3.3 Associations between cortisol and stroke severity 
  
Eighteen studies investigated the associations between cortisol and stroke severity (of 
these 18, four included only those with a SAH). 
 
Ischaemic or haemorrhagic stroke 
 Stroke severity was measured using a variety of rating scales, however the most 
frequently used scales were the National Institutes of Health Stroke Scale (NIHSS) 
and the Scandinavian Stroke Scale (SSS). Twelve studies (n=1155) found a 
statistically significant correlation between elevated cortisol levels and more severe 
strokes(Reding, Orto et al. 1985, Olsson 1990, Olsson, Marklund et al. 1992, Murros, 
Fogelholm et al. 1993, Fassbender, Schmidt et al. 1994, Slowik, Turaj et al. 2002, 
Christensen, Boysen et al. 2004, Anne, Juha et al. 2007, Urra, Cervera et al. 2009, 
Neidert, Katan et al. 2011, Zierath, Tanzi et al. 2011, Tu 2013) and one (n=25) found 
an association (not statistically significant)(Finklestein, Benowitz et al. 1982) . The 
remaining five (n=262) found no association (Olsson, Astrom et al. 1989, 
Theodoropoulou, Metallinos et al. 2006, Harms, Reimnitz et al. 2011, Dziedzic, Pera 
et al. 2012, Wahab 2015).  
 
Subarachnoid haemorrhage 
Subarachnoid haemorrhage severity was measured using the Hunt-Hess score, the 
Fisher score or the Glasgow Coma Scale score.  Of the four studies involving only 
participants with a SAH, one (n=51) found a small correlation between higher 
morning cortisol levels and Glasgow Coma Scale 22,  one (n=60) found a correlation 
between higher cortisol and the Fisher scale(Parenti, Cecchi et al. 2011), one (n= 25) 
found a negative correlation between cortisol concentrations and the Fisher CT 
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grade(Shin, Joo et al. 2011) and one (n=30) found no correlation between urinary 
cortisol and the Hunt-Hess score(Bendel, Koivisto et al. 2008).  
 
2.3.4 Associations between cortisol and stroke outcome (including dependency, 
morbidity and mortality) 
 
Cortisol, dependency and length of stay 
Twelve studies (n=1131) reported the association between cortisol and dependency, 
of which nine (n=1011) found that higher cortisol was associated with more 
dependency(Feibel, Hardy et al. 1977, Murros, Fogelholm et al. 1993, Johansson, 
Ahren et al. 2000, Slowik, Turaj et al. 2002, Christensen, Boysen et al. 2004, 
Marklund, Peltonen et al. 2004, Dimopoulou, Kouyialis et al. 2005, Neidert, Katan et 
al. 2011, Tu 2013), and three studies (n=120) did not(Reding, Orto et al. 1985, 
Fassbender, Schmidt et al. 1994, Schwarz, Schwab et al. 2003) (table 1). Of the nine 
studies which found an association, eight measured cortisol within 24 hours of stroke 
onset, as did two out of the three studies which found no association. Three studies 
reported the relationship between cortisol and length of stay; two (n=38) reported that 
higher cortisol was associated with a longer length of intensive care unit stay(Poll, 
Bostrom et al. 2010) (Weant, Sasaki-Adams et al. 2008), and one of these also found 
an association between higher cortisol and overall length of stay(Weant, Sasaki-
Adams et al. 2008). The third study (n=25) found no relationship between cortisol and 
length of hospital stay, however this study was in a rehabilitation hospital, and so 
cortisol was measured relatively late (mean of 37 days) after stroke(Finklestein, 
Benowitz et al. 1982). 
 
Cortisol and morbidity 
Five studies examined the relationship between cortisol and delirium. Three (n=187) 
found a correlation between elevated cortisol and delirium(Olsson, Marklund et al. 
1992, Gustafson Y 1993, Marklund, Peltonen et al. 2004), one (n=20) found a non-
significant trend towards this association(Olsson 1990) and one (n=23) found that a 
high adrenocorticotrophic hormone level (ACTH) was associated with 
delirium(Fassbender, Schmidt et al. 1994) (see table 1 for summary of effect sizes). 
Five studies examined the relationship between cortisol and depression. Three studies 
(n=117) found a correlation between an abnormal DST and depression(Finklestein, 
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Benowitz et al. 1982, Reding, Orto et al. 1985, Theodoropoulou, Metallinos et al. 
2006) one (n=12) found a non-significant association between higher cortisol and 
depression(Harney, Fulton et al. 1993) and one (n=62) found no relationship(Olsson, 
Astrom et al. 1989). Finally, one (n=66) study investigated the relationship between 
cortisol and infection and found a positive correlation(Harms, Reimnitz et al. 2011), 
two studies (n=131)  investigated the relationship between cortisol and blood pressure 
and also found a positive correlation(Feibel, Hardy et al. 1977, Ahmed, De La Torre 
et al. 2004) and one study(n=44)   found an  association between electrocardiographic 
abnormalities after SAH and elevated morning cortisol levels(Djurdjevic, Jovanovic 
et al. 2010). 
 
Cortisol and mortality 
Of the eleven studies (n=1084) (Feibel, Hardy et al. 1977, Korsic, Brinar et al. 1990, 
O'Neill, Davies et al. 1991, Murros, Fogelholm et al. 1993, Slowik, Turaj et al. 2002, 
Christensen, Boysen et al. 2004, Marklund, Peltonen et al. 2004, Anne, Juha et al. 
2007, Weant, Sasaki-Adams et al. 2008, Neidert, Katan et al. 2011, Tu 2013) which 
examined the relationship between cortisol and mortality, all found that elevated 
cortisol was associated with increased mortality (see table 1 for summary of effect 
sizes);  this was not statistically significant in two of the studies (n=39)(O'Neill, 
Davies et al. 1991, Weant, Sasaki-Adams et al. 2008). 
 
Cortisol and outcome, independent of stroke severity 
Only six studies adjusted for stroke severity when examining the relationship between 
cortisol and outcome. Four studies (n=693) (Christensen, Boysen et al. 2004, Anne, 
Juha et al. 2007, Neidert, Katan et al. 2011, Tu 2013) found that cortisol was 
independently associated with death after stroke and three out of four (n=642) also 
found higher cortisol to be independently associated with poorer functional outcome 
(Christensen, Boysen et al. 2004, Neidert, Katan et al. 2011, Tu 2013). The remaining 
two studies (n=215) found that cortisol was not an independent predictor of outcome 







2.3.5 Methodological Quality 
 
The STROBE score ranged from 6-21, with a median score of 18 (appendix 2). The 
lower quality studies (particularly those with a STROBE score of less than 10) did not 
report the relationship between cortisol and stroke outcome, and so these papers will 



































































Duplicates removed using EndNote: 333 
 
53 studies were excluded for the following reasons: 
 3 not in English and unable to translate 
 19 had no primary data 
 7 included participants under 18 
 7 involved less than 10 stroke patients 
 8 used patients who had a stroke more than 1 
year before study 
 1 used patients with TIA, not stroke 
 2 included TIA patients and can’t separate 
the data 
 2 included patients with brain injury and not 
just stroke 
 2 were wrong study kind e.g. RCT 
 1 used same study population as another 
included study 
 1 not in peer reviewed journal 
  
11268 titles and abstracts screened 
106 full texts obtained 
 
53 studies included in final review 
 
11162 studies excluded 
Number of Studies retrieved from initial searches: 
 Medline: 3720 
 EMBASE: 7881 
 Psychinfo: 1431 
 Total 11601 
Reference lists of key papers scrutinized and 7 





This is the first systematic review of studies of cortisol levels in relation to stroke 
severity and outcomes. Fifty-three studies met our inclusion criteria. The 
methodological quality of these studies was generally high. 
 
Summary of main findings 
Cortisol levels were high (meaning above the reference range (absolute range 200 
nmol/L(Anne, Juha et al. 2007) to 1120 nmol/L(Zhao, Liu et al. 1989))) in the first 
seven days after stroke onset.  Those studies including participants with less severe 
strokes (not requiring critical care) found a decrease in cortisol over the first week 
following stroke. By three months cortisol levels were generally in the normal 
reference range, for all strokes regardless of severity. We are not able to conclude 
what the trajectory of cortisol is between these two time points (seven days and three 
months) as few studies investigated this. Diurnal variation in cortisol appears to be 
lost in those with more severe strokes, but is preserved in those with more minor 
strokes. 
Elevated cortisol levels were correlated with increased stroke severity in the majority 
of studies that explored this association. Studies tended to find that elevated cortisol 
levels were associated with higher dependency, length of hospital stay, depression, 
delirium and mortality. The association between cortisol levels and delirium was 
examined in five of the included studies. Overall the majority (three out of five 
studies, n=117) found an association between higher cortisol levels and development 
of delirium, although one study found no association (n=62) (Fassbender, Schmidt et 
al. 1994) however the major limitation to all of these five studies is the small sample 
size (n ranged from 12-88). None of these five studies reported a power calculation, 
and it is unlikely that any of them were adequately powered (individually at least) to 
draw firm conclusions about associations between stroke and delirium. However, they 
do provide a signal that there might be an association, which requires further 
exploration. It is important to note that even if an association were shown in larger 
studies, we do not know the direction of causality- whether stroke precipitates high 
cortisol levels which causes delirium, or whether pre-existing high cortisol 






Discussion about the included studies 
There are some limitations in the included studies: Only one of the included studies 
reported sample size calculations and several studies only measured cortisol on one 
occasion rather than exploring changes over time, meaning that short-term 
physiological stressors such as acute illness may have contributed significantly to the 
cortisol levels reported. Furthermore, all the studies recruited participants from a 
hospital setting, meaning that results may not be applicable to those with minor 
strokes. Thirteen studies (Jenkins, Buckell et al. 1969, Finklestein, Benowitz et al. 
1982, O'Neill, Davies et al. 1991, Davalos, Ricart et al. 1996, Johansson, Ahren et al. 
2000, Christensen, Boysen et al. 2004, Christensen, Johannesen et al. 2004, 
Szczudlik, Dziedzic et al. 2004, Theodoropoulou, Metallinos et al. 2006, Lueken, 
Leisse et al. 2009, Michalaki, Margeli et al. 2010, Wahab 2015) included only those 
able to provide informed consent, meaning that those with aphasia or delirium would 
have been excluded. This could have reduced the generalizability of the findings 
particularly as delirium has been found to be associated with higher cortisol 
(Gustafson Y 1993).  It is also possible that the results presented are confounded by 
unmeasured variables, for example an association between cortisol and stroke may 
reflect a causal relationship with a hormone, neurotransmitter or other physiological 
parameter which was not measured in any of the included studies. Finally, it must be 
acknowledged that the STROBE statement, used to assess quality of the included 
studies, gives equal weight to all aspects of quality, such that providing information 
about the source of funding for the work is given the same marks as providing 
appropriate statistical analysis, when although both of these points are important, the 
analysis is (arguably) more crucial to the overall quality of the paper.  
 
Strengths of the review 
This systematic review has several strengths. The protocol had pre-defined inclusion 
and exclusion criteria. Screening and data extraction was performed independently by 
two authors, reducing the risk of transcription and data extraction error or omission. 






Limitations of the review 
Some limitations of this review should be acknowledged. I did not include abstracts 
from conference proceedings, however this was deliberate crucial details are often 
missing from these publications. Only six abstracts of conference proceedings would 
have met the inclusion criteria. From the limited information available in these 
proceedings, interestingly, it would appear than none of them reported negative 
findings, with four out of six reporting abnormalities in cortisol after SAH(Djurdjevic, 
Jovanovic et al. 2010), (Takala, Laukka et al. 2013), (Hannonl, Behan et al. 2012), 
(Tolli, Bellander et al. 2010) one reporting evening cortisol levels above the reference 
range after ischaemic stroke(Lee, Kim et al. 2011) and one reporting an association 
between high cortisol and stroke severity(Hall, Malik et al. 2010).    Ischaemic and 
haemorrhagic strokes, including SAH, were included in the review. It could be argued 
that as SAH has a different aetiology and risk factor profile to ischaemic and 
haemorrhagic stroke, it should have been excluded; however I have taken care to 
report the findings from those studies including SAH separately. Furthermore, SAH 
does have several factors in common with other stroke types, for example sudden 
onset of disease and long-term neurological sequelae. I was not able to perform a 
meta-analysis because the studies were too heterogeneous, particularly with respect to 
the timing and method of cortisol sampling. Finally, publication bias may have 
favored publication of those papers showing a positive association between cortisol 
and stroke, leading us to overestimate the strength of the association.  
 
Previous non-systematic narrative reviews have found a correlation between cortisol 
and functional impairment and mortality after stroke (Mitchell 1997, Olsson 1999, 
Franceschini, Tenconi et al. 2001), however two of these previous papers included 
discussion about cortisol after stroke only as part of a broader review of endocrine or 
of cognitive changes(Olsson 1999, Franceschini, Tenconi et al. 2001)  and the third, 
whilst providing a more extensive overview, was published in 1997, and consequently 
includes only 17 studies(Mitchell 1997). This systematic review provides a more 
comprehensive overview of all studies to date and synthesizes the evidence. 
 
Overall, if cortisol dysregulation was shown to be an independent predictor of poor 
outcome after stroke, even after correcting for stroke severity, this would provide 
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justification for further investigating the mechanism of this. Whilst I have found some 
evidence of an independent association between cortisol and functional outcome, and 
between cortisol and mortality after stroke, we do not know what the direction of 
causality is (no studies were able to measure cortisol pre-stroke and so it is possible 
that those with poorer outcomes may have had higher cortisol levels before stroke 
onset, for example).  Further larger studies designed to unpick the complex 
relationship between the HPA axis and stroke are required before, for example, trials 




Cortisol levels are high for at least seven days after stroke and are within the normal 
range in the majority of people by three months. Elevated cortisol after stroke is 
associated with greater dependency, morbidity and mortality. However, there is 
currently insufficient evidence to conclude that these relationships are independent of 
stroke severity. Understanding the mechanism underlying these relationships may 
allow development of therapeutic interventions to improve outcomes after stroke and 























 Consulting service users about proposed research projects is a way of ensuring that 
the study is not only acceptable to participants, but also of ensuring that the research 
questions are truly relevant to them. Furthermore, service users have been found to be 
a good way of disseminating research results into a public domain, and can offer 
valuable advice on how to present these results in a way that is accessible to the lay 
public (Hanley 2004). However, user groups have attracted some criticism and 
scepticism from the scientific community. For example, one major criticism levelled 
at user groups made up of volunteers from a large group of stroke survivors, is that 
they tend to be those who have had milder strokes and are from higher socio-
economic groups, and therefore not truly representative of the stroke survivor 
population as a whole (Hanley 2004). However, it must be acknowledged that it is not 
reasonable to expect a small number of people to be truly representative of the target 
population (in this instance, stroke survivors), and indeed in many instances it is not 
necessary for them to be so. Rather it is useful to see other perspectives despite the 
fact that they may not be representative of the whole study population (Hanley 2004).  
 
  
 3.2 Methodology 
 
A user group was convened prior to the study commencing. The group comprised of 
six service users who had recently had a stroke (within the last 12 months) and who 
were attending a community rehabilitation centre on a weekly basis. The service users 
were all residents of Edinburgh, but hailed from a variety of areas of the city. The 
median age of the service users was 64 (range 48-67). The service users were asked if 
they were happy to participate in the group, prior to my attendance, but were not 
volunteers taken from a larger pool of service users. The service users were given a 
verbal briefing about their role as a user group member and the aims of the meetings 
and were also provided with some written briefing information on the role of a user 
group and about the study (appendix 3). Two meetings were scheduled in total, one 
prior to the study commencing and one when the study had been recruiting for one 
year. Group members were interviewed together, before being given the opportunity 
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to speak to me individually about the study. The minutes of the meetings were 
collated and circulated to group members for agreement and action points based on 
the discussions were then formulated.  
 
3.2.1 The main aims of the first user group meeting were: 
 
1. To find out how the service users view the study information sheets. The 
questions posed were: 
a. Are the information sheets clear? Do you understand the study and 
what is being asked of participants 
b. Do you think the study is important?  
c. What aspects of the study do you think participants might find 
daunting or difficult and how can I best minimise these? 
d. Any other suggestions to improve the acceptability of the study to 
participants? 
 
2. To find out how the users view recruitment: 
a. When do they think the best time to approach a potential participant is 
(time of day and time from stroke) 
b. What are the potential barriers to patients agreeing to take part? 
c. How best can researchers overcome these barriers? 
 
3. To determine how users feel about the number and intensity of assessments 
and follow-up visits 
a. Will the proposed number of assessments be acceptable to stroke 
participants? 
b. Will the number of follow-up visits required seem onerous, or is the 















3.3.1 Meeting One 
 
Information Sheets: 
The group felt that the information sheets were informative and gave a good overview 
of the study. All felt that they understood the study after reading the sheet. Some 
commented that the sheet was quite long, and so they would require to be given 
sufficient time to read this and digest it. They didn’t have any specific suggestions 
with respect to changes to the sheets. 
Recruitment: 
 
Service users understood the need to recruit participants in the first few days after 
stroke. Some of the group felt that being approached about research in the first few 
days after stroke may be too much to cope with, as they found the experience of 
having a stroke very overwhelming and difficult to come to terms with. However 
some of the group members felt that they would have been interested in research even 
in the early days following stroke, as it would have provided a “welcome diversion” 
and it “would have been nice to talk to someone” who wasn’t discussing direct 
aspects of clinical care. The group agreed that following a stroke, lots of adjustments 
had to be made in terms of how they felt about themselves and in particular in terms 
of confidence. They felt that feeling “useful” as part of a study may help some people. 
They also were, however, keen to point out that fatigue was a significant feature early 
after stroke and felt that a researcher should bear this in mind. All agreed that research 
into memory and thinking after stroke would be a good thing. 
 
Number of assessments/follow-up: 
 
Some of the group felt that the number of follow-up visits in hospital might be too 
much for some people, depending on how they are feeling. The remainder of the 
group felt that as each follow-up visit will be quite short, that this would be 
acceptable. 
All agreed that they would be happy to be seen in their own home at 4 months and 1 
year. One of the group was keen to point out that planning and organisation is now 
key to his life as day to day tasks take significantly longer to perform than they used 
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to. To this end, both a letter (one week prior to the visit) and then a telephone call 
(one day prior to the visit) to remind participants of the visits were recommended. 
 
General Comments: 
The group wondered if feedback will be given to individuals about their performance 
in memory tests. They felt that if participants performed badly in the testing, this may 
be another source of worry. They did however agree that if a participant wanted to 
know the results, they should be given them, but with an explanation that this will be 
monitored over time and that any on-going problems will be investigated. All agreed 
that it would be desirable for participants to have access to the study results overall 
when they are available. A newsletter was felt to be a good way of letting participants 
knows the results.  
Conclusions and action points: 
Following the user group meeting, the study protocol was finalised, incorporating 
suggestions, such as the reminders about follow-up visits, and a plan to provide a 
















3.3.2 Meeting Two 
A second user group meeting was convened one year into the study, and four of the 
original six users were able to participate in this second meeting. The aims of the 
second meeting were: 
1. To discuss how to maximise participant retention in the study 
2. To discuss any other suggestions about how to improve the participant 
experience in the study 
 
Participant retention: 
All felt that the topic of the study is of interest and that stroke survivors are definitely 
concerned about cognition. They all felt that the number of follow-up visits would 
have an impact on retention, however they agreed that the study seems to have the 
number about right. Personal feedback about any changes in cognition and 
appropriate referral if a problem was found were thought to be the key issues which 
would ensure participants are retained. It was felt that although a newsletter would be 
interesting to read, it would be more general and so it was felt that this would have 
less impact on retaining participants. No other specific suggestions were raised in 
terms of improving retention. 
 General comments: 
The user group did not have any further suggestions about improvements to the study 
protocol. 
Conclusions and action points:  
Specific feedback to participants will be give when requested, and the participant’s 
general practitioner will be informed of any concerns regarding cognition, with the 









The user group provided useful insights into how information is presented to 
participants, both verbally and in written form and also provided some helpful 
insights into the first days and weeks after stroke and how best to recruit and retain 
participants at this vulnerable time in their lives. The group provided insights about 
how to give feedback to participants and the format this might take, and particularly 
emphasised the value of individual feedback and discussion with the researcher about 
any ongoing problems with thinking and memory, and how this is a significant 
attribute of the study.  
There are several benefits to involving service users in the planning and 
implementation of research studies. Service users are able to offer different 
perspectives to health care professionals, and can help to ensure that issues important 
to them are prioritised. Service users may also help to ensure that money and 
resources are not wasted on research which has no relevance and doesn’t just measure 
outcomes that are important to the researchers, but not to patients. Finally, service 
users can help to disseminate research results by assisting with production of 
accessible information about the results and also through contacts with other patient 
groups (Hanley 2004).  
Whilst the benefits of including a user group in the design and implementation of 
studies are acknowledged, it is also important to note that there may be some 
disadvantages to user groups. For example, it is imperative that although the 
suggestions of the stroke survivor be incorporated where possible, the scientific rigour 
of the study is not compromised in doing so. Suggestions of the user group can also 
lead to ethical and scientific conflicts in protocol design. For example, a study 
designed to investigate the role of routine oxygen supplementation after stroke found 
that their user group would prefer to have a waiver of consent for those without 
capacity rather than proxy consent, as they felt that the doctor looking after them 
would be better placed to make the decision about study entry, than a family member, 
who may be more “emotionally involved” with the patient (Ali 2005). This also 
illustrates the importance of education and guidance for the user group, in particular 
about the role and remit of the group, before the main meetings are arranged. It is 
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more costly and time consuming to involve service users in research. Generally, 
whilst the service users are not paid for their involvement, expenses are met by the 
research fund.  Finally, it is important that consideration is given to selection of the 




























Chapter 4: General Methods 
 
 
4.1 Study Design 
 
The study comprised of a cohort of participants admitted to the acute stroke unit at the 




Ninety-five participants were recruited from the acute stroke unit at the Royal 
Infirmary of Edinburgh. The recruitment flow chart is shown in figure 4.1. 
 
Inclusion criteria were:  
1. Clinically confirmed stroke (by a stroke physician) 
2. Age ≥ 60 years (because patients over the age of 60 have higher rates of 
delirium) 
 
Exclusion criteria were: 
1. Patients with a diagnosis of transient ischaemic attack  
2. Subarachnoid haemorrhage (as these patients are generally admitted under the 
care of the neurosurgeons, not the stroke physicians, and because the 
underlying aetiology is fundamentally different, i.e. usually an intracranial 
aneurysm)   
3. Other stoke mimic found on brain imaging, such as a tumour 
4. Current or recent use (within 6 months) of oral or inhaled corticosteroids 
5. Active alcohol withdrawal 
6. Inability to speak English prior to stroke 
  
 
Participants were recruited within 120 hours of stroke onset; for those participants 
who had their stroke during the night, the time of stroke onset was taken to be the 
time when they were last seen well.  Potential participants (those who met the 
inclusion criteria) were approached, in alphabetical order, by one of the clinical team 
and asked if they would like to discuss the study with the research team. I (AJB) then 
approached those patients who agreed to meet me, and discussed the study and 
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provided the written study information sheet (appendix 4). Potential participants were 
then allowed up to 24 hours to read the information and consider whether to take part. 
I then revisited, having provided sufficient time for them to consider the study, 
discussed the study, answered any questions and assessed their capacity to provide 
consent. For those deemed to have the capacity to provide informed consent, a 
consent form was completed by the participant (appendix 4) For those deemed to lack 
capacity, the study was also discussed with their next of kin (who were also provided 
with written information (appendix 4) , and subsequently asked to complete a consent 
form (appendix 4)). Proxy consent was then obtained for those who provided assent to 
participate, but who lacked the capacity to provide informed consent themselves (e.g. 
because of aphasia, delirium or dementia). Participants who lacked capacity at 
recruitment, and for whom proxy consent was obtained, but who regained capacity 
during the course of the study (for example because of resolution of delirium or 
improvement in aphasia) were retained in the study, providing they were agreeable to 
continue and to sign a consent form.  
 
Participants with aphasia were provided with accessible information sheets (see 
appendix 5) to aid their ability to understand the study, however the Research Ethics 
Committee required that if a participant had severe enough aphasia to require the 
aphasia friendly information, proxy consent must be obtained.  If participants were 
unable to follow basic commands due to a dense receptive aphasia, they were 
excluded from the study and if any participants remained unable to complete 
cognitive assessment after 2 weeks due to severe aphasia, they were then excluded 
from the study.  
 
Participants (and proxy’s where relevant) were provided with a copy of their signed 
consent form, and a copy was also placed in the participants medical notes. A letter 
was sent out to each participant’s General Practitioner (GP) informing them about the 
study and providing contact information, should any subsequent queries arise.  
 


























































831 admissions to stroke ward 
screened for eligibility 
304 patients met inclusion 
criteria 
95 participants recruited 
527 patients did not meet the 
inclusion criteria for the 
following reasons: 
Not a clear diagnosis of stroke: 
141 
Under age of 60: 96 
Presented late: 83 
Taking steroids: 74 
Probable TIA: 33 
Requires proxy, but no-one 
suitable: 30 
End of life imminent: 23 
Rapid discharge: 13 
Don’t speak English: 9 
Alcohol withdrawal: 7 
Vision too poor/ blind: 4 
Taking part in an incompatible 
alternative study: 4 
Not a local resident: 3 
Infected with norovirus: 1 
209 patients declined to take 
part for the following reasons: 
No reason given: 158 
Proxy declined: 27 
Feels too unwell: 14 
Going home imminently: 10 


























































Participants recruited from the 







(days 3, 28 only) 
Days  
3, 5, 7, 14, 21, 28 
Months 




4.3 Baseline data collection 
 
 
Stroke: The pathological stroke type (ischaemic or haemorrhagic), Oxfordshire 
Community Stroke Project classification (from clinical assessment performed at time 
of admission: by convention we used the maximum deficit to rate this) and National 
Institute of Health Stroke Scale score (for stroke severity, rated by me (AJB), based 
on the maximum deficit) were documented at the time of recruitment. 
 
Clinical condition: Baseline clinical observations (heart rate, blood pressure, oxygen 
saturations and temperature) were recorded at the time of recruitment, along with 
medications and admission blood results. The APACHE II (The Acute Physiology 
and Chronic Health Evaluation System II (Chisakuta 1990)) score was used as a 
measure of current illness burden. Past medical history, and current medications 




4.4 Delirium assessment 
 
Participants were assessed for the presence of delirium after the onset of stroke at 
days 1, 3, 5, 7, 14, 21 and 28, and also at 4 months and 12 months. Those recruited 
after day 1 were seen from day 3 or day 5 onwards. Those participants who were 
discharged from hospital after a short admission were seen as per protocol whilst an 
in-patient and were then seen at home on day 28 and at 4 months and 12 months. I 
(AJB) was trained in the diagnosis of delirium, and in the use of the screening tests 
employed, by experienced raters (AMJM and Dr Roanna Hall). Training involved 
reading of the manual and guidelines for each of the tests (where available) and then 
several sessions when I observed experienced raters applying the tests, and finally 
sessions where I applied the tests under observation by the experienced raters.   
 
The presence and severity of delirium was screened for using the CAM-ICU (Ely 
2001), which includes the Richmond Agitation and Sedation Scale (RASS) (Sessler 
CN 2002), and the Delirium Rating Scale-Revised-98 (Trzepacz PT 2001). Attention 
was  assessed by digit span (forwards and backwards) and a computerised testing 
77 
 
instrument validated for the detection of attentional deficits in delirium (The DEL-box 
mark 2 (Brown LJE 2012)). A diagnosis of delirium was made based on the DSM-IV 
criteria (section 1.2.5) using the results of the screening tests to help to inform the 
diagnosis, and to assess specific features of delirium (such as sleep-wake cycle, 
psychosis and so on). A diagram to show the delirium assessment procedure is shown 


















Figure 4.3 Flow chart to show the delirium assessment procedure undertaken 
at each assessment. The time required per test from the patients perspective is 














4.4.1 The Confusion Assessment Method for the Intensive Care Unit 
(CAM-ICU)  
The CAM-ICU was developed from the original Confusion Assessment Method 
(Inouye, van Dyck et al. 1990) for use by non-psychiatrists to screen mechanically 
ventilated patients in the ICU for delirium. These patients are unable to produce 
speech (sometimes termed ‘non-verbal’) and thus the tool does not require the ability 
to verbalise. This tool was therefore selected for use in the acute stroke unit, as it is 
possible to screen those with aphasia, and it has successfully been used in previous 
studies of delirium after stroke (McManus 2009). The CAM-ICU is a diagnostic 
algorithm consisting of four features, which are based on the DSM diagnostic criteria: 
1. Acute onset or fluctuating course 
2. Inattention  
3. Disorganized thinking 
4. Altered level of consciousness (assessed using the Richmond Agitation 
Sedation Scale, RASS, see below) 
It is possible to test all of the features in those who are non-verbal, for example 
participants are requested to squeeze the tester’s hand in response to the attention 
screening examination and are asked to follow a series of physical commands as part 
of the assessment of disorganised thinking (for example, they are required to hold up 
2 fingers on one hand and then to add a third finger to those being held up). Those 
who have a dense aphasia and are not therefore able to follow these instructions, were 
excluded from this study, as per the prespecified protocol, although in the participants 
recruited it was not necessary to exclude anyone for this reason. It is also possible to 
test the features in those who have a hemiparesis following stroke, as all of the 
commands can be completed using just one arm. The CAM-ICU has been shown to 
have a sensitivity of 93-100% and specificity of 98-100%, and a high inter-rater 
reliability (κ = 0.96) in the detection of delirium (Ely 2001), although this was in the 
general ICU population, not specifically after stroke (the gold standard against which 
the CAM-ICU was rated was a psychiatrist assessing the patient and diagnosing 
delirium using DSM-IV criteria). Indeed, in non-critically ill hospitalised patients the 
CAM-ICU has been shown to have poor sensitivity (18%), although very high 
specificity (>98%) for diagnosis of delirium (Neufeld, Hayat et al. 2011), and so the 
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CAM-ICU algorithm was not the cornerstone of making a diagnosis of delirium, 
rather it was used to help inform the diagnosis, based on DSM-IV criteria.   
 
4.4.2 The Richmond Agitation and Sedation Scale (RASS) 
 
The Richmond Agitation and Sedation scale (Sessler CN 2002) is an integral part of 
the CAM-ICU and is a measure of alertness. It is an observational scale, with a score 
of 0 equating to the participant being ‘alert and keenly responsive’. The scale ranges 
from -5 (unrousable) to +4 (combative). The RASS has been shown to have good 
sensitivity (82%) and specificity (85%) for diagnosis of delirium (compared with the 
gold standard of a psychiatrist making a diagnosis based on DSM-IV criteria) in the 
general elderly (aged >65) Emergency Department population (Han, Vasilevskis et al. 
2015). 
 
4.4.3 The Delirium Rating Scale-Revised-98 (DRS-R-98) 
The DRS-R-98 is a 16 item, clinician rated scale, which includes 13 severity items 
and 3 diagnostic items. It has been shown to have a sensitivity of 92% and specificity 
of 95%, when a cut-off score of 17.75 is used to detect delirium (those with a score of 
> 17.75 have a positive screening test for delirium), however this is in a non-stroke 
population (Trzepacz PT 2001). The scale has also been found to be particularly 
useful in longitudinal studies where repeated measurements, including documentation 
of small changes in symptoms, are desirable (Trzepacz PT 2001). The DRS-R-98 was 
initially designed to evaluate the breadth and severity of delirium, and unlike other 
delirium rating scales (such as the CAM) was not based on any particular diagnostic 
criteria. In this study information from the nursing and clinical notes, as well as 
information gathered from interviewing the participant, was used to complete all 
sections of the DRS-R-98. This included responses given in the MoCA, where 
relevant, for the sections assessing memory, orientation and visuospatial ability. There 
are some inherent problems with the DRS-R-98 scale, for example it does not contain 
any items that assess for abnormal level of arousal, which as previously discussed, is a 
key feature of delirium. Furthermore, the score for the DRS-R-98 is more likely to be 
confounded by underlying dementia, as the scale includes memory items, although a 
recent study on a population with a high dementia prevalence found that the DRS-R98 
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performed well compared with diagnosis based on  DSM-IV and International 
Classification of Diseases 10th edition (ICD-10) criteria (Sepulveda E et al 2015). The 
DRS-R-98 is a linear scale, with each item scoring either 0-3 or 0-2 points. The points 
are then added together to give a final score, with a higher score indicating more 
severe delirium. This means that equal weighting is given to inattention and long-term 
memory problems, but as I have already described inattention is the core feature of 
delirium, whereas long-term memory impairment may be associated with dementia, 
rather than being a manifestation of delirium. Finally, as some items may be reliant on 
participant recollection (if features such as hallucinations are not documented in case 
notes or recalled by clinical staff) inaccuracies resulting in a lower score may be 
introduced. For these reasons, once again the DRS-R-98 was not used to diagnose 
delirium, but rather to help to inform the diagnosis, based on DSM-IV criteria and to 
assess specific features and how they changed over time. 
4.4.4 Digit Span Forwards and Backwards (from the Wechsler Adult 
Intelligence Scale III). 
 
Digit span consists of progressively lengthening strings of numbers, read aloud by the 
tester and repeated aloud by the subject. The numbers are repeated in the same order 
given by the tester for the Digit Span Forwards test, and are repeated in reverse order 
for the backwards strand of the test. The scale is a test of attention and concentration 
and hence performance will be hindered by delirium, and is also a test of working 
memory and executive function (Golden 2002). Digit span scores are influenced by 
prior cognitive ability (IQ) and are detrimentally affected by the presence of dementia 
(Tieges, Brown et al. 2014). The value of objective tests for attentional deficits (rather 
than subjective judgements made from an overall clinical impression) have been 
demonstrated in several studies, although there is no current consensus as to which 
test is best employed to measure attention in studies of delirium (Tieges, Brown et al. 
2014). Ideally any such test should be simple from a cognitive testing point of view, 
but demanding in terms of testing attention. Digit Span is discussed in more detail as a 
cognitive test in section 6.3.3.5.      
 
4.4.5 DEL-box Mark 2 
 
The Edinburgh Delirium Test Box Mark 2 (DEL-box, figure 4.4) is a computerised 
battery powered device which has been produced to provide sustained visual attention 
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tasks, as an assessment for the presence of delirium, which do not rely on the 
subjective assessment of the participants behaviour (Brown LJE 2012). The test box 
comprises two large illuminating response buttons, which light in a random fashion. 
Each task requires the subject to count the total number of illuminations they see. The 
tasks increase in complexity, with increasingly complex distracting stimuli being 
added to progressive tasks. The testing protocol used in this study consisted of seven 
test series, of increasing complexity, with one point  scored for each correct test series 
response (the maximum score therefore being seven). In a small study (n=58) the 
DEL-box was shown to have good accuracy at distinguishing delirium from dementia 
and at distinguishing delirium from cognitively normal controls (Brown LJE 2012). 
The DEL-box Mark 2 has not been tested before in stroke patients, and in stroke 
patients in particular, visual fields should be checked prior to commencing the test, to 
ensure that a visual field deficit doesn’t confound the test. If a homonymous 
hemianopia (or other visual field defect which may have significantly affected the 
participant’s ability to complete the test) was detected, the DEL-box testing section of 












4.4.6 The Observational Scale of Level of Alertness (OSLA) 
 
The OSLA is a tool developed in Edinburgh, with the aim of detecting the 
bidirectional spectrum of change in alertness seen in delirium (Tieges 2013). This was 
developed as existing alertness scales had been found not to provide sufficient fine 
grained detail to detect subtle changes in arousal within the same participant and 
between participants. The scale has five anchored items which assess eye opening, 
eye contact, posture, movement and communication. A score of 4 or more (out of a 
possible 19) is taken to be abnormal. As this tool has only previously been used in 





4.4.7 Chart Confusion Assessment Method (Chart CAM) 
 
For those participants who were recruited after day 1 following stroke, a retrospective 
review of casenotes was undertaken from the time of admission until time of 
recruitment, using the Chart CAM (Inouye 2005) as a frame of reference. The Chart 
CAM is a validated method for identifying delirium using chart review, and was 
found to have overall agreement with the Confusion Assessment Method (CAM)  of 
82%, and an interrater reliability kappa score of 0.41(Inouye, Leo-Summers et al. 
2005). The Chart CAM involves systematically searching casenotes for any evidence 
of acute mental status change. Although it showed reasonable agreement with the 
CAM in the initial validation study, it must be noted that this was performed in the 
United States of America, where casenotes are different to those typically found in the 
United Kingdom (UK). For example, the nursing notes may have more clinical details 
in the American notes than they would in the UK. However, the Chart CAM provides 
a validated framework for extracting clinical information about mental status from 
casenotes, and in the absence of a UK version, was adopted for this study.  Nursing 
and medical notes were reviewed, looking for any evidence of possible delirium. In 
addition to the casenote review the participant’s case was discussed with the clinical 
team, with specific reference to any concerns about acute changes in cognition, level 
of arousal and attention (and any other features that would be in keeping with a 
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diagnosis of delirium). Finally, if available, the participant’s condition over the days 
following admission to hospital was discussed with an informant. Any acute changes 
in cognition, attention or arousal (not coma), determined by casenote review and 
either informant or clinician history, which met the criteria for delirium, as set out in 
DSM-IV, were taken to be delirious episodes. 
 
 
4.5 Delirium Diagnosis 
 
As previously stated, the diagnosis of delirium was made by me, using the 
information gathered from the screening tests described above, to inform the 
diagnosis. Each of the four criteria laid out in DSM-IV (section 1.2.5) were addressed 
in turn, using the screening tool most applicable to each section to inform the 
diagnosis. For example, The OSLA and RASS scores were used to assess whether 
there was an altered level of arousal (Criterion 1), with an abnormality in either of 
these scores allowing a positive diagnosis for Criterion 1. In this same systematic way 
each criterion was addressed, with the screening tests applicable being used to inform 
the diagnosis. Criterion 1 also requires the ‘reduced ability to sustain or shift 
attention, and for this section the results of the pertinent parts of the CAM-ICU, Digit 
Span and DEL-box tests were utilised, with an abnormal score for attention in any one 
of these tests allowing a positive score for this section. The DRS-R-98, CAM-ICU, 
digit span and MoCA were all used to help inform the scoring for criterion 2 (‘A 
change in cognition or the development of a perceptual disturbance that is not better 
accounted for by a pre-existing, established or evolving dementia,’) and CAM-ICU, 
DRS-R98, Chart CAM and informant/clinician discussion were used to inform the 
diagnosis for criterion 3 (‘The disturbance develops over a short period of time 
(usually hours to days) and tends to fluctuate during the course of the day.’) Finally, 
the casenotes, laboratory results and my own clinical judgement were used to inform 
the diagnosis for criterion 4 (‘There is evidence from the history, physical 
examination or laboratory finding that the disturbance is caused by the direct 












4.6.1 Pre-morbid Intelligence Quotient (IQ) 
 
The National Adult Reading Test (NART) 
 
The National Adult Reading Test (Nelson 1991) was used to assess pre-morbid 
cognitive ability or intelligence quotient (IQ). The test was taken at the first 
opportunity when the patient was well enough to complete it (and so not during an 
episode of delirium for example).  This test requires subjects to read aloud a set of 50 
words which are irregularly spelt and have non-obvious pronunciation, for example 
“ache” and “depot”. The responses are individually scored as correct or incorrect 
according to their pronunciation and this score is used to derive a premorbid IQ 
estimate. This is based on the assumption that reading ability is independent of 
cognitive decline (due to pathological processes such as dementia) and is a strong 
predictor of intelligence in the normal healthy population. McGurn  and colleagues 
demonstrated that the NART is a valid estimate of premorbid IQ in those with mild to 
moderate dementia and several studies have demonstrated that NART correlates 
highly with full-scale IQ tests in the normal healthy population (McGurn, Starr et al. 
2004). The NART was included in the study, as pre-morbid IQ significantly affects 
performance on many cognitive tests and so needs to be adjusted for in any 
subsequent analysis (Lezak 2004). A small number of participants who had a severe 
stroke, deteriorated rapidly and died were never well enough to complete the NART.  
 
 
4.6.2 Pre-morbid cognitive impairment 
 
The Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) 
The IQCODE was used to assess for prior, undiagnosed, cognitive impairment. This 
consists of a sixteen point questionnaire which is completed by someone who knows 
the participant well (usually the next of kin). The questions relate to changes in 
various aspects of cognition over the preceding 10 years, with the informant having to 
rate whether the participant has improved, deteriorated or stayed the same over the 10 
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years. The IQCODE has been validated as a screening test for dementia, and indeed 
has been found to perform at least as well as the Mini Mental State Examination 
(MMSE) (Jorm 1995). The short form of this questionnaire was developed in 1994 
and is the version used in this study. The short form of IQCODE has been shown to 
be more suitable for detecting early cognitive decline, which is the main goal of the 
test in this study (Jorm 1995).  
 
 
4.6.3 Current cognition 
 
Current cognition was tested using a battery of neuropsychological tests described 
below, as well as the Montreal Cognitive Assessment (MoCA).  
 
Montreal Cognitive Assessment (MoCA) 
 
At baseline, 1 month, 4 months, and 12 months cognition was assessed using the 
MoCA (Nasreddine 2005). This test was selected as it has been found to have superior 
sensitivity over the more commonly used Mini Mental State Examination (MMSE) 
for detecting mild cognitive impairment (MCI) and has also been shown to have 
greater sensitivity to deficits in executive function, attention and delayed recall in 
those with cerebrovascular disease (Pendlebury 2010). The Addenbrook’s Cognitive 
Examination-Revised (Mioshi, Dawson et al. 2006) is an alternative test which is 
commonly used in clinical practice, however has the disadvantage of being a longer 
test than the MoCA and hence was felt to be too burdensome to use for those in the 
immediate aftermath of an acute stroke. The MoCA tests eight cognitive domains, 
namely visuospatial/executive, naming, memory, attention, language, abstraction, 
delayed recall and orientation. Participants are given an extra point if they have had 
12 years or less of formal education and the overall score is out of a maximum of 30 





Battery of Neuropsychological Tests 
 
The neuropsychological test battery was administered at the 1 month, 4 month and 12 
month follow-up assessments. All tests were attempted with each participant, unless 
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This test is part of the Wechsler Memory Scale-III (WMS-III) (Wechsler 1997). The 
subject is shown a series of 5 geometric designs of increasing complexity. The subject 
is given ten seconds to look at the first design, the design is then covered and the 
subject is asked to draw the design from memory. This process is repeated for the 
remaining four designs and the subject is then instructed to “try to remember all of the 
designs as later I will ask you to draw them again from memory.” After 30 minutes 
the participant is asked to draw the designs again. Once they have completed this they 
are finally asked to simply copy each design as accurately as possible, this time 
without any time restrictions and without the image being removed before they 
commence drawing. Visual Reproduction is a test of visuospatial memory, and 





2. Verbal Memory 
 
Controlled Oral Word Association Test 
 
The Controlled Oral Word Association Test was used as a test of verbal fluency. The 
first part of the  test involves the examiner giving a letter of the alphabet out loud (for 
this study the letters F, A and S, were used), and instructing the subject to speak out 
loud as many words as possible beginning with that letter in a one minute period. 
Subjects are told that proper nouns and the same words with different suffixes are not 
allowed. The second part of the test involves subjects being asked to name as many 
animals as possible in a one minute period. The animal names can begin with any 
letter. This test has been shown to be sensitive to frontal executive dysfunction 
(Hodges 2007) and semantic memory impairment. Performance is dependent on 
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education and has been shown to decline with ageing and in dementia (Hodges 2007). 
In general, category fluency (animal names) is usually superior to letter fluency.  
 
HVLT-R List Learning 
 
The Neuropsychological Assessment Battery HVLT-R List Learning Test (Stern 
2003) was used as a test of episodic memory. The test has previously been shown to 
be able to differentiate between cognitively normal older adults and those with mild 
cognitive impairment or dementia when appropriate cut-off scores are used (Gavett, 
Poon et al. 2009). The test involves subjects being asked to try to remember a list of 
12 words read aloud to them. The list is read three times and after each reading, the 
subject is asked which words they can recall. There is then a 20 minute delay (during 
which other cognitive testing is undertaken) and subjects are then asked if they can 
recall any of the 12 words (delayed recall). Finally a longer list of words is read to the 
subject, some of which were on the original list and some which were not. The subject 










The digit span forwards tests the ability of subjects to repeat a string of digits 
verbatim, beginning with two digits and increasing up to a maximum of nine 
consecutive digits. The reverse digit span tests the ability of subjects to repeat a string 
of digits in reverse order, beginning with a string of two digits and increasing up to a 
maximum of eight digits. For example the examiner may say “nine, one, seven,” and 
the subject must respond “seven, one, nine.” The numbers are read by the examiner at 
a rate of one per second, without clustering (which aids recall). This is a measure of 
attentional processes, and is dependent upon working (or “short-term”) memory, 
which in turn is dependent upon frontal executive function. Reduction in digit span 
scores is a feature of impaired attention, as seen in delirium, moderate to severe 
dementia and also in focal left hemisphere lesions (Hodges 2007). Subjects with 
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aphasia will therefore often have a reduced digit span score. In general, those with 




Digit Symbol Substitution Test (DSST) 
 
The DSST is a part of the WMS-III (Wechsler 1997) and is a test of attention and 
processing speed. Subjects are presented with rows of numbers with blank boxes 
beneath them and are required to insert the appropriate symbols in the blank boxes 
using a key given at the top of the page. The test score is the number of correct 
symbol substitutions made in 90 seconds. The DSST score shows decline with age 
(Salthouse 1992) and in cognitive impairment, although it has been shown to be very 
sensitive to cognitive changes at high levels of cognition, but less sensitive to 
cognitive changes at low levels of cognition (such as in severe dementia) (Proust-





These tests involve subjects being asked to call out the names of six rows of coloured 
dots as rapidly as possible (task one), with the time taken to complete this being 
recorded. Subjects are then asked to call out the colour of ink six rows of words are 
printed in (task two) rather than the word itself (see row 2 figure 4.5 below), and 
finally are asked to call out the colour of ink that six rows of colour words are written 
in (task three), again with the time being recorded (see row three, figure 4.5) below.  
The tests are based on the fact that it takes longer to call out the names of coloured 
dots than it would do to read aloud words, and that it takes even longer to name the 
colour of ink in which a colour word is printed, especially if the colour of the word 
and the name of the word are not the same (for example blue is printed in green ink) 
A marked slowing of response in the third task is interpreted as cognitive slowing 
which is thought to be due to poor processing speed and a failure of selective attention 
(Hodges 2007). A markedly prolonged time to complete the third task when compared 
with the first and second task has been shown to be associated with early-stage 
Alzheimer’s Dementia, as well as a variety of other brain pathologies including 




•     •     •    • 
Task one (shortened version) 
 
 
when hard and over 
 
Task two (shortened version) 
 
 
blue yellow red green 
 

























4.7 Other outcome measures 
 
At each of the follow-up visits (1 month, 4 months and 12 months), additional 
information about functional outcome was gathered as described below. 
 
Nottingham Extended Activities of Daily Living score 
 
The Nottingham Extended Activities of Daily living score (Nouri and Lincoln 1987) 
(Nottingham Extended ADL score) is a self-report questionnaire about activities 
actually done in the last few weeks. The scale has 22 ADL activities, and each activity 
is assigned a score of 0 or 1 depending on the response given. Four possible response 
options are given for each activity:  “not at all,” and “with help,” either of which score 
0 points, and “on my own with difficulty,” or “on my own,” either of which score 1 
point. The maximum score for the test is therefore 22 points. This scoring tool has 
been shown to be valid in subjects who have had a stroke (Lincoln and Gladman 
1992) and also has good test-retest reliability in this group (Nouri and Lincoln 1987) 
Whilst using a summative score for this tool as an outcome measure has been 
criticised for not providing a sensitive measure of small changes in function (das Nair, 
Moreton et al. 2011), it does provide a useful way of measuring general functional 




4.8 Salivary cortisol sampling 
 
Saliva, for measurement of cortisol, was obtained on the day of recruitment at two 
time points (0930) and (1530), and again on each subsequent assessment day at the 
same times. For the follow-up visits (1 month, 4 months and 12 months) those 
participants who were judged to have an intact swallow mechanism and be 
cognitively intact enough to follow written instructions (at the time of hospital 
discharge) were sent a saliva swab and instructions for collection of the saliva in the 
post the week before the scheduled visit. They were asked to collect a saliva sample 
on waking on the morning of my visit and to store it in their fridge for me to collect in 
the afternoon. A second sample was then collected by me in the afternoon following 
cognitive testing (at around 1530). For those who were unable to collect their own 
saliva sample, two visits were made to the participants home, one in the morning and 
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one in the afternoon. Samples were collected using either Salimetrics Oral Swabs (for 
those with an intact swallowing mechanism, as judged by the clinical team looking 
after the participant) or Salimetrics Children’s Swabs (for those with an impaired 
swallowing mechanism). These two methods of collection are equivalent with respect 
to cortisol levels, according to the manufacturer’s documentation . The swabs are 
made of an inert polymer, and are small, soft and tubular (see figures 4.6 and 4.7). 
The Oral Swabs are placed in the mouth, under the tongue or in the side of the mouth, 
and the Children’s Swabs are held in place in the participant’s mouth, by the person 
collecting the swab, for 60-90 seconds. The device collects approximately 200µL of 
saliva. Participants were closely assisted to obtain the samples and the written 
guidance on safe and effective use of the swab was closely followed. Participants 
were asked to abstain from eating, drinking, smoking or cleaning their teeth in the 20 
minutes prior to sampling, as per the guidelines for use of the swabs. Following 
collection, samples were placed in a sealed tube, centrifuged for 10 minutes at 




















































4.9 Analysis of CT brain scans 
 
All participants underwent admission CT brain scanning (within 24 hours of stroke 
onset) as part of their clinical care prior to recruitment to the study. Subjects were 
scanned in a Toshiba 64-slice or 128-slice scanner (the 64-slice scanner being 
replaced by a new 128-slice scanner during the study period). Brain scans were stored 
in the clinical Patient Archiving and Communication System (PACS). A standard 
method of extracting information on stroke lesion location, anterior and posterior 
white matter lesions (using the Van Swieten scale (van Swieten, Hijdra et al. 1990)) 
and global cerebral atrophy (Pasquini, Leys et al. 2007), which has been successfully 
used in a previous study of fatigue after stroke (Kutlubaev, Shenkin et al. 2013) and 
also in a study of thrombolytic treatment after stroke (Wardlaw JM, Bradey N et al. 
2015), was used for this study (see appendix 6) . Following recruitment to the study, 
but prior to delirium and cognitive assessments, the baseline clinical CT brain scan 
was rated using the standardised proforma previously described.  Subsequently the 
scans were rated, in batches of ten, blind to all other data, by an experienced 
neuroradiologist (Professor Andrew Farrall, AJF). Scans were read by both AJB and 
AJF so that an inter-rater reliability analysis could be performed. With the exception 
of the inter-rater reliability, all results presented in chapter 8 are based on the data 
extracted solely by AJF. Further details are presented in chapter 8. 
 
4.10 Statistical analysis 
All statistical analyses were carried out using Statistical Package for the Social 
Sciences (SPSS) version 14 and 19, with the exception of the random effects 
modelling which was carried out by Dr Mike Allerhand using the R statistics package 
and mixed effects multiple regression modelling which was carried out by Dr Daniel 
Davis using the Stata 13.1 statistics package. Assistance with the power calculation 








4.11 Power calculation  
 
Assuming a sample size of 120 participants, and a delirium incidence of 30-40 % 
(Gustafson Y 1993), the main analyses are comparisons of cortisol levels between 
patients with (~N=40) and without (~N=80) delirium. Setting alpha at p=0.05 we have 
>80% power to detect medium-sized (Cohen’s d=0.5) differences for these analyses. 
For logistic regression to determine predictors of specific cognitive decrements, 
setting alpha at p=0.05 and assuming an inter-correlation between risk factors of 0.3, 
and that 40% of participants show cognitive decline (from the time of stroke), n=84 
provides 80% power to detect an odds ratio of 2.0 and n=94 provides 80% power to 
detect an odds ratio of 1.9. Hence, an attrition rate between a quarter and a third over 
one year is tolerable. 
 
 
4.12 Ethical approval 
 
The study was approved by the Scotland A Research Ethics Committee (reference 
























It has long been hypothesised that glucocorticoids play a role in cognitive ageing, and 
indeed that glucocorticoid excess may reduce the brain’s capacity to withstand 
neuropathological insults (Sapolsky, Krey et al. 1986). The effects of glucocorticoids 
on the brain, and in particular on the hippocampus, have been described as a nonlinear 
‘inverted-U’ dose response curve. For example, in the hippocampus mild to moderate 
stressors may enhance synaptic plasticity, but more severe and prolonged stressors 
may cause hippocampal dendritic atrophy, and eventually permanent loss of 
hippocampal neurones (Sapolsky, Krey et al. 1986).  
 
As discussed in chapter 1 section 1.4, glucocorticoids (specifically cortisol in humans) 
have been hypothesised to play an important role in the pathogenesis of delirium 
(MacLullich, Ferguson et al. 2008). Physiological stressors such as surgery and acute 
illness, and indeed psychological stress, may precipitate delirium (Fong, Tulebaev et 
al. 2009). As discussed in detail in section 1.4.4.1, impaired negative feedback 
regulation of cortisol, as well as loss of the circadian rhythm, has been demonstrated 
in ageing and also in those with neurodegenerative disease (Ferrari, Cravello et al. 
2001, MacLullich, Ferguson et al. 2008). Delirium has also been shown to be 
associated with an impaired negative feedback (evidenced by an abnormal 
dexamethasone suppression test) in elderly patients with respiratory tract infection 
(O'Keeffe and Devlin 1994).     
 
There are only five previous studies of cortisol and delirium after stroke. In a small 
study (n=23), Fassbender and colleagues (Fassbender, Schmidt et al. 1994) found an 
early and large activation of the HPA axis in response to acute stroke, but did not find 
any significant difference in cortisol levels between those who did and those who did 
not develop delirium (termed “acute confusional state” in this study.) Gustafson and 
colleagues (Gustafson Y 1993) studied 83 patients with acute stroke and found that 
both basal and post dexamethasone suppression test plasma cortisol levels were 
significantly higher in those with delirium. Interestingly, this study reported that 43% 
of participants developed delirium. This is higher than the majority of other studies, 
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which have tended to report an incidence of around 25% (Shi, Presutti et al. 2012). 
Stroke severity was not reported using a score (such as the NIHSS) in this study, 
rather the severity of paresis was recorded as none, slight, extensive or total. Thirty-
five percent had no paresis, and only 16% had total paresis, suggesting that the study 
population probably did not have more severe stroke as an explanation for the higher 
delirium incidence. One possibility is that the method by which delirium was 
diagnosed was less prescriptive than that used in other studies. The authors were not 
clear as to how often participants were assessed during the first week after stroke, and 
describe using interviews with staff, patients and relatives to inform the DSM criteria, 
but are not specific about whether this information was used in isolation to make a 
diagnosis, or if objective testing was also required to confirm a diagnosis. Olsson 
(Olsson 1990) studied 20 stroke patients and found that those with “disorientation” 
had higher urinary cortisol compared with those who were orientated. This study did 
not look to diagnose delirium specifically, and those with undiagnosed dementia, for 
example, may therefore have been included in the “disorientated” group. A 
subsequent study by the same author (Olsson, Marklund et al. 1992) included 16 
participants with stroke, and found that those with an “acute confusional state” had 
significantly higher urinary cortisol following dexamethasone suppression test, when 
compared to those without acute confusional state. The major limitation of this study 
is the small sample size.  The final, and largest (n=88) of the previous studies, 
performed by Marklund and colleagues (Marklund, Peltonen et al. 2004),  found that 
high serum cortisol in the first week after stroke was associated with disorientation. 
The diagnosis of disorientation was made using a 3 point scale (of the authors’ own 
devising), and factors such as level of consciousness and orientation to time and place 
were considered. A diagnosis of delirium based on DSM criteria was not a part of the 
methodology.   
 
 
In this chapter data gathered from measurement of salivary cortisol are presented, and 
then the hypothesis that delirium after stroke is associated with high circulating levels 








5.2.1 Delirium assessment and salivary sample collection:  
 
Delirium was diagnosed in the cohort according to DSM-IV criteria, as outlined in 
chapter 4. Diurnal salivary cortisol samples were obtained from each participant at 
each assessment time point (days 3,5 and 7, day 14 and 28 and 4 months and 12 
months), and this methodology, including how samples were collected is also outlined 
in chapter 4. The normal range for salivary cortisol levels in healthy volunteers has 
been found to be 10-27nmol/l at 8am and 2-4nmol/l at 8pm (Laudat, Cerdas et al. 
1988). The ‘normal range’ of salivary cortisol levels in stroke patients is difficult to 
define, as it is dependent on stroke type, severity and intercurrent illness, amongst 
other factors (Barugh, Gray et al. 2014).  
 
 
5.2.2 Salivary cortisol analysis: 
 
Saliva was collected using Salivette Swabs, and Salivette Children’s Swabs (figure 
4.5 and 4.6 chapter 4) for those with impaired swallowing mechanism (Salimetrics, 
Newmarket, Suffolk, UK). Following collection the Salivettes were centrifuged for 10 
minutes at 3000rpm, at room temperature, and then stored at -80 ̊ C. Samples were 
transported to The Dresden LabService Gmbh (Tatzberg 47-49, 01307, Dresden, 
Germany) on dry ice, where salivary cortisol Enzyme-Linked Immunosorbent Assays 
(ELISA) were performed. 
 
  
5.2.3 Statistical analysis: 
 
Morning and afternoon cortisol levels from each time point were plotted on simple 
line graphs and morning to afternoon ratios (to explore cortisol variability throughout 
the day) were calculated and plotted. The data was then explored and histograms to 
identify the distribution of the data were plotted.  Participants were then divided into 
two groups, those who developed delirium at any time point over the course of the 
study and those who did not, and descriptive statistical analysis of the two groups was 
performed. A Mann Whitney U test was performed to compare unadjusted cortisol 






Spearman’s correlations were used to explore the relationship between cortisol levels 
and baseline characteristics of participants, specifically; age, NIHSS score, APACHE 
II score on admission, IQCODE score and Charlson Comorbidities Index. Biserial 
correlations were used to explore the relationship between cortisol levels and sex 
(binary outcome, male or female). Spearman’s correlations were used to investigate 
the relationship between cortisol levels and continuous measures of delirium taken on 
the same day as the cortisol samples (the DRS-R98 and the Del-box) and biserial 
correlations were used to investigate the relationship between cortisol and 
dichotomised (positive or negative) measures of delirium (CAM-ICU (taken on the 
same day as the cortisol samples) and delirium diagnosis at any time point during the 
12 months). For those who developed delirium, Spearman’s correlations were used to 
explore the relationship between cortisol levels on the day of delirium diagnosis and 
delirium severity (as measured by the DRS-R98) on the same day. Finally, biserial 
correlations were used to investigate the relationship between the peak morning and 
peak afternoon cortisol levels during the first 14 days after stroke (morning and 
afternoon samples taken on the same day) and diagnosis of delirium at any point 
throughout the study period and to explore the relationship between median cortisol in 





Multicollinearity was tested using variance inflation factor statistics. 
Binary logistic regression, using the enter method, was used to explore the 
relationship between delirium diagnosis at any time throughout the study (as a binary 
outcome, yes or no) and median salivary cortisol levels in the  week after stroke (day 
0-7). Models were constructed using median morning and median afternoon cortisol 
levels. The first week was chosen as cortisol levels were found to be high in the first 
week after stroke in the systematic review reported in chapter 2. A second set of 
models, using binary logistic regression were constructed using the peak cortisol 
levels (morning, afternoon and the ratio of morning to afternoon) during the first 14 
days after stroke. The first 14 days was used for this analysis (rather than the first 7 
days) in order to capture any later peaks. Important covariates selected a priori were 
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age, sex, NIHSS score, IQCODE, Charlson Comorbidities index and APACHE II 
score, thus the analysis was designed to estimate the effect of cortisol on delirium 
independent of stroke severity, acute illness severity, chronic illness burden and prior 
cognitive impairment.  
Finally a generalised linear random effects model was fitted to investigate the effect 
of cortisol (morning, afternoon and ratio of morning: afternoon) over time on 
presence or absence of delirium. This analysis was performed by Dr Mike Allerhand, 
Centre for Cognitive Ageing and Cognitive Epidemiology statistician, University of 
Edinburgh. The outcome variable was presence of delirium at any point during the 
study (yes or no), and the predictor variable was salivary cortisol level. The model 
was specified with binomial errors and a logit link function, which is appropriate for 
predicting the odds of group membership using a binary outcome variable (in this 
instance delirium, yes or no). The analysis was conducted using the GLMER function 
in the LME4 R statistics package. As these were both hypothesis-driven but also 





























95 participants were recruited, and of these 26 developed delirium at some point 
throughout the 12 month study period. Participant baseline information is summarised 
in table 5.1. Those who developed delirium were older, more likely to be female, less 
likely to be independent in activities of daily living (ADLs) prior to stroke, more 
likely to have a pre-existing cognitive impairment (evidenced by IQCODE score), 
more likely to have had a more severe stroke (as measured by the NIHSS score) and 
more likely to have had a TACS stroke, when compared with those who did not 
develop delirium. Table 5.2 summarises the timing of onset, duration and severity of 
delirium for each of the 26 participants that developed delirium during the study 
period. The median day of delirium onset was day 4 (IQR day 2 - day 6), the median 
duration was 2 days (IQR 1 day - 6 days). The median delirium severity score, at the 































Table 5.1 Baseline characteristics for the whole cohort, and for those who developed 





a Mann-Whitney U test  
b Pearson chi-square 
 
 















Age 77 years (71-84) 83.5years (79-85.3)  74 years (68.5-82) <0.001 a 
Male sex N=56 (59%) N=10 (38%) N=46 (67%) 0.013b 
Time in formal 
education 




N=81 (85%) N=17 (65%) N=64 (67%) 0.006b 
IQCODE score 3.25 (3-3.69) 3.56 (3.19-4.6) 3.19 (3.0-3.7) 0.022 a 







 NIHSS score  5 (4-8) 8.5 (5-12.75) 5 (3-7) 0.009 a 
APACHE II 
score 






















Table 5.2 Timing and duration of delirium for the 26 participants who developed 























1 12 21 9 19 
2 5 12 7 25 
3 1 12 12 27 
4 1 Participant died - 24 
5 2 Participant died - 33 
6 5 7 2 22 
7 14 15 1 11 
8 1 3 2 4 
9 4 8 4 22 
10 3 5 2 30 
11 3 Participant died - 30 
12 365 - - 22 
13 1 5 4 7 
14 6 112 - 24 
15 5 7 2 23 
16 5 7 2 17 
17 28 112 - 8 
18 5 112 - 22 
19 4 112 - 35 
20 4 5 1 18 
21 1 5 4 17 
22 5 Participant died - 28 
23 1 5 4 12 
24 28 112 - 22 
25 3 5 2 6 
26 6 14 8 23 
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5.3.1 Cortisol levels: Descriptive statistics 
 
It was not possible to obtain diurnal cortisol results for all 95 participants at each 
assessment. The reasons for missing samples were that: the participant declined, was 
too unwell to take the test or forgot to take the sample prior to a home visit. 
Descriptive data for cortisol at each time point, including number of samples 
available, are given in table 5.3. As expected, morning cortisol levels were higher 
than the afternoon levels at each time point.  Histograms for morning and afternoon 
cortisol levels taken on day 5 are shown in figures 5.1 and 5.2 (histograms for other 
time points can be found in appendix 7) and were chosen as being representative of all 
of the histograms from all of the time points cortisol was measured at. These show 
that cortisol levels are positively skewed, although this effect is lessened when 
extreme outliers are removed. However, as the data cannot be said to be normally 
distributed, non-parametric statistical analysis was used. Scatterplots (appendix 8) 
revealed two extreme outliers (participant 2 and participant 71, neither of whom 
developed delirium). All bivariate and multivariate analysis were run with and then 
without the outliers. No significant differences in results were found between these 



































Timing of cortisol sample n Median 
(nmol/L) 
IQR (nmol/L) 
9am cortisol day 3  48 23.74 17.33-30.87 
3.30pm cortisol day 3  45 14.13 9.15-19.42 
Ratio am: pm cortisol day 3  43 1.71 1.22-2.99 
9am cortisol day 5  70 24.43 18.70-32.52 
3.30pm cortisol day 5  66 14.10 10.37-19.60 
Ratio am: pm cortisol day 5  64 1.68 1.19-2.48 
9am cortisol day 7  52 21.76 16.80-30.27 
3.30pm cortisol day 7  47 12.43 10.38-16.89 
Ratio am: pm cortisol day 7  45 1.52 1.32-2.41 
9am cortisol day 14  37 22.69 16.03-29.04 
3.30pm cortisol day 14 30 12.81 9.50-17.00 
Ratio am: pm cortisol day 14  27 1.76 1.13-2.28 
9am cortisol day 28 77 22.80 17.73-34.73 
3.30pm cortisol day 28 74 12.80 9.25-17.01 
Ratio am: pm cortisol day 28 65 1.92 1.41-2.85 
9am cortisol 4 months 65 23.07 16.26-30.55 
3.30pm cortisol 4 months  74 12.62 8.65-16.49 
Ratio am: pm cortisol 4 months 59 1.83 1.20-2.60 
9am cortisol 12 months  68 24.50 17.28-21.31 
3.30pm cortisol 12 months  67 11.70 6.53-22.15 


























5.3.2 Cortisol levels in those with and without delirium 
 
Descriptive data for cortisol levels at each time point, split into those who developed 
delirium at any point throughout the 1 year study period, and those who did not are 
shown in table 5.4. Both groups showed diurnal variation in cortisol levels, with 
higher levels at 9.30 am compared with 3.30pm. Morning and afternoon cortisol 
levels in those who did and those who did not develop delirium at each time point are 
also illustrated in box and whisker plots in figure 5.3 (a-j) Line graphs illustrating 
morning and afternoon cortisol levels and variability in cortisol (as indexed by 
morning to afternoon cortisol ratio) are shown in figure 5.4 (a-c).  
 
 
5.3.3 Bivariate analysis 
 
Cortisol levels were significantly higher in the delirium group, when compared with 
the non-delirium group, at 9.30 am on day 3 (median 29.76 nmol/L versus median 
22.58nmol/L, Mann-Whitney U test p=0.04), 3.30pm on day 5 (median 18.18nmol/L 
versus median 13.45nmol/L, Mann-Whitney U test p=0.04), 9.30 am and 3.30pm on 
day 14 (am median 32.18nmol/L versus 18.35nmol/L, Mann-Whitney U test p=0.01 
and pm median 15.94nmol/L versus 11.92 nmol/L, Mann-Whitney U test p=0.02), 
3.30pm on  day 28 (pm median 16.41nmol/l versus 12.19nmol/L, Mann-Whitney U 
test p=0.03) and at 9.30 am at 4 months (median cortisol 29.81nmol/L versus 22.43 
nmol/L, Mann-Whitney U test p= 0.04). There were no significant differences 













Table 5.4 Cortisol levels: descriptive data comparing those who did and those who did not 






  Delirium 
(n=26) 
 p◊ 
 n Median IQR n Median IQR  
9.30 am cortisol 
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Figure 5.3 (a-j) Box and whisker plots of cortisol levels (morning and afternoon) for those 
who did and those who did not develop delirium 
 
 























































Figure 5.4 Line graphs of 9.30 am (a), 3.30 pm (b) and ratio of morning to afternoon (c) 
median salivary cortisol levels in those who did (blue line) and did not (red line) develop 



























Day 3 Day 5 Day 7 Day 28 Month 4 Month 12
9am median cortisol levels (nmol/L) for those 
who had delirium at any point, those who did not 
and for the whole cohort







Day 3 Day 5 Day 7 Day 28 Month 4 Month 12
3.30pm median cortisol levels (nmol/L) for those 
who had delirium at any point, those who did not 
and for the whole cohort


















5.3.4 Correlations between cortisol levels and baseline characteristics 
 
Correlations between cortisol levels and baseline characteristics are shown in table 5.5. This 
shows that 9.30 am cortisol taken on day 3 significantly correlated with age, admission 
NIHSS score and admission APACHE II score. 3.30pm cortisol on day 3, day 14 and day 28 
significantly correlated with admission APACHE II score, as did 9am cortisol at 12 months. 
3.30pm cortisol on day 3 and day 28 significantly correlated with admission NIHSS score. 
3.30 pm cortisol on day 5 significantly correlated with participants’ age as did the ratio of 
morning to afternoon cortisol at 12 months. Finally 3.30 pm cortisol at 4 months significantly 













Day 3 Day 5 Day 7 Day 28 Month 4 Month 12
Ratio of morning: afternoon median cortisol 
levels (nmol/L) for those who had delirium at any 
point, those who did not and for the whole 
cohort











Age (years) NIHSS score on 
admission 
APACHE II score 
on admission  




9am cortisol day 
3 
0.357 (p=0.013) 0.425(p=0.003) 0.503 (p=<0.001) 0.041 (p=0.798) 
 
 
0.143 (p=0.331) 0.187 (p=0.203) 
3.30pm cortisol 
day 3  
0.168 (p=0.269) 0.381 (p=0.010) 0.362 (p=0.015) -0.108 (p=0.505) -0.054 (p=0.725) 0.230 (p=0.129) 
Ratio am:pm 
cortisol day 3  
-0.002 (p=0.988) 0.009 (p=0.955) 0.159 (p=0.308) 0.004 (p=0.983) 0.159 (p=0.309) 0.203 (p=0.191) 
9am cortisol day 
5  
0.297 (p=0.012) 0.139 (p=0.251) 0.232 (p=0.054) -0.066 (p=0.609) 
 
0.012 (p=0.920) -0.085 (p=0.486) 
3.30pm cortisol 
day 5  
0.392 (p=0.001) 0.075 (p=0.547) 
 
0.237 (p=0.055) 0.085 (p=0.513) 0.02 (p=0.874) -0.098 (p=0.432) 
Ratio am:pm 
cortisol day 5  
-0.087 (p=0.493) -0.091 (p=0.477) -0.091 (p=0.472) -0.017 (p=0.898) 0.046 (p=0.720) 0.062 (p=0.626) 
9am cortisol day 
7 
-0.043 (p=0.762) -0.170 (p=0.229) -0.024 (p=0.868) 0.024 (p=0.878) 
 
 
-0.174 (p=0.216) -0.036 (p=0.797) 
3.30pm cortisol 
day 7 
0.139 (p=0.351) -0.050 (p=0.737) 0.243 (p=0.099) -0.150 (p=0.357) -0.104 (p=0.486) -0.248 (p=0.093) 
Ratio am:pm 
cortisol day 7 
-0.144 (p=0.346) -0.118 (p=0.439) -0.164 (p=0.281) 0.082 (p=0.623) -0.197 (p=0.195) 0.149 (p=0.329) 
9am cortisol day 
14 
0.338 (p=0.041) -0.052 (p=0.459) 0.303 (p=0.068) 0.134 (p=0.459) 
 
 
0.072 (p=0.670) 0.338 (p=0.041) 
3.30pm cortisol 
day 14 
0.537 (p=0.002) 0.225 (p=0.232) 0.419 (p=0.021) 0.173 (p=0.379) 0.084 (p=0.658) 0.064 (p=0.737) 
Ratio am:pm 
cortisol day 14 







9am cortisol day 
28 
0.049 (p=0.672) 0.046 (p=0.691) 0.038 (p=0.740) -0.010 (p=0.936) 
 
-0.074 (p=0.521) -0.001 (p=0.996) 
3.30pm cortisol 
day 28 
0.390 (p=0.001) 0.233 (p=0.045) 0.357 (p=0.002)  -0.048 (p=0.698) 0.273 (p=0.019) -0.182 (p=0.120) 
Ratio am:pm 
cortisol day28 
-0.203 (p=0.105) -0.213 (p=0.089) -0.220 (p=0.078) 0.008 (p=0.950) -0.219 (p=0.08) -0.11 (p=0.932) 
9am cortisol 4 
months 
0.168 (p=0.181) 0.122 (p=0.333) -0.078 (p=0.536) 0.154 (p=0.236) -0.045 (p=0.721) -0.123 (p=0.328) 
3.30pm cortisol 4 
months 
0.072 (p=0.541) 0.109 (p=0.356) 0.113 (p=0.336) 0.130 (p=0.291) 0.307 (p=0.008) -0.140 (p=0.234) 
Ratio am:pm 
cortisol 4 months 
0.033 (p=0.805) -0.070 (p=0.600) -0.165 (p=0.212) -0.011 (p=0.937) -0.251 (p=0.055) -0.112 (p=0.400) 
9am cortisol 12 
months 
-0.250 (p=0.04) 0.065 (p=0.598) -0.252 (p=0.038) -0.053 (p=0.675) 
 
0.053 (p=0.669) -0.094 (p=0.445) 
3.30pm cortisol 
12 months 




















5.3.5 Correlations between cortisol levels and measures of delirium 
 
Table 5.6 shows correlations between cortisol levels at each time point and measures 
of delirium taken at the same time point. Afternoon cortisol levels significantly 
correlated with the three delirium rating scores (DRS-R98, DEL-box and CAM-ICU) 
on day 3 and day 5 after stroke and correlated with one score (DRS-R98) on day 14 
and with two (DEL-box and CAM-ICU) on day 28. Morning cortisol levels 
significantly correlated with the three delirium rating scores on day 14 and with the 
CAM-ICU alone on day 28.   The ratio of morning to afternoon cortisol correlated 
significantly with the CAM-ICU on day 3, with all three delirium rating scores on day 
5 and with the DRS-R98 on day 28.  
There were no significant correlations between any of the cortisol measurements 

































Table 5.6 Correlations between cortisol levels at each time point and measures of 











9am cortisol day 3 0.226(p=0.063) -0.150(p=0.182) 0.187(p=0.104) 
3.30pm cortisol day 3  0.322(p=0.015) 0.412(p=0.005) -0.66(p<0.001) 
Ratio am:pm cortisol day 
3  
-0.182(p=0.121) 0.167(p=0.161) -0.256(p=0.049) 
9am cortisol day 5  0.07(p=0.29) 0.021(p=0.43) -0.010(p=0.47) 
3.30pm cortisol day 5  0.30(p=0.007) 0.259(p=0.019) -0.239(p=0.03) 
Ratio am:pm cortisol day 
5  
0.273(p=0.01) 0.336(p=0.004) 0.34(p=0.003) 
9am cortisol day 7 0.067(p=0.318) 0.029(p=0.424) -0.176(p=0.106) 
3.30pm cortisol day 7 0.126(p=0.200) -0.344(p=0.012) -0.006(p=0.483) 
Ratio am:pm cortisol day 
7 
0.071(p=0.321) 0.260(p=0.051) 0.132(p=0.194) 
9am cortisol day 14 0.343(p=0.02) -0.394(0.012) 0.453(p=0.003) 
3.30pm cortisol day 14 0.369(p=0.025) -0.144(0.233) 0.131(0.249) 
Ratio am:pm cortisol day 
14 
0.171(p=0.201) -0.315(p=0.062) 0.195(p=0.170) 
9am cortisol day 28 -0.135(p=0.121) -0.175(p=0.076) 0.234(p=0.022) 
3.30pm cortisol day 28 0.167(p=0.077) -0.37(p=0.001) 0.208(p=0.041) 
Ratio am:pm cortisol 
day28 
0.330(p=0.004) 0.209(p=0.059) -0.104(p=0.210) 
9am cortisol 4 months 0.090(p=0.243) 0.080(p=0.267) 0.180(p=0.155) 
3.30pm cortisol 4 months 0.100(p=0.204) 
 
0.092(p=0.220) NA 
Ratio am:pm cortisol 4 
months 
-0.072(p=0.299) 0.068(p=0.308) NA 
9am cortisol 12 months 0.008(p=0.008) -0.016(p=0.449) 0.050(p=0.345) 
3.30pm cortisol 12 
months 
0.205(p=0.050) -0.086(p=0.246) 0.168(p=0.089) 
Ratio am:pm cortisol 12 
months 
-0.186(p=0.074) 0.047(p=0.358) -0.076(0.279) 





5.3.6 Correlations between median cortisol levels (day 0-7) and delirium 
diagnosis 
 
Table 5.7 shows the Biserial correlations between median 9am and median 3.30pm 
cortisol levels in the first week after stroke and diagnosis of delirium at any time point 
during the study. This shows that there is a significant correlation between median 
afternoon cortisol levels and delirium diagnosis, but no significant correlation was 








Median cortisol level (nmol/L) (day 0-7) Delirium diagnosis at any point in study 
(Biserial correlation) 
Median 9am cortisol 0.170 (p=0.1) 







5.3.7 Correlations between cortisol levels at the time of delirium diagnosis 
and delirium severity 
 
The median day that delirium was diagnosed was day 5 after stroke (IQR day 4-day 
7). Table 5.8 shows the Spearman’s correlations between cortisol levels on the day of 
delirium diagnosis and delirium severity on that same day (DRS-R98). This shows 
that both 3.30pm cortisol and the morning to afternoon ratio are significantly 












Table 5.8 Correlations between cortisol levels at the time of delirium diagnosis and 
delirium severity (rated by the DRS-R98) 
 
 
Cortisol sample (nmol/L) 
 
DRS-R98 (Spearman’s rho) 
9am cortisol on day delirium diagnosed 0.225(p=0.157) 
3.30pm cortisol on day delirium 
diagnosed 
0.398(p=0.05) 
Ratio of morning: afternoon cortisol on 





5.3.8 Correlations between peak cortisol levels in the first 14 days after 
stroke and delirium diagnosis 
 
The median day that peak levels of cortisol were obtained was day 5 after stroke onset 
(IQR 3-7). Table 5.9 shows the Biserial correlations between delirium diagnosis at 
any point during the study and peak cortisol during the first 14 days. This shows that 
peak 3.30pm cortisol is significantly correlated with delirium diagnosis, but peak 
morning levels and the peak ratio are not.   
 
 
Table 5.9 Correlations between peak cortisol levels in the first 14 days after stroke 
and delirium diagnosis  
 
Cortisol sample (nmol/L) Delirium diagnosed at any point in study 
(Biserial correlation) 
Peak 9am cortisol  0.048(p=0.652) 
Peak 3.30pm cortisol 0.302(p=0.004) 
















5.3.9 Multivariate analysis: 
 
The assumptions for logistic regression including linearity and independence of errors 
were tested and met. Multicollinearity was tested using variance inflation factor 
statistics.  The models are corrected for all of the variables presented.  
 
Median 9.30 am cortisol (days 0-7): 
Complete data were available for 86 participants and the model accounted for 
between 33% and 48 % of the variance in delirium status. Table 5.10 shows the odds 
ratio and 95% confidence intervals (CI) for each of the predictor variables. This 
shows that only age and NIHSS score on admission were independent predictors of 
delirium incidence, with mean 9am cortisol (days 0-7) approaching statistical 
significance (OR 0.95, p=0.08) 
 
Median 3.30pm cortisol (days 0-7): 
Complete data were available for 83 participants and the model accounted for 
between 27% and 40% of the variance in delirium status. Table 5.11 shows the odds 
ratio and 95% confidence intervals for each of the predictor variables. This shows that 
only age and NIHSS on admission were independent predictors of delirium incidence. 
 
Ratio of median morning to afternoon cortisol (days 0-7): 
Complete data were available for 83 participants and the model accounted for 
between 30% and 45% of the variance in delirium status. Table 5.12 shows the odds 
ratio and 95% confidence intervals for each of the predictor variables. This shows that 
only NIHSS score on admission was an independent predictor of delirium incidence. 
 
Peak 9.30 am cortisol (days 0-14) 
Complete data were available for 84 participants and the model accounted for 
between 37% and 55% of the variance in delirium status. Table 5.13 shows the odds 
ratio and 95% confidence intervals for each of the predictor variables. This shows that 
only age, NIHSS score on admission and IQCODE score were independent predictors 







Peak 3.30pm cortisol (days 0-14) 
Complete data were available for 82 participants and the model accounted for 
between 27% and 41% of the variance in delirium status. Table 5.14 shows the odds 
ratio and 95% confidence intervals for each of the predictor variables. This shows that 
only participant age was an independent predictor of delirium incidence, with NIHSS 
score at admission approaching significance (OR 1.18, p=0.06) 
 
Ratio of peak morning: afternoon cortisol (days 0-14)  
Complete data were available for 80 participants and the model accounted for 
between 34% and 52% of the variance in delirium status. Table 5.15 shows the odds 
ratio and 95% confidence intervals for each of the predictor variables. This shows that 
only age, NIHSS score on admission, IQCODE score and APACHE II score were 







Table 5.10 Results of the multivariate analysis with median 9 am cortisol as the 
predictor variable. 
 
Variable Odds ratio 95% CI p 
Age (years) 1.12 1.02-1.22 0.01 
Sex (female) 1.66 0.47-5.86 0.43 
NIHSS on admission 1.31 1.09-1.57 0.004 
IQCODE score 1.71 0.66-4.41 0.27 
Charlson 
Comorbidities Index 
0.90 0.59-1.37 0.62 
APACHE II 1.10 0.86-1.41 0.44 
Median 9 am cortisol 
(day 0-7) 











Table 5.11 Results of the multivariate analysis with median 3.30pm cortisol as the 
predictor variable 
 
Variable Odds ratio 95% CI p 
Age (years) 1.10 1.01-1.19 0.03 
Sex (female) 1.61 0.45-5.74 0.46 
NIHSS on admission 1.19 1.01-1.41 0.04 
IQCODE score 1.88 0.71-4.94 0.21 
Charlson 
Comorbidities Index 
0.98 0.64-1.50 0.92 
APACHE II 1.02 0.83-1.25 0.88 
Median 3.30pm 
cortisol (day 0-7) 




Table 5.12 Results of the multivariate analysis with the ratio of median 9am to 
3.30pm cortisol levels as the predictor variable 
 
 
Variable Odds ratio 95% CI p 
Age (years) 1.08 0.99-1.18 0.06 
Sex (female) 0.49 0.13-1.90 0.30 
NIHSS on admission 1.20 1.02-1.41 0.03 
IQCODE score 1.78 0.66-4.76 0.26 
Charlson 
Comorbidities Index 
0.96 0.63-1.48 0.86 
APACHE II 1.08 0.87-1.34 0.50 
Median morning: 
afternoon cortisol 
ratio (day 0-7) 










Table 5.13 Results of the multivariate analysis with peak 9am cortisol (day 0-14) as 
the predictor variable 
 
Variable Odds ratio 95% CI p 
Age (years) 1.10 1.01-1.21 0.04 
Sex (female) 0.44 0.11-1.71 0.24 
NIHSS on admission 1.32 1.1-1.59 0.003 
IQCODE score 3.44 1.03-11.5 0.05 
Charlson 
Comorbidities Index 
0.97 0.61-1.56 0.91 
APACHE II 1.07 0.81-1.42 0.62 
Peak 9am cortisol 
(day 0-14) 




Table 5.14 Results of the multivariate analysis with peak 3.30 pm cortisol (day 0-14) 
as the predictor variable 
 
Variable Odds ratio 95% CI p 
Age (years) 1.12 1.02-1.23 0.02 
Sex (female) 1.27 0.34-4.81 0.72 
NIHSS on admission 1.18 0.99-1.41 0.06 
IQCODE score 1.96 0.71-5.41 0.20 
Charlson 
Comorbidities Index 
0.97 0.63-1.50 0.88 
APACHE II 1.01 0.81-1.25 0.97 
Peak 3.30pm cortisol 
(day 0-14) 













Table 5.15 Results of the multivariate analysis with the ratio of peak morning to 
afternoon cortisol (day 0-14) as the predictor variable 
 
Variable Odds ratio 95% CI p 
Age (years) 1.12 1.01-1.24 0.03 
Sex (female) 1.69 0.36-7.80 0.50 
NIHSS on admission 1.25 1.05-1.51 0.02 
IQCODE score 3.98 1.11-14.20 0.03 
Charlson 
Comorbidities Index 
1.03 0.63-1.70 0.90 
APACHE II 0.99 0.79-1.26 0.95 
Peak morning : 
afternoon cortisol 
ratio (day 0-14) 







5.3.10 Association between delirium and salivary cortisol over time 
 
A generalised linear random effects model was fitted, using delirium (yes or no) as 
the outcome variable and cortisol levels over time as the predictor variables. Two 
participants (participants 2 and 71) were excluded from the analysis as they were 
extreme outliers on at least one of the assessment time points (see appendix 8). The 
total number of paired cortisol measurements and delirium assessments were 335 in 
the no delirium group and 130 in the delirium group. The model showed that the 
probability of developing delirium increased per unit (nmol/L) increase in both 
morning and afternoon cortisol, but neither of these effects reached statistical 
significance (p=0.70 and p=0.46 respectively). The probability of developing delirium 
decreased per unit increase in morning to  afternoon cortisol ratio, and also decreased 
per week after stroke onset, but again neither of these effects reached statistical 







Table 5.16 Results of the generalised linear random effects model, with delirium as 












































Variable Odds ratio 95% CI p 
Morning cortisol 
(nmol/L) 
1.02 0.84-1.19 0.70 
Afternoon cortisol 
(nmol/L) 
1.05 0.82-1.25 0.46 
Ratio of morning to 
afternoon cortisol 
(nmol/L) 
0.77 0.02-2.10 0.79 
Time after stroke 
(weeks) 
0.99 0.85-1.10 0.87 
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5.4 Discussion:  
 
This study is the largest to date to examine the associations between cortisol levels 
and delirium after stroke. Afternoon cortisol levels were found to be higher in those 
diagnosed with delirium in the first 14 days after stroke, and afternoon cortisol levels 
also correlated with delirium severity.  Morning cortisol levels were not associated 
with delirium diagnosis or severity in bivariate analyses. There was no evidence that 
cortisol was an independently associated with delirium, once confounders had been 
controlled for, although morning cortisol levels in the first 2 weeks after stroke 
approached statistical significance (OR=0.95, p=0.08). Only advancing age and 
NIHSS score were consistently independently associated with delirium in the 
multivariate analysis. Finally, there was no evidence from generalised linear random 
effects modelling to support a role for cortisol in the pathogenesis of delirium after 
stroke in the 1 year following acute stroke in this study.  
 
 
A relationship between salivary cortisol and delirium after stroke remains 
conceivable. It is known that physiological and psychological stressors may 
precipitate delirium (MacLullich et al., 2008) and furthermore, we have shown in 
chapter 2 that acute stroke is associated with elevated cortisol levels, particularly in 
the first 7 days.  As previously discussed, at present there are just five published 
studies which have investigated the relationship between cortisol levels after stroke 
and delirium (Fassbender et al., 1994, Gustafson Y, 1993, Marklund et al., 2004, 
Olsson, 1990, Olsson et al., 1992), with four out of five (n=207) reporting higher 
cortisol levels in those with delirium and one reporting no difference (n=23).  
However, all have a small sample size (median n=23, IQR18-85.5) and none of them 
measured either cortisol nor screened for delirium with the frequency or regularity of 
this study.  Whilst we have failed to show an independent relationship between 
cortisol and delirium, there does seem to be a tendency towards higher cortisol in 
those with delirium. It must be acknowledged that the power calculation used to 
determine the sample size for this study, was based on an incidence of delirium of 
40% (as found in the study by Gustafson and colleagues) (Gustafson Y, 1993). More 
recent studies have tended to find a lower incidence of delirium after stroke (around 
25% in a recent systematic review (Shi et al., 2012)), which may partly be accounted 
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for by the advent of new treatments for acute stroke (such as thrombolysis) and the 
universal provision of stroke unit care. This means that this study had less power to 
detect the effect of cortisol on delirium, than was originally predicted. A larger study 
with greater power would be needed to establish whether cortisol truly has an 
independent effect on delirium status, or whether it is simply a marker of other 
factors, such as stroke severity. It must be noted that large studies in this patient 
population are difficult to do, because participants are often very unwell following 
stroke and yet must be assessed for delirium and have cortisol levels measured 
regularly. Proxy consent is often required (either because of the severity of stroke or 
because of pre-existing dementia) and this, along with the fact that a long-term 
follow-up period is desirable (because delirium can persist) make recruitment 
challenging. These difficulties are reflected in the small sample sizes in previous 
studies. Meta-analysis would also be challenging with the studies currently available, 
as methodologies employed vary considerably from study to study, particularly in the 
method of cortisol measurement. 
 
Stroke severity (as measured by the NIHSS score) and age were both independently 
associated with delirium in this study. This is interesting, and supports the existing 
evidence with respect to predictors of delirium after stroke. The largest study of 
delirium after stroke to date (n=527) (Oldenbeuving et al., 2011) found that stroke 
severity and age were independent predictors of delirium (although age only became 
an independent predictor if brain atrophy was left out of the model, presumably 
because the two may co-vary), and as previously described these factors both have 
plausible pathophysiological mechanisms which might explain their consistent 
association with delirium. Age is associated with neurone loss, reduced blood flow to 
the brain, and reduced vascular density in the brain, all of which may increase 
susceptibility to delirium. Pathological processes in the brain such as those seen in 
vascular dementia or Alzheimer’s dementia are also more common in the ageing 
brain, and these also increase the risk of delirium (Maldonado, 2013). Stroke severity 
is a complex variable, as the severity score may not always correlate with the actual 
size of the brain lesion, although in many cases it will. Furthermore, stroke severity is 
not necessarily a marker of overall illness severity, although again there is often a 
correlation between the two (and those with a large TACS are also more at risk of 
intercurrent illness, such as pneumonia). However, overall the stroke severity score is 
129 
 
a marker of the direct brain insult and subsequent brain tissue damage and loss 
(Mitsias et al., 2002), all of which are likely to increase the risk of delirium.  
 
 
Only one previous study, by Ahmed and colleagues (Ahmed et al., 2004) examined 
salivary cortisol levels after stroke (rather than plasma or urinary levels). It found a 
mean salivary cortisol level (at admission) of 18.4nmol/L in the morning and 
6.7nmol/L in the afternoon. In this study I found a mean morning level of 25.9nmol/L 
and a mean afternoon level of 17.7 nmol/L during the first week after stroke. The 
reason for the slightly higher levels in this study are not clear. It may partly be 
accounted for by the fact that collection devices and assays used differed, however 
assays in this study were calibrated to industry standards. Stroke severity is known to 
influence cortisol levels in a bidirectional fashion, in that those with very severe 
strokes in ICU have been shown to have low cortisol levels and lose the diurnal 
circadian rhythm , whereas more generally the more severe the stroke, the higher the 
cortisol level is (Barugh et al., 2014). The mean NIHSS score in the Ahmed study was 
7, and the median NIHSS in this study was 5, indicating similar stroke severity. The 
Ahmed study was smaller (n=58) and the study participants were younger (mean age 
of 66, compared with 77 in this study), and although delirium wasn’t reported, it’s 
incidence is likely to have been lower, because participants were younger (and 




There are some limitations to this study. Participants were recruited as soon after 
stroke as possible, however because the time of stroke onset was taken to be when the 
participant was last seen well, there were delays between this time and first 
assessment. There were also delays when proxy consent was required, as proxies, 
understandably, often required 24 hours or more to consider the study before granting 
consent. These factors meant that some participants were not assessed, nor did they 
have salivary cortisol measured until day 5 after stroke onset.  Participants were not 
assessed every day following recruitment, rather they were assessed on alternate days. 
This methodology was used to reduce the burden of assessments for participants, 
however the chart-CAM and clinician and informant information was used to provide 
information about the days when formal assessments weren’t scheduled. It is possible 
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that brief episodes of delirium were missed, although this could also be the case if 
participants were assessed daily. There was selection bias in the study, as proxies 
were more likely to decline consent compared with potential participants themselves, 
resulting in a bias towards selection of those with capacity at recruitment. The 
multivariate analysis presented in this chapter must be interpreted with caution. It is 
recommended that, as a guide, 10 cases of data for each predictor in the model are 
required, although this is something of an oversimplification, as the sample size 
required will ultimately depend on the size of the effect that is being investigated 
(Field 2009). As the effect size of cortisol on delirium after stroke was unknown, the 
simple rule of thumb of 10 cases for each predictor was adhered to. One method of 
correcting for multiple comparisons is to use a Bonferroni correction, whereby the p 
value which is taken to imply a significant relationship is taken to be 0.05 divided by 
the number of comparisons made (Field 2009). For the multivariate models presented 
in this chapter, applying a Bonferroni correction does not alter the overall result, but it 
does mean that none of the variables in the models would be significantly associated 
with the diagnosis of delirium. Finally, as discussed above, the sample size was small, 
although this remains the largest study to date of cortisol and delirium after stroke. 
 
 
In summary, I have not found evidence of an independent association between 
salivary cortisol levels after stroke and the development of delirium. A tendency 
towards higher morning and afternoon cortisol levels in the 14 days after stroke in 
those who developed delirium was demonstrated, but the study did not have sufficient 
power to determine categorically whether these relationships are real. However, these 











Chapter 6: Delirium, cognitive function (over 1 





Delirium is a strong risk factor for the development of dementia in the elderly 
population in general (Davis et al., 2012), and in hospitalised general medical patients 
delirium has been shown to be an independent risk factor for the subsequent 
development of dementia (Rockwood et al., 1999). Dementia is common after stroke, 
affecting around 12% of those with a first ever stroke (when those with pre-existing 
dementia are excluded), and around 41% of stroke survivors overall (when those with 
recurrent stroke and those with pre-existing dementia are included) (Pendlebury, 
2012a). When compared with controls, stroke survivors have around a nine-fold 
excess risk of dementia in the first year after their stroke (Pendlebury, 2012a). A 
recent large prospective cohort study of the general population of the United States of 
America (aged 45 or over, 23 572 participants, of whom 515 had an incident stroke 
during the 6 year study period) found that incident stroke was associated with an 
accelerated and persistent decline in global cognition and executive function and an 
acute decline in verbal memory and new learning ability (Levine et al., 2015). 
Delirium has been shown to be an independent predictor of cognitive decline 2 years 
after stroke in a study of 120 stroke patients, with those who developed delirium after 
stroke having between a five and seven fold increased risk of having dementia at 
follow-up (van Rijsbergen et al., 2011). However, it is important to note that 
participants in this study were only screened for delirium twice during the first week 
after stroke (and were then only monitored for presence of delirium if delirium was 
detected in the first week), meaning that delirium which developed later would not 
have been identified. Furthermore, only 50 participants were able to complete the 2 
year follow-up due to high mortality rates in both groups, although the mortality rate 
was higher in the delirium group, with 65% dying before follow-up was completed. 
Other risk factors associated with poststroke dementia include advancing age, prior 
cognitive decline, brain atrophy and white matter changes on imaging and stroke 




 Pre-existing dementia is a risk factor for development of delirium in the general 
population and also in stroke survivors (Fong et al., 2012, Pendlebury, 2012b). 
However the way in which delirium and dementia are linked is not clear. It may be 
that an episode of delirium unmasks previously unrecognised dementia, or that 
delirium itself causes permanent neuronal damage leading to dementia, or indeed that 
delirium is a marker of a predisposition or vulnerability to dementia (Fong et al., 
2012). Longitudinal studies have shown that those with pre-existing Alzheimer’s 
dementia who go on to develop delirium have a worse prognosis than those with 
dementia alone, in terms of mortality and cognitive decline (Fong et al., 2012). It is 
not clear if this is also true of stroke survivors, with pre-existing dementia (of 
Alzheimer’s or vascular type). 
 
Previous studies of delirium after stroke have found that those who developed 
delirium had higher rates of institutionalisation, and poorer functional outcome, when 
compared to those who did not develop delirium (McManus, 2009). This may be 
related to cognitive decline, but also may be due to physical frailty, both of which 
may preclude independent function and living.  
 
This study examines the relationship between delirium after stroke (at any point 
during the 12 month study period) and cognitive function over the 12 months after 
stroke. It also investigates the functional outcome for participants at 1 month, 4 
months and 12 months after stroke.   
 
The hypothesis addressed in this chapter is: Delirium after stroke is associated with 
decrements in cognition in the 1 year after stroke. 
 














95 participants with an acute stroke were recruited as described in chapter 4.  
 
6.2.1 Baseline Cognitive Assessment 
 
At recruitment (day 0-5 post stroke onset) the National Adult Reading Test (NART) 
was administered, to estimate crystallised intelligence (Nelson, 1991), the Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE) was completed by an 
informant and was used as a measure of premorbid cognitive impairment. Those with 
an average IQCODE score of <3.19 were deemed to have normal cognition (prior to 
stroke onset), those with a score of ≥3.19-3.43 were deemed to have evidence of pre-
existing mild cognitive impairment and those with a score of ≥3.44 were deemed to 
have evidence of pre-existing dementia (Harwood et al., 1997, Li et al., 2012). The 
Montreal Cognitive Assessment (MoCA) was used as a brief test of global cognition 
(Nasreddine, 2005). Digit Span Forwards and Backwards was used to test attention 
and processing. 
 
6.2.2 Follow-up Cognitive Assessments 
 
Follow-up assessments were undertaken at 1, 4 and 12 months post stroke. Prior to 
each visit the participant’s GP was contacted to ensure that the participant had not 
died, and that they were well enough to be visited. The participant was then contacted 
by telephone to arrange the visit, and a letter was sent in the post to confirm the time 
and date of this appointment. The participants then completed a cognitive test battery, 
which is outlined in detail in chapter 4, section 4.6. The battery took around 50 
minutes to complete, but testing was stopped if participants became too fatigued or 
declined to continue. The Montreal Cognitive Assessment was also completed at 
follow-up. All follow-up visits took place in the participants own home (or place of 
residence if relevant, such as a nursing home). Most of the follow-up visits were 
conducted by me, however 54 out of 249 were conducted by one of three Community 
Research Nurses (Avril Cairns, Catherine Beveridge or Frances Docherty), during a 
six month period of the study when I was on maternity leave. The nurses were all 
trained in how to administer the cognitive tests by me, and all attended at least two 
home visits with me to observe, prior to performing one visit each themselves whilst I 
observed.   
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6.2.3 Follow-up delirium assessments 
 
Participants were assessed for evidence of either persistent or new onset delirium at 
each follow-up visit (1 month, 4 months and 12 months), using the same methodology 
as was used during the initial post-stroke assessments (described in detail in chapter 4 
section 4.4). Briefly, this involved assessment for the features of delirium using the 
CAM-ICU, DRS-R98, OSLA and DEL-box, the results of which were used to inform 
diagnosis based on DSM-IV criteria. The participant’s next of kin, where available, 
was questioned about any episodes of altered cognition in the period between follow-
up, and any episodes suspicious of delirium were discussed with the participant’s GP 
(if they had been consulted). Any hospital admissions were noted and also discussed 
with the participant’s GP thereafter. Delirium was diagnosed if CAM-ICU or the chart 
CAM (in the case of a retrospective diagnosis) was positive and DSM-IV criteria 
were fulfilled.  
 
6.2.4 Functional outcome 
 
At each of the follow-up assessments (1 month, 4 months and 12 months), the 
Nottingham Extended Activities of Daily Living Scale (Lincoln and Gladman, 1992) 
was completed for each participant. This is described in more detail in section 4.7, but 
briefly comprises 22 self-rated items about everyday functional ability. The test is 
scored out of a maximum of 22 points with a higher score indicating better functional 
ability. For those participants who were unable to complete the questionnaire 
themselves, a proxy was asked to complete it on their behalf. Information about place 
of residence was also recorded at each follow-up visit and length of stay in hospital 
was obtained from the hospital computerised records system. 
  
6.2.5 Statistical analysis 
 
Data were assessed for normality of distribution using histogram plots.  
In order to explore the pattern of global cognitive change across the year of follow-up, 
median MoCA scores at each time point, for the whole cohort, for those who 
developed delirium at any point during the study and for those who did not develop 
delirium, were plotted on a line graph. In order to explore the effect of delirium 
severity on the trajectory of global cognition over 12 months, those who developed 
delirium were divided into four groups, based on the DRS-R98 score at the time of 
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delirium diagnosis (those with a score of <18, 18-21, 22-25 and >25) and a line graph 
of the MoCA trajectory for each group was plotted. 
In order to explore the relationship between prior cognitive status (prior to stroke- 
normal, mild cognitive impairment or dementia, based on IQCODE score) and 
delirium (incident, persistent, resolved or never) at each time point, a Pearson chi-
square analysis was performed. 
 
 In order to investigate the differences between those who did and those who did not 
develop delirium in terms of baseline cognition (Crystallised intelligence measured 
using the NART and pre-morbid cognition assessed using the IQCODE) and global 
cognition (assessed using the MoCA) group comparisons were made using the Mann-
Whitney U test. 
 
In order to explore the differences in cognitive test scores between the group who did 
and the group who did not develop delirium, comparisons were made using ANOVA 
(for the parametric data) or Kruskal-Wallis test (for the non-parametric data) at each 
time point. To account for the effect of active delirium at the time of testing, any 
participant with an active delirium was excluded from these analysis, but were 
included at subsequent time points, if their delirium has resolved (no participant was 
excluded for the whole of the follow-up). All analysis, except where otherwise stated, 
were performed using SPSS version 14 and version 19. 
 
In order to explore the effects of delirium on the trajectory of the cognitive test scores 
over the 12 month study period, mixed effects multiple regression modelling was 
carried out by Dr Daniel Davis using the Stata 13.1 statistics package. Longitudinal 
change in cognitive outcome was estimated using random-effects models, where 
individuals were allowed to have random intercepts (cognitive score at first 
measurement) and random slopes (rate of change in cognition). The time metric was 
“time in study” and only linear relationships were considered. Covariance matrices 
were unstructured. The following covariates were considered for the intercept and 
slope: age, sex, NIHSS score on admission, IQCODE score, Charlson Comorbidities 
Index score and APACHE II score. Model fit was assessed using maximum likelihood 







95 participants were included in the study, 26 (27%) of whom developed delirium at 
some point during the 12 months following acute stroke. Baseline characteristics are 
summarised in chapter 5 section 5.1. Cognitive assessments were performed on all 
participants at the time of recruitment (days 3-5 post stroke), and were available for 
80 (84%) participants at day 28, 83 (87%) participants at 4 months and for 73 (77%) 
participants at 12 months.  
 
Of the 26 who developed delirium during the study, cognitive assessments were 
available for 20 (77%) at day 28, 21 (81%) at 4 months and 15 (58%) at 12 months. 
Of the remaining 69 who did not develop delirium throughout the course of the study, 
cognitive assessments were available for 60 (87%) at day 28, 62 (90%) at 4 months 
and 58 (84%) at 12 months. Reasons for not completing cognitive assessments are 
summarised in table 6.1. There were significant differences between the groups in 
terms of reasons for not completing cognitive testing. Those in the delirium group 
were more likely to have died, however those without delirium were more likely to be 
too unwell to complete testing at 1 month.  
 
An episode of incident delirium (meaning a new diagnosis of delirium) at the follow-
up visits was uncommon, in fact occurring only once throughout the whole study 
duration. This may be because I was required to ensure participants were well enough 
to participate (by contacting them, their carer or their GP) prior to visiting them. 
Persistent delirium was present in 8 participants at the 1 month follow-up, 15 had 
resolved delirium and the remaining 64 had never had delirium up to that point. At the 
4 month follow-up, 2 participants had persistent delirium, 21 had resolved delirium 
and the remaining 64 had never had delirium. Finally at the 12 month follow-up, 1 
participant had incident delirium, no-one had persistent delirium, 20 had resolved 
delirium and 63 participants had never had delirium. Those with persistent delirium at 
1 month were more likely to have underlying mild cognitive impairment or dementia 
(as diagnosed by IQCODE score), however there was no significant relationship 
between delirium status and prior cognition found at 4 months and 12 months (table 









Table 6.1 Reasons for failure to complete cognitive assessments at each time interval, 
for those who did and those who did not develop delirium 
 
Time post stroke Delirium No Delirium p◊ 
1 month 
Total able to complete testing = 80 
Too unwell n=3 
Died n=2 
Declined n=1 




Total able to complete testing = 83 
Died n=4 
Declined n=1 




Total able to complete testing = 73 





































Table 6.2 Prior cognitive status, assessed by IQCODE score, for those who did and 
those who did not develop delirium 
 
IQCODE: Informant Questionnaire of Cognitive Decline in the Elderly.  IQCODE 















Time post stroke Delirium 
status 
Stratification based on IQCODE (N=87) p◊ 
Normal MCI Dementia 



























Persistent 0 0 2 
 
Resolved 7 3 11 
 
Never 35 11 18 
 
12 months Incident 0 
 







Resolved 7 3 13 
 




6.3.1 Delirium, functional outcome and length of stay after 
stroke 
 
The median Nottingham ADL score (as a measure of functional outcome) improved 
over the course of the 12 month follow-up period, as would be expected due to 
recovery from the stroke and also attrition of those with more severe strokes (table 
6.3). This improvement was even more marked in the group who developed delirium, 
which may have been due to resolution of delirium over time (the majority of delirium 
occurred in the first two weeks after stroke onset). At each time point, those who 
never developed delirium had significantly better functional outcome compared to 
those who developed delirium at some point.  
There were significant differences between groups with respect to place of residence 
prior to stroke, with those who went on to develop delirium being more likely to 
require care at home or be in a nursing home, compared to those who didn’t develop 
delirium. After stroke, those who developed delirium were again more likely to 
require care at home or require nursing home care compared to those who didn’t 
develop delirium. Length of stay was significantly longer for those who developed 
















Table 6.3 A group comparison of functional outcome and length of hospital stay between 
those who did and those who did not develop delirium  









(out of 22) 
1 month: 11 (4-16) 
4 months: 14 (6-19) 
12 months: 15 (5.5-
19.5) 
1 month: 3.5 (1-9.75) 
4 months: 5 (1.75-
14.25) 
12 months: 18 (3.75-
18) 
1 month: 12 (6.75-
17) 
4 months: 16 (10-20) 








Own home:  n=81 




Nursing Home: n=1 
Own home n= 17 




Nursing Home n=1 
Own home n= 64 




Nursing Home n=0 
0.006b 
Place of 
residence at 1 
month 
Own home: n= 45 
Own home with 





Nursing Home: n= 2 
Remain in hospital 
n= 21 
Own home: n= 4 
Own home with 





Nursing Home: n= 2 
Remain in hospital 
n= 8 
Own home: n= 41 
Own home with 





Nursing Home: n= 0 




residence at 4 
months 
Own home: n= 49 
Own home with 





Nursing Home: n= 4 
Remain in hospital 
n= 11 
Own home: n= 4 
Own home with 





Nursing Home: n= 4 
Remain in hospital 
n= 5 
Own home: n= 45 
Own home with 





Nursing Home: n= 0 






Own home: n=51 






Nursing Home: n=6 
Own home: n=4 






Nursing Home: n=5 
Own home: n=47 










12 (6-30) 26.5 (11-52) 10 (5.5-23) 0.002a 
 




6.3.2 Baseline cognition, global cognition and delirium 
 
There was no difference in crystallised intelligence (measured by the NART) between those 
who did and did not develop delirium (table 6.4). Those who developed delirium had 
significantly fewer years in full time education  and were more likely to have evidence of 
prior mild cognitive impairment or dementia (as assessed by the IQCODE) when compared 
with those who did not develop delirium. MoCA scores were significantly lower in the 
delirium group compared with the no delirium group throughout the study period. There was 
an overall trend for improvement in MoCA scores throughout the year. This may, at least in 
part, be explained by a learning effect (because of repeated administration of a similar test), 
and attrition of those with the most severe cognitive impairment, as well as resolution of 
delirium and resolution of intercurrent acute illness such as infection.   
 
 
Table 6.4 Baseline assessments of crystallised intelligence (NART), Prior cognition 
(IQCODE) and serial measurement of global cognition (MoCA) over the 1 year after stroke 
 
 
IQCODE: Informant Questionnaire of Cognitive Decline in the Elderly.  IQCODE ≤3.19 = 
normal, 3.2-3.43 = mild cognitive impairment, MCI, ≥3.44 = dementia 
 
◊Mann Whitney U test 
a Pearson’s chi-square 
 
 
 Whole cohort Delirium No delirium p◊ 
































MoCA  Baseline: 22 (17-25) 
N=93 
Day 28: 24 (19-27) 
N=80 




Baseline: 13.5 (5-19) 
N=24 
Day 28: 18 (8.25-
22.75) N=20 
4 Months: 20 (9.5-
26.5) N=21 
12 Months: 20 
(15-26) N=15 
Baseline:24 (19.5-
27)       N=69 
Day 28: 25 (21-27) 
N=60 
4 Months: 26 (23-29) 
N=62 











6.3.3 Cognition and delirium in the 1 year after stroke 
 
The cognitive battery was administered in its entirety at 1 month, 4 months and 12 months 
follow-up visits. However, there is a large amount of missing data for the battery, partly 
because of attrition due to death, declining to continue the study or moving away, as detailed 
in table 6.1 previously. Furthermore, not all participants completed all of the tests at each 
visit. Reasons for failing to complete testing were fatigue, participants declining to complete 
a particular test, significant dementia (resulting in the participant being unable to understand 
the instructions for the test) and poor eyesight (deteriorated since recruitment). Attrition was 
greater in the delirium group, than in the group who never developed delirium. The results of 
each cognitive test (median and IQR) are presented as raw scores (unadjusted for NART and 
IQCODE). Table 6.5 shows the raw scores for each test at each time point, for the whole 
cohort, and also for those who did and did not develop delirium. Tables 6.6 to 6.8 show the 
cognitive tests for these three groups at individual time points (1 month, 4 months and 12 
months). In order to examine the influence of an episode of delirium on future cognition, 
group differences were examined between participants who had delirium during the study 
period and those who did not. In order to account for the effect of an acute episode of 
delirium on cognitive testing, any participant with an active delirium at the time of follow up 
has been excluded from this analysis (this applies to 8 participants at 1 month, 2 at 4 months 
and 1 at 12 months).  
 
 
6.3.3.1 Verbal fluency 
 
Median verbal fluency scores for both letter (FAS) and animal naming were stable 
throughout the study period (1 month to 12 months) in the whole cohort. At each follow-up 
there was a significant difference between the group who had resolved delirium and those 
who never developed delirium, determined by post hoc analysis.  
 
 
6.3.3.2 Visual reproduction 
 
Taking the cohort as a whole, there was a trend towards improvement in all scores in the 
visual reproduction battery. This may be accounted for by a learning effect (as the test was 
identical at each follow-up assessment), but may also be accounted for by improvement in 
those who recovered from delirium and attrition (due to death) of those who were frailest and 
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had an underlying cognitive impairment. In the delirium group there was a small 
improvement in immediate and delayed recall over the 1 year, however there was a small 
deterioration in the percentage retention test. It must be noted that the numbers of participants 
completing this test in the delirium group are small (N of between 4 and 10). In the no 
delirium group, scores for all aspects of visual reproduction tended to improve over the 
course of the year, which may be accounted for by the reasons previously discussed. 
 
6.3.3.3 HVLT-R List Learning 
 
The scores for total recall for HVLT-R list learning improved in all groups (whole cohort, 
delirium and no delirium) over the 1 year follow-up period. This may in part have been a 
learning effect, as although different word lists were used at each follow-up time point, 
strategies which improve performance (such as grouping categories together) may have been 
learned. The discrimination index score section of the test stayed relatively stable throughout 
the year taking the cohort as a whole and in the group that never developed delirium. There 
was a tendency to improvement in the delirium group, which may reflect a learning effect and 
attrition of those with the most severe cognitive impairment. Post hoc analysis showed that 
there was a significant difference between the delirium and no delirium groups for both parts 
of the test at 1 month and 4 months, and also for the total recall test at 12 months (with the 
delirium group scoring significantly less well), however there was no significant difference 
between the groups for the discrimination index test at 12 months. Overall this would indicate 
poorer verbal memory in the delirium group compared with the no delirium group. 
 
 
6.3.3.4 Victoria Stroop 
 
The interference and difference scores remained stable for the whole cohort throughout the 
course of the 1 year follow-up period. Taking the group who developed delirium at some 
point during the study period separately, there was an overall decrease in the difference score 
at the 4 month follow-up visit, a pattern which was not seen in the group who never had 
delirium. The reason for this deterioration is not clear, and there was an improvement seen at 
the 12 month follow-up. However, it must be noted that the number of participants was only 
13 in the delirium group at 4 months, and so a poor performance by a few participants would 





6.3.3.5 Digit span (forwards and backwards) 
 
Scores for digit span forwards and backwards remained relatively stable in the whole cohort 
throughout the course of the year. At 1 month there was a significant difference in digit span 
backwards scores between those who developed delirium at some point and those who did 
not (with those in the delirium group having lower scores). There was no significant 
difference in digit span forwards scores. At 4 months and 12 months there was no significant 





6.3.3.6 Digit Symbol Substitution Test (DSST) 
 
Scores on the DSST improved over time in the whole cohort, and taking the delirium and no 
delirium groups separately, each group showed an improvement over time. This may have 
been a learning effect, as the same test was administered at each follow-up, and may also be 
due to attrition of those with more severe cognitive impairment. Scores were significantly 
lower in the delirium group compared with the no delirium group at all 3 follow-up time 























Table 6.5 Cognitive test scores (unadjusted), for the whole cohort, for those who developed delirium and those who did not, over time. 
 
Cognitive test Whole cohort –median score (IQR) Delirium-median score (IQR) No delirium-median score (IQR) 
 Day 3-
5 














1 month 4 months 12 
months 







































































































































































































































































































































































































































































































































































































◊Mean and SD, as normally distributed 
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Table 6.6 Group differences in raw cognitive test scores at 1 month between 
participants who had delirium at any point and those who never developed delirium, 
excluding those with active delirium at the 1 month assessment 
 
 






































































































































◊Mean and SD as normally distributed 
aKruskal-Wallis test (post-hoc, pairwise comparisons) 





Table 6.7 Group differences in raw cognitive test scores at 4 months between 
participants who had delirium at any point and those who never developed delirium, 
excluding those with active delirium at the 4 month assessment 
 
 






































































































































◊Mean and SD as normally distributed 
aKruskal-Wallis test (post-hoc, pairwise comparisons) 




Table 6.8 Group differences in raw cognitive test scores at 12 months between 
participants who had delirium at any point and those who never developed delirium, 
excluding those with active delirium at the 12 month assessment 
 
 







































































































































◊Mean and SD as normally distributed 
aKruskal-Wallis test (post-hoc, pairwise comparisons) 




6.3.4 Trajectory of global cognition over 12 months, controlled for the 
effect of delirium 
 
As can be seen in figure 6.1 there was a trend for improvement in MoCA score for the 
whole cohort over the 12 month follow-up period. When stratified into groups based 
on delirium severity (figure 6.2) all except those in the worst severity group showed 
an improvement in global cognition. Those with the worst severity scores showed a 
decline, however there was significant attrition from this group, such than n=2 at 12 
months. Those with a higher DRS-R98 score (indicating more severe delirium) had a 
significantly lower MoCA score when compared to those with lower DRS-R98 scores 
at baseline, 1 month and 4 months, but this effect was not significant at 12 months 
(table 6.9). 
 In a mixed effects multiple regression model, the rate of change per day for the whole 
cohort over time was 0.003 points per day ( which is 0.09 points per month, and 1.09 
points for the year) increase in MoCA (95% CI 0.0005-0.006, p=0.02) score. Table 
6.10 shows that each episode of delirium was associated with a 5 point decrease in the 
MoCA score overall (95% CI -7.07- -3.78, p<0.001), but taking the whole group who 
had delirium, there was no significant effect on the rate of change per day of the 
MoCA (Coefficient 0.001, 95% CI -0.002-0.004, p=0.48). This means that delirium 
doesn’t have a significant effect on the rate of change of the MoCA score, but does 


















Table 6.9 Group comparisons of MoCA scores, as a measure of global cognition, at baseline, 
1 month, 4 months and 12 months, stratified by DRS-R98 score.  
 
 
Time point  MoCA score 



































































Table 6.10 Mixed effects multiple regression models showing the effect of delirium on 










Variable Coefficient 95% CI p 
Delirium (effect on 
overall MoCA 
score) 
-5.42 -7.07- -3.78 <0.001 
Delirium (effect on 
MoCA trajectory) 
-0.02 -0.06-0.02 0.37 
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Figure 6.1 A line graph showing the trajectory of global cognition, measured using the 
Montreal Cognitive Assessment, over 12 months for the whole cohort and for those who did 










Figure 6.2 A line graph showing the trajectory of global cognition, stratified by delirium 













Baseline Day 28 4 months 12 months
A graph to show the trajectory of the MoCA 
scores for those who did (n=26) and did not 
(n=69) develop delirium and for the whole cohort 
(n=95)








MoCa at baseline MoCA at 1 month MoCA at 4 months MoCa at 12 months
Line graph to show MoCa trajectory over 12 
months stratified by DRS-R98 score at the time of 
delirium diagnosis
<18 18-21 22-25 >25
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Figure 6.3 A graph to show all 95 individual Montreal Cognitive Assessment trajectories 










Recruitment Day 28 4 months 12 months
A graph to show individual Montreal Cognitive 
Assessment trajectories over 12 months
2 3 4 5 6 7 8 9 10 11
12 13 14 15 17 18 19 20 21 22
23 24 25 26 27 28 29 30 31 32
33 34 35 36 37 38 39 40 41 42
43 44 45 46 47 48 49 50 51 52
53 54 55 56 57 58 59 60 61 62
63 64 65 66 67 68 69 70 71 72
73 74 75 76 77 78 79 80 81 82





6.3.5 Trajectory of neuropsychological test battery scores over 12 months, 
controlled for the effect of delirium.  
 
As can be seen in table 6.11, in mixed effects multiple regression models, the presence of 
delirium did not have a statistically significant effect on the trajectory of any of the 
neuropsychological test scores over time, although the HVLT-R list learning test approached 




Table 6.11. Mixed effects multiple regression models showing the effect of delirium on the 





















Variable Coefficient 95% CI p 
Digit span  -0.056 -0.263-0.151 0.60 
Verbal fluency 0.342 0.135-0.550 0.46 
HVLT-R List 
Learning 
-0.150 -0.31-0.009 0.07 
Visual reproduction -1.040 -3.21-1.13 0.35 
Victoria Stroop -0.022 -0.60-0.015 0.24 





This study found that delirium after stroke was associated with a higher IQCODE score 
(indicating presence of a pre-existing cognitive impairment or dementia), and fewer years in 
formal education. There was no difference in crystallised intelligence, measured by the 
NART (as a marker of pre-morbid IQ) between those who did and those who did not develop 
delirium. Global cognition, measured by the MoCA, was significantly poorer in the delirium 
group at each time point throughout the 12 months after stroke. However, there was a trend 
towards improvement in MoCA scores in the whole cohort throughout the 12 month follow-
up, with the exception of those who developed the most severe delirium (rated by the DRS-
R98 score). Those with a more severe delirium had significantly lower MoCA scores at 
baseline, 1 month and 4 months compared to those with lower severity scores. The presence 
of delirium at any point during the 12 month follow-up did not affect the rate of change of the 
MoCA scores over the 12 months after stroke. Finally, being diagnosed with delirium at any 
point during the study did not affect the rate of change of the neuropsychological test battery 
scores over the 12 months after stroke. As would be expected based on previous studies, 
those who developed delirium had a worse functional outcome, longer length of hospital stay 
and were more likely to require institutional care or a package of care at home, compared 
with those who did not develop delirium. 
 
 
In this cohort, delirium was common, occurring in 27% of participants. Although the majority 
of delirium occurred in the first 7 days post stroke, persistent delirium was seen in 7 
participants at the 1 month follow up and in 2 participants at the 4 month follow up. This 
illustrates the importance of careful assessment for delirium alongside more general cognitive 
testing at follow up in longitudinal studies of cognition after stroke, as delirium may 
significantly confound results if not recognised. Previous longitudinal studies of cognition 
after stroke have tended not to assess for delirium at any follow-up assessments (van 
Rijsbergen et al., 2011, Pendlebury, 2012a).  
 
 
There was a trend for cognitive function to improve over the course of the 12 months after 
stroke. There are a number of possibilities as to why this may have been the case. Firstly, 
attrition was greatest in the delirium group and was highest of all in the subset of participants 
who had the highest delirium severity scores (the only group in whom global cognition 
157 
 
deteriorated over the 12 months). Attrition of these participants will skew the results. 
However, as can be seen in figure 6.3, many participants did complete the 12 month follow-
up period and did show improvements in global cognitive function. There may have been a 
learning effect for the cognitive tests over time, which could account for some of the 
improvement seen. Care was taken to use different versions of tests, where available, 
however participants may have learned strategies for cognitive testing which can be applied 
to any version of the test. There may also have been an effect of recovery from acute illness, 
be that delirium, intercurrent infection and the stroke itself, all of which may have contributed 
to the improvement seen.  
 
Previous studies of the trajectory of cognitive changes after stroke have tended to find an 
increase in dementia burden (with an associated decrease in cognitive function test scores) in 
the cohorts over time (Pendlebury, 2012a), although few studies have reported ascertainment 
of dementia rates after the first year post stroke. As previously discussed, a significant 
weakness of the majority of these studies is the failure to assess participants for delirium, 
which as we have shown, is a confounder. Just 3 previous studies have investigated cognitive 
changes after stroke in relation to delirium; Henon and colleagues (Henon et al., 1999) 
recruited 202 participants with stroke, assessed them for delirium during their in-patient stay 
and then performed MMSE as a measure of global cognition at 6 months. They did not 
ascertain evidence of delirium in the time between discharge and 6 months. Sheng and 
colleagues (Sheng et al., 2006) recruited 156 participants, who were assessed for delirium at 
baseline, and were followed-up for cognitive assessment, but again not for delirium 
assessment, at 1 month, 6 months and 12 months. Finally van Rijsbergen and colleagues (van 
Rijsbergen et al., 2011) followed up 50 stroke patients 2 years after stroke onset and 
performed neuropsychological testing, but again there was no ascertainment of episodes of 
delirium in the intervening time. All three studies found that delirium after stroke was 
associated with adverse outcomes. Henon and colleagues found an association between 
delirium and poorer functional outcome, van Rijsbergen found delirium to be an independent 
predictor of severe cognitive impairment at 2 years and Sheng and colleagues found delirium 
to be associated with higher mortality and poorer functional outcome. As briefly discussed in 
the introduction, a large population based study (Levine et al., 2015) of cognitive changes 
after stroke (n=515), recently found an acute decline in cognition following incident stroke, 
and also a persistent cognitive decline over 6 years post-stroke.  However, again no 
assessments for delirium were performed post-stroke, and those with cognitive impairment 
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prior to stroke were excluded from the analysis. This is important as I have found that those 
with pre-existing cognitive impairment were more likely to develop delirium after stroke, but 
also showed improvement in global cognition, at the same rate of change as those who never 
developed delirium.  
 
 
Overall, these findings, if reproduced by future larger studies, have important implication for 
stroke survivors and for clinicians, as cognitive impairment is one of the reasons that patients 
are discharged to institutional care (Hajek et al., 2015), rather than to their own home. The 
potential for improvement in global cognition between the time of first assessment after 
stroke and 12 month follow-up, found in this study, as well as the persistent nature of 
delirium in some cases, means that caution should be used in making such decisions, and 
ideally, these decisions should be revisited at least 4 months after stroke onset, when there 
may have been improvement in cognition, and when persistent delirium is likely to have 




There are some limitations to this study which should be acknowledged. As has been 
discussed elsewhere in this thesis, the time from stroke onset until first assessment for 
presence of delirium was up to 5 days post-stroke (median day 3, IQR 3-5). This was because 
of delays in the recruitment process for those requiring proxy consent, but was also due to 
delays in presentation to hospital for some participants. This may have resulted in an 
underestimate of prevalent and also incident delirium, however every effort was made to 
ascertain if features of delirium had been present in the time prior to recruitment. There was 
more attrition in the delirium group, compared with the non-delirium group. From the 
literature, it is clear that this is inevitable, as those who develop delirium after stroke have 
higher mortality rates (McManus, 2011), however this does mean that there will be some bias 
towards those who are more robust, for the 1 year cognitive data. Furthermore, when those 
with delirium were stratified into levels of severity, based on the DRS score at the time of 
delirium onset, it became clear that those with more severe delirium had worse outcomes not 
only in terms of cognition but also had higher mortality rates. This meant that for those with 
severe delirium, the numbers remaining at 12 months were very small. It must also be 
acknowledged that although the study found that being diagnosed with delirium at any point 
in the study did not affect the trajectory of the neuropsychological test battery scores, these 
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tests were only performed at the follow-up assessments, at which point the majority of those 
with delirium had recovered. The study size is relatively small, taken in the context of stroke 
studies in general, however only 3 previous studies have investigated cognition after stroke 
longitudinally and investigated the effects of delirium on the long-term cognitive outcome, as 
previously discussed, all of which had methodological weaknesses. As discussed in section 
5.4, the multivariate analysis should be interpreted with caution. The number of variables 
entered into the model did not exceed 1 per 10 cases of data, however the effect size of 
delirium on the cognitive trajectory was not considered when building the models. As 
discussed in section 5.4, a Bonferroni correction may be used to account for multiple 
comparisons, but once again when this was applied to the data presented in this chapter, the 
main findings were not altered. There is missing data in the study, because of attrition, and 
also because participants were not all able to complete every test at every visit.  Finally the 
IQCODE was used as a screening tool for pre-morbid cognitive decline, as it was not possible 
to perform pre-morbid cognitive testing because of the nature of stroke. This does mean that 
the study is not able to determine the cognitive trajectory for participants from before stroke 
onset up to the 12 month follow-up, and so although improvement was seen between the first 
cognitive assessment (post-stroke) and 12 month follow-up, there may have been a 
deterioration in cognition in the cohort overall if we were able to compare the 12 month 
results with cognitive function pre-stroke.  
 
 
In summary, this study has shown that delirium after stroke is common and may persist for 
up to 4 months after stroke onset. Global cognitive function tended to improve over the 
course of the 1 year after stroke, and the improvement in cognition showed a trend towards 
being more marked in the group who developed delirium at some point in the study, 
compared with those who never developed delirium, although this effect was not statistically 
significant. This overall trend towards improvement in cognitive function may be due to a 
learning effect for the cognitive tests, attrition of the frailest, most cognitively impaired 











Chapter 7: Cortisol levels, delirium and cognitive 




There is broad agreement amongst the majority of studies of cortisol and its relationship to 
cognition (in non-stroke patients) that there is an association between elevated cortisol levels 
(measured in blood, saliva or cerebrospinal fluid) and poorer cognitive function, although 
there is considerable heterogeneity in study methodology.  
 
Three population-based studies have investigated the associations between cortisol and 
cognition: the Baltimore Memory Study (Lee et al., 2007), the KORA-Age Study (Johar et 
al., 2015) and the Rotterdam Study (Schrijvers et al., 2011), however none of these 
specifically included stroke participants. The Baltimore Memory Study measured salivary 
cortisol in 967 community dwelling adults, aged 50-70. Four samples were taken during one 
visit, one before cognitive testing, one during testing, one after testing and one at the 
conclusion of the visit. In multivariate analysis, controlling for age, sex, household wealth, 
education and ethnicity, higher cortisol was found to be significantly associated with poorer 
cognitive performance. Overall, the authors conclude that the study found a dose response 
relationship between cortisol and cognition, with higher cortisol levels being associated with 
poorer performance in a variety of cognitive domains throughout the neocortex and in the 
hippocampus (Lee et al., 2007). The KORA-Age study took a population based sample of 
733 participants in Germany over the age of 64. Participants underwent a telephone-
administered cognitive test and were then categorised into those with normal cognition 
(n=101), those with MCI (n=101) and those with dementia (n=33).  Three salivary cortisol 
levels were measured for each participant; one on awakening, one 30 minutes after 
awakening and one in the evening, prior to going to bed. Participants collected the samples 
themselves, following verbal and written instructions. The study found that cognitive 
impairment was associated with reduced morning to evening cortisol levels, however in 
multivariate analysis, when gender was stratified for, the relationship was significant in men 
(n=375), but not women (n= 358). One flaw of this study is that cognitive status was 
determined by telephone interview, which may be difficult for those with hearing 
impairment, and may therefore give an overestimate of cognitive impairment. The third 
population based study (Schrijvers et al., 2011) (a part of the Rotterdam Study), involved 
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participants (n=3341) who were free from dementia at baseline. It did not find any 
association between baseline morning serum cortisol levels and subsequent development of 
dementia, however neither diurnal cortisol measurements nor serial cortisol measurements 
were taken.  
 
Cortisol in cerebrospinal fluid has been shown to be associated with dementia, with cortisol 
levels correlating negatively with cognitive test scores (Gil-Bea et al., 2010), and an 
association between the ApoE genotype (associated with Alzheimer’s dementia) and higher 
cortisol levels has also been demonstrated (Peskind et al., 2001). No such association was 
found between cortisol levels and MCI (Gil-Bea et al., 2010, Popp et al., 2015), suggesting 
that perhaps HPA axis dysregulation (resulting in elevated cortisol levels) is a consequence of 
dementia, or that dysregulation does not become detectable until dementia has developed. 
However, the diagnostic criteria used for MCI tend to vary between studies, and it may 
simply be that the diagnostic criteria are not robust enough, meaning that the overall picture 
is clouded by diagnostic uncertainty (Pendlebury et al., 2013).  
  
 There are no previous studies of the relationship between cortisol levels and cognitive 
outcome specifically after stroke. As discussed in chapter 2 , cortisol levels are elevated after 
acute stroke (for at least seven days) and higher cortisol levels after stroke have been found to 
be associated with higher dependency levels, longer length of stay, morbidity (such as 
depression) and mortality. As discussed in chapter 5, it is plausible that dysregulation of the 
HPA axis after stroke may be implicated in the pathogenesis of post-stroke cognitive 
impairment and dementia. Basal levels of cortisol are known to enhance memory formation, 
but stress levels supress this function (Chapman and Seckl, 2008).  Furthermore, stress levels 
of cortisol are known to reduce neuronal survival following insults, such as stroke. The 
hippocampus, which plays a crucial part in several domains of memory, such as verbal 
memory, is particularly vulnerable to the deleterious effects of cortisol (Chapman and Seckl, 
2008). As discussed in chapter 1, section 1.4.3, delirium may affect the HPA axis and 
cognition after stroke (although the direction of causation cannot be inferred from these 
studies) and so it is also important to take into account the possible effect of delirium on 
cortisol levels and on cognition in this study. 
 
In summary, high cortisol levels have been shown to be associated with poorer cognitive 
function in the general older adult population in two out of three large studies, and CSF 
cortisol has been shown to be elevated in dementia. The relationship between cortisol and 
162 
 
MCI is less clear, with no strong association being found, however this must be interpreted 
with caution, as the definition of MCI has been heterogeneous amongst studies to date. It is 
plausible that cortisol may be associated with cognitive function after stroke, but no studies to 
date have investigated this association. 
 
The aim of this study was to investigate the relationship between salivary cortisol levels after 
stroke, delirium and cognitive function in the 1 year after stroke.  
 
The hypothesis addressed in this chapter is: Dysregulation of the HPA axis in the first week 
after stroke is associated with cognitive decline at up to 12 months, when the effect of 


































Participants with acute stroke, aged over 60, were recruited consecutively from the acute 
stroke unit at the Royal Infirmary of Edinburgh, by me (Geriatric Medicine Registrar (AJB)), 
between October 2012 and March 2014, as described in detail in chapter 4. Exclusion criteria 
were: diagnosis of subarachnoid haemorrhage or TIA, tumour or other stroke mimic seen on 
imaging, current or recent use (within 6 months) of oral or inhaled corticosteroids, active 
alcohol withdrawal and inability to speak English prior to stroke. Informed consent was 
obtained from those deemed to have capacity (as assessed by AJB) or proxy consent was 
obtained from those who lacked capacity to provide consent. Ethical approval was obtained 
for the study from the Scotland A Research Ethics committee. The NHISS score and 
APACHE II scores were completed at baseline, as a measure of stroke severity and current 
illness burden respectively. These are described in more detail in section 4.3. 
  
 
7.2.2 Delirium assessment 
 
Participants were assessed for the presence of delirium, based on DSM IV criteria, on 
alternate days during the first week after stroke onset and then on days 14, 28, and at 4 
months and 12 months. A detailed description of the protocol for delirium assessment is 
given in section 4.4. 
 
 
7.2.3 Cognitive assessment 
 
Participants completed the Montreal Cognitive Assessment (MoCA, to assess global 
cognition), National Adult Reading Test (to assess pre-morbid IQ, see section 4.6.1) and  
Digit Span Forwards and Backwards (to assess attention and working memory) at baseline, or 
as soon as practically possible after recruitment if illness precluded completion at baseline 
(all were completed within 2 weeks of recruitment). An informant (usually the nearest 
relative) completed the IQCODE at baseline, to screen for undiagnosed pre-existing cognitive 
impairment (those with an IQCODE score of <3.19 were deemed to have normal cognition 
(prior to stroke onset), those with a score of ≥3.19-3.43 were deemed to have evidence of pre-
existing mild cognitive impairment and those with a score of ≥3.44 were deemed to have 
evidence of pre-existing dementia (Harwood et al., 1997, Li et al., 2012)).  At 1 month, 4 
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months and 12 months post-stroke participants underwent more detailed neuropsychiatric 
testing. This consisted of a cognitive test battery comprising the MoCA, Digit Span Forwards 
and Backwards, Verbal Fluency (FAS and animals), Visual Reproduction, List Learning, 
Victoria Stroop Test and Digit Symbol Substitution Test. The tests and testing protocol are 
described in detail in section 4.6.   
 
7.2.4 Salivary cortisol sample collection 
 
Saliva was collected the morning (0930) and afternoon (1530) at each assessment. Thus 
samples were collected on the day of recruitment, and then on alternate days for the first 
week after stroke, and then at day 7 and day 14, 1 month, 4 months and 12 months after 
stroke onset. The collection process and devices are described in detail in section 4.8. 
 
7.2.5 Salivary cortisol assays 
 
Salivary cortisol was measured using an Enzyme-Linked Immunosorbant Assay (ELISA). 
This was performed by The Dresden LabService Gmbh (Tatzberg 47-49, 01307, Dresden, 
Germany) 
 
7.2.6 Statistical Analysis 
 
Group comparisons were made to compare cortisol levels between those who had delirium 
(either in isolation, or on a background of MCI or dementia), dementia only and those who 
were cognitively normal, using the Kruskal-Wallis test. Spearman’s correlations between 
cortisol levels and cognitive test scores were then calculated. Dr Daniel Davis performed 
mixed effects multiple regression modelling, using the statistical package Stata 13.1, to 
examine the effects of cortisol and delirium on global cognitive function (measured by the 
MoCA) at baseline and over the 12 month follow-up period. Longitudinal change in cognitive 
outcome was estimated using random-effects models, where individuals were allowed to have 
random intercepts (cognitive score at first measurement) and random slopes (rate of change 
in cognition). The time metric was “time in study” and only linear relationships were 
considered. Covariance matrices were unstructured. The following covariates were 
considered for the intercept and slope: age, sex, NIHSS score on admission, IQCODE score, 
Charlson Comorbidities Index score and APACHE II score. Model fit was assessed using 







95 participants were recruited from the acute stroke unit at the Royal Infirmary of Edinburgh, 
as described in detail in chapter 4. Baseline data are reported in chapter 5 (table 5.1). 
 
 
7.3.1 Cortisol levels and their relationship with delirium and dementia 
 
Group comparisons were made to compare salivary cortisol levels between those who 
developed delirium (with or without underlying dementia or MCI), those who had 
MCI/dementia only, and those who had neither delirium nor dementia (table 7.1). There were 
no significant differences between any of the three groups’ cortisol levels at any of the time 
points. Differences between the groups’ cortisol levels approached significance at the 4 
month (am) time point. At this time point those with delirium on MCI/dementia had the 





























Table 7.1 Group comparisons of median salivary cortisol levels at baseline, 1 month, 4 
months and 12 months after stroke onset, based on delirium and MCI/dementia status (those 
with delirium defined as delirium diagnosed ever during the course of the study) 
 















































































































7.3.2 Correlations between cortisol levels and cognitive test scores 
 
As the data are non-parametric, Spearman’s correlations were used to examine the 
relationships between median cortisol levels in the first 7 days after stroke and cognitive 
function at baseline (table 7.2) and also to examine the relationship between peak cortisol 
levels in the first 14 days after stroke and cognitive function at baseline (table 7.3). Median 
week one cortisol levels did not correlate with any of the cognitive test scores. Peak afternoon 
cortisol levels correlated with the baseline MoCA score (with a higher cortisol levels 
correlating with a lower MoCA score), but not with any other scores, and peak morning and 
the peak ratio cortisol levels didn’t correlate with any of the cognitive test scores. 
At 1 month follow-up (table 7.4), the ratio of morning to afternoon cortisol correlated with 
MoCA and list learning scores (total recall and delayed recall), with a higher ratio (indicating 
maintenance of the normal circadian rhythm) being associated with higher scores. No 
significant correlation between cortisol levels and cognitive test scores were found at 4 





























Table 7.2 Correlations between median morning, median afternoon and median ratio 























Cognitive test Median morning 
cortisol level 
(days 0-7) 




Rho, p value 
Median ratio of 
morning to afternoon 
peak cortisol level  
(days 0-7)  
Rho, p value 
































































Table 7.3 Correlations between peak morning, peak afternoon and peak ratio (morning: 




ρ= Spearman’s Rho correlation coefficient 
Cognitive test Peak morning 
cortisol level 
(days 0-14)  
Rho, p value 
Peak afternoon 
cortisol level 
(days 0-14)  
Rho, p value 
Ratio of morning 
to afternoon peak 
cortisol level 







































































Table 7.4 Correlations between contemporaneous cognitive test scores and cortisol levels, at 1 month, 4 months and 12 months after stroke  
Cognitive test 1 month cortisol level 
Rho, p value 
4 months cortisol level 
Rho, p value 
12 months cortisol level 
Rho, p value 
AM PM Ratio 
(am:pm) 
AM PM Ratio 
(am:pm) 

















































































































































































Table 7.4 (continued) Correlations between contemporaneous cognitive test scores and cortisol levels, at 1 month, 4 months and 12 months 














































7.3.3 Trajectory of global cognition over 12 months and its relationship 
to salivary cortisol levels and delirium 
 
As discussed in chapter 6, there was an overall trend for improvement in the MoCA 
score (as a measure of global cognition) in the whole cohort over the 12 month 
follow-up period.  Mixed effects multiple regression models were used to examine the 
effect of salivary cortisol (median at baseline, days 0-7) on MoCA scores at baseline 
after stroke (table 7.5). This shows that neither morning nor afternoon median cortisol 
levels at baseline nor the morning: afternoon ratio of cortisol at baseline are 
associated with MoCA scores at baseline. Mixed effects multiple regression models 
were then used to investigate the effects of median baseline cortisol levels (days 0-7) 
on the rate of change of the MoCA over 1 year (MoCA trajectory) (table 7.5). This 
showed that neither morning nor afternoon median salivary cortisol levels, nor the 
ratio of morning to afternoon cortisol levels significantly affected the rate of change 
of the MoCA score over 1 year. 
Mixed effects multiple regression models were then used to investigate the effect of 
cortisol and delirium on the baseline MoCA score (table 7.6). This showed that when 
adjusted for the presence of delirium, only the median morning: afternoon ratio of 
cortisol was associated with the baseline MoCA. Finally, mixed effects multiple 
regression models were used to investigate the effects of cortisol and delirium on the 
rate of change of the MoCA score over 1 year (table 7.7).  This showed that when 
adjusted for the presence of delirium, cortisol was not associated with the rate of 





















Table 7.5 Mixed effects multiple regression modelling investigating the effect of 
baseline salivary cortisol (median, days 0-7) on MoCA scores at baseline and on the 




(MoCA score at 
intercept) 
95% CI p 
Median morning 
cortisol levels at 
baseline (nmol/L)-
effect on baseline 
MoCA  
-0.003 -0.010-0.005 0.50 
Median afternoon 
cortisol levels at 
baseline (nmol/L)-
effect on baseline 
MoCA 
-0.001 -0.001-0.0001 0.11 
Median morning: 
afternoon cortisol 
levels at baseline 
(nmol/L)-effect on 
baseline MoCA   
0.216 -0.02-0.451 0.07 
Median morning 
cortisol levels at 
baseline (nmol/L)-
effect on MoCA 
trajectory 
2x10-5 -4x10-5-8x10-5 0.57 
Median afternoon 
cortisol levels at 
baseline (nmol/L)-
effect on MoCA 
trajectory 
1x10-5 -4x10-5-2x10-5 0.58 
Median morning: 
afternoon cortisol 
levels at baseline 
(nmol/L)-effect on 
MoCA trajectory 












Table 7.6 Mixed effects multiple regression model-investigating the relative effects 




(change in MoCA 
score per day) 
95% CI p 
Median morning 
cortisol levels 
-0.002 -0.009-0.005 0.58 
Median afternoon 
cortisol levels  




0.253 0.019-0.488 0.03 
Delirium (present 
at any point in the 
12 months) 






Table 7.7 Mixed effects multiple regression model-investigating the relative effects 
of baseline salivary cortisol (median, days 0-7) and delirium on the MoCA trajectory 
over 12 months. 
 
   
Variable Coefficient 
(change in MoCA 
score per day) 




0.313 -0.828-1.455 0.59 
Delirium (present 
at any point in the 
12 months) 
















7.3.4 Trajectory of neuropsychological test battery over 12 months and 
its relationship to salivary cortisol levels and delirium 
 
 
Mixed effects multiple regression models were used to investigate the effect of 
delirium and salivary cortisol levels (median, days 0-7) on the trajectory of the 
neuropsychological tests (excluding the MoCA) in the 12 months after stroke (table 
7.8). This shows that when adjusted for the effects of delirium, salivary cortisol levels 




Table 7.8 Mixed effects multiple regression models-investigating the effects of 
baseline salivary cortisol (median, days 0-7) and delirium on the trajectory of each 
neuropsychological test over 12 months. (Models were built separately for each 
neuropsychological test)  
 
Variable Coefficient 
(change in score 
per day) 
 
95% CI p 
Digit span 1.25x10-5 -0.002-0.002 0.99 
Verbal fluency -1.1x10-5 -0.003-0.003 0.99 
HVLT-R List 
Learning 
-0.001 -0.003-0.0004 0.12 
Visual 
reproduction 
-0.006 -0.024-0.012 0.52 
Victoria Stroop 0.0002 -0.0002-0.0006 0.34 




















This study found that there were no significant differences in salivary cortisol levels 
between those who developed delirium (with or without pre-existing dementia), those 
who had dementia only and those who had neither delirium nor dementia. Median 
cortisol levels in the first week for the whole cohort did not correlate with any of the 
cognitive test scores. Peak afternoon cortisol levels (in the first 14 days after stroke) 
significantly correlated with baseline MoCA scores, but not with any of the other 
cognitive tests, and neither morning peak levels nor the peak morning to afternoon 
ratio correlated with any of the cognitive test scores. At 1 month follow-up neither 
morning nor afternoon cortisol levels correlated with cognitive test scores, but the 
ratio of morning to afternoon cortisol correlated with the MoCA score and the list 
learning recall and delayed recall scores. At 4 months and 12 months cortisol levels 
did not correlate significantly with any of the cognitive tests. In mixed effect multiple 
regression analysis, no association between baseline cortisol levels and baseline 
MoCA scores was found. When adjusted for the presence of delirium, the median 
morning: afternoon ratio of cortisol during week 1 after stroke was significantly 
associated with the baseline MoCA score (table 6). A larger ratio (meaning 
preservation of the normal diurnal pattern) was associated with a higher MoCA score, 
and so conversely loss of the normal diurnal pattern (indicated by a lower morning to 
afternoon ratio) was associated with a lower MoCA score There was no significant 
association between cortisol levels during week 1 after stroke and the rate of change 
of the MoCA nor the neuropsychological test battery scores in the 12 months after 
stroke.  
 
This provides the first evidence of a possible relationship between the HPA axis and 
cognitive decline after stroke. The association between baseline global cognition 
(measured at the first assessment after stroke onset) and salivary cortisol is intriguing. 
It is interesting that no association was found between cortisol and the trajectory of 
cognitive function in the year after stroke, implying that if the association is real, the 
effects of cortisol on cognition are greatest in the first few days after stroke. The 
effect of delirium may confound this finding, as although the presence of delirium 
was controlled for in the statistical model, it is possible that a brief episode of 
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delirium, or sub-syndromal delirium (whereby some of the features of delirium are 
present, but the full diagnostic criteria are not met) may have been missed, but that 
this may have had a detrimental effect on the baseline MoCA score. Additionally, 
there may also be short-term effects on cognition (and indeed on cortisol levels) of the 
stroke itself and any other intercurrent illness present at the time of assessment. It is 
also interesting that in this small study it was the ratio (morning: afternoon), but not 
absolute values of cortisol that were associated with cognition. This implies that it 
may be the loss of diurnal rhythm, resulting in higher circulating levels of cortisol in 
the afternoon and evening, which is associated with cognitive decline. This finding 
replicates those of the population based KORA-age study (Johar et al., 2015) 
(described in the introduction), which found a loss of diurnal rhythm in cortisol was 
associated with cognitive decline (in men but not in women, although there were 
relatively few women in the cognitively impaired group). A second population based 
study (of 914 non-demented participants) from Amsterdam by Gerritsen and 
colleagues (Gerritsen et al., 2011) also found a loss of diurnal rhythm in association 
with cognitive decline, but only in those who were APOE-ε4 allele carriers. This 
study also found that higher evening cortisol levels were associated with a more rapid 
decline in delayed recall, which is thought to be a hippocampal dependant memory 
function. It is important to note that neither of the aforementioned studies included 
participants after stroke per se, and neither are able to infer the direction of causation 
in terms of whether loss of a diurnal cortisol rhythm is a cause or a consequence of 
cognitive decline.  
 
The finding of an association between a loss of diurnal cortisol rhythm and cognitive 
decline in those who have recently had a stroke is important as it is often assumed that 
the pathological processes underlying cognitive decline after stroke are predominantly 
vascular. The findings of this study suggest that cortisol may also play a role, perhaps 
by deleterious actions on neurones (particularly in the hippocampus). If this 
association is replicated in larger prospective studies (which would be required in 
order to infer the direction of causality) it would offer intriguing targets for 
therapeutic intervention.   
 
There are some limitations to this study which should be acknowledged. The study 
findings are confounded by the fact that there was significant attrition of participants 
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from the delirium group in particular, who are more likely to have underlying 
cognitive impairment. This means that those who underwent cognitive testing at 4 
months and 12 months were generally physically and cognitively more robust. There 
is a large amount of missing data, particularly from the cognitive tests and again the 
frailer participants were more likely to ask to terminate testing early and hence have 
data missing from their cognitive profile. Cortisol samples were taken in the morning 
and afternoon for reasons of practicality. It could be argued that samples should have 
been taken earlier in the morning and later in the evening to give a clearer indication 
of the diurnal variation, however this would have posed logistical problems and may 
have reduced the number of samples collected. Although every effort was made to 
ascertain whether participants had been free from delirium in the time between 
hospital discharge and follow-up visits, it is possible that brief new episodes may have 
been missed. It was also difficult to establish the duration of a new episode of 
delirium which had occurred in the community, particularly if it was brief and did not 
lead to hospital admission (as was the case for one participant). These factors mean 
that the true incidence and duration of delirium and its impact on post-stroke 
cognitive trajectory may have been underestimated. Finally, as discussed in section 
5.4, caution is required in the interpretation of the multivariate models presented in 
this chapter, as although the number of predictors in the model did not exceed 1 per 
10 participants, the effect size of cortisol on cognition and delirium after stroke was 
not known, and therefore not taken into account. Once again, as described in section 
5.4, a Bonferroni correction may be applied in order to account for multiple 
comparisons, however again the main findings presented in this chapter were not 
altered when this correction was applied to the analysis.  
 
 
In summary, this study has shown that median cortisol levels in the first week after 
stroke are associated with the presence of delirium and, after adjusting for the 
presence of delirium, the median morning: afternoon ratio of cortisol during week 1 
after stroke was significantly associated with the baseline MoCA score. There was no 
significant association between cortisol levels in the first week after stroke and the 
trajectory of global cognition (measured by the MoCA) over 12 months, in the subset 
of participants who completed the full 12 months of the study.  
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Chapter 8: Delirium after stroke and 
neuroimaging biomarkers on Computed 
Tomography (CT) scans 
 
8.1 Introduction  
 
In conditions other than stroke, neuroimaging studies have found a possible link 
between delirium and the presence of white matter lesions (WMLs), however the 
studies are small and have methodological weaknesses, such as failing to control, for 
age (Soiza et al., 2008), or assessing for delirium retrospectively (Hatano, 2013). A 
recent, more methodologically sound, study of 146 participants without dementia 
undergoing elective surgery, found no association between brain atrophy, WMLs 
(detected using MRI) and delirium incidence or severity (Cavallari, 2015).  
 
Almost all patients with a suspected stroke admitted to hospital in developed countries 
will have a CT brain scan soon after admission (within 24 hours of admission in the 
United Kingdom). Whilst some patients may go on to have an MRI brain scan as well, 
many patients will not be able to tolerate this because of the time required to complete 
the scan and also because some find that the MRI scanner is noisy or makes them feel 
claustrophobic. Furthermore,  up to one fifth of patients are not able to undergo MRI 
scanning either because they are too unwell or because they have an intracerebral or 
intraocular metallic foreign body or a pacemaker (Wardlaw, 2004). Computed 
Tomography, whilst providing a less detailed scan, is much quicker to complete 
(usually completed from beginning to end within ten minutes) and suitable for nearly 
all, and so studies using CT closely reflect the whole clinical population. Furthermore, 
whilst CT is primarily performed from a clinical point of view to exclude 
haemorrhage, early signs of ischaemic stroke can also be seen on CT, such as 
swelling, hypodensity and hyperdense vessels, as well as any old stroke lesions. The 
presence and severity of white matter lesions (WMLs) and any cerebral atrophy can 
also be determined from CT brain scans. Indeed, for some parameters such as global 
cerebral atrophy and presence of moderate-severe white matter lesions  CT and MRI 





As discussed in section 1.5.5 few studies have investigated the relationship between 
neuroimaging biomarkers, such as brain atrophy and white matter lesions, and 
delirium after stroke. To date, just two published studies have investigated this. 
Henon and colleagues recruited 202 participants, of whom 120 had a computed 
tomography (CT) scan and 82 had a Magnetic Resonance Imaging (MRI) scan. They 
found that those with delirium had more cortical atrophy , though there was no 
correction for age (Henon et al., 1999).  Oldenbeuving and colleagues reported that in 
527 stroke participants, brain atrophy on CT scan was associated with an increased 
risk of delirium in the first week after stroke. However, participants were assessed for 
just one week after stroke (or up to 15 days if they were diagnosed with delirium in 
the first week), meaning that delirium occurring after day 7 of stroke onset would be 
missed (Oldenbeuving, 2011).  
  
The stroke lesion itself is known to influence outcome in terms of morbidity and 
mortality, for example haemorrhagic stroke confers a higher risk of mortality than 
ischaemic stroke (even after correcting for age and stroke severity)(Anderson, 2009). 
Again, as previously discussed, conflicting results have been found in terms of the 
types of acute stroke lesions which confer the highest risk of delirium, with Gustafson 
and colleagues finding that haemorrhagic stroke and left sided lesions conferred the 
highest risk, whilst Oldenbeuving and colleagues found an association with right 
hemisphere lesions (Henon et al., 1999, Oldenbeuving, 2011).  To my knowledge no 
previous studies have investigated the relationship between old stroke lesions seen on 
neuroimaging and delirium after stroke.  
 
 
This aims of this section of the study are to: 
1. Analyse the relationship between post-stroke delirium and brain atrophy 
2. Analyse the relationship between post-stroke delirium and WMLs 
3. Analyse the relationship between post-stoke delirium and acute and previous 
stroke lesions 
 
The main hypothesis addressed in this chapter is:  Baseline pathology detected on 
admission CT brain scans, namely global brain atrophy, white matter lesions and a 







All 95 participants recruited to the longitudinal cohort study of delirium and long-
term cognitive impairment after stroke underwent CT brain scanning as part of their 
routine clinical care, prior to recruitment to the study, after stroke. Subjects were 
scanned in a Toshiba 64-slice or 128-slice scanner (the 64-slice scanner being 
replaced by a new 128-slice scanner during the study period). Brain scans were stored 
in the clinical Patient Archiving and Communication System (PACS). The study 
protocol, including how delirium was diagnosed, are described in detail in Chapter 
Two. 
 
8.2.2 Data extraction 
 I (AJB), a Geriatric Medicine Registrar, underwent training with an experienced 
neuroradiologist (Dr Andrew J Farrall, AJF), on how to read and extract data from CT 
brain scans. This training consisted of a face to face briefing on how to use the data 
extraction tool and practical demonstrations, face to face, of how to analyse the scans 
in a systematic way. I also participated in the Acute CT Cerebral Evaluation of Stroke 
Study (ACCESS) as part of my training (www.neuroimage.co.uk), which involved 
interpreting scans and comparing responses against those of experts. A standard 
method of extracting information on stroke lesion location, anterior and posterior 
white matter lesions (using the Van Swieten scale (van Swieten et al., 1990)) and 
global cerebral atrophy (Pasquini et al., 2007), which has been successfully used in a 
previous study of fatigue after stroke (Kutlubaev et al., 2013) and also in a study of 
thrombolytic treatment after stroke (Wardlaw JM et al., 2015), was used for this study 
(see appendix 6) . Following recruitment to the study, but prior to delirium and 
cognitive assessments, I rated CTs using the standardised proforma previously 
described. AJF subsequently rated all scans, in batches of ten, blind to all other data. 
Scans were read by both me and AJF so that an inter-rater reliability analysis could be 
performed. With the exception of the inter-rater reliability, all results presented are 





8.2.3 Delirium diagnosis 
Delirium was diagnosed as outlined in detail in section 1.2.5 and section 4.5 
8.2.4 Statistical analysis  
Due to the use of short ordinal scales and the non-normal distribution of some of the 
data non-parametric statistical analysis was used. The Mann- Whitney U test (for 
continuous data) or the chi-square test (for nominal categorical data) was used to 
investigate the relationship between delirium diagnosis and baseline characteristics. 
Inter-rater reliability: 
The agreement between the two observers (inter-rater reliability) was tested by 
calculation of weighted kappa values. Weighted kappa values were chosen because 
the categories are ordered (i.e. none, mild, moderate or severe for both WMLs and 
atrophy) which allows account to be taken of the magnitude of discrepancy between 
the two raters.  A kappa value of <0.2 signifies a poor strength of agreement, 0.21-
0.40 fair, 0.41-0.60 moderate, 0.61-0.80 good and 0.81- 1.00 very good (Altman, 
1991).  
Neuroimaging features and delirium: 
 
Pearson’s chi-square test was used to investigate the relationship between delirium 
diagnosis (at any time point in the 12 month study period) and presence of an acute 
ischaemic lesion, acute haemorrhage, presence of a hyperdense artery, global cerebral 
atrophy (rated none, mild, moderate or severe) and WMLs (rated none, mild moderate 
or severe) and presence of an old stroke lesion.  
 
Multivariate analysis:  
 
Binary logistic regression, using the enter method, was used to explore the 
independent contributions of each variable. Delirium (binary outcome, yes/no) was 
the dependent variable. Predictor variables selected a priori, based on the hypothesis 
and findings in previously published studies, were WMLs (linear scale where 0 = 
none, 1 = mild 2=moderate and 3=severe), atrophy (linear scale from 0-4 as described 
for WMLs), presence of an acute stroke lesion and presence of an old stroke lesion. 
Co-variates selected a priori were age, sex, NIHSS score at admission (as a measure 




All 95 participants had a CT brain scan and were included in this sub-study. 
Participant baseline descriptive information is presented in section 5.3. Twenty-six 
participants (27%) were diagnosed with a delirious episode at some point during the 
12 month study period. 
An acute stroke lesion was present in 40 (42%) participants overall, of whom 32 
(34%) had an ischaemic lesion and 8 (8.4%) had a primary haemorrhagic lesion (table 
8.1). Old vascular lesions were seen in 39 (41%) participants, cerebral atrophy (of any 
degree ranging from mild to severe) was present in 89 (93.6%) participants and 
WMLs were present in 70 (73.6%) participants. The atrophy and WMLs were 
symmetric in the majority of participants (85% of those with atrophy and 85% of 
those with WMLs). Finally, only one participant had an entirely normal scan, without 































Table 8.1 Descriptive statistics of participants with and without delirium in the 12 
months after stroke 
 
 
Characteristic Delirium (n=26),  No delirium (n=69),  p 
Age, median (IQR) 83.5 (79-85.3) 74 (68.5-82) <0.001 
Length of stay, days, 
median (IQR) 
26.5 (11-51.8) 10 (5.5-23) 0.002 
 n(%) n(%)  
Males 10 (37) 46 (67) 0.01 
Thrombolysed 11 (42) 13 (19) 0.58 
Short IQCODE score 
≥3.4 
15 (56) 18 (26) 0.004 
Acute ischaemic lesion 10 (37) 22(32) 0.545 
Acute haemorrhage or 
haemorrhagic 
transformation 
4(14.8) 4(6) 0.134 
Hyperdense artery present 2(7.4) 5(7.2) 0.825 
Atrophy present 






















White matter lesions 
present 
























Old vascular lesion 
present 
Classification: 
Old cortical infarct 
Old striatocapsular infarct 
Old lacunar infarct 
























8.3.1 Inter-rater reliability (between neuroradiologist and Geriatric 
Medicine registrar) 
The weighted kappa score for the rating of cerebral atrophy was 0.41 (moderate 
agreement) and the weighted kappa score for the rating of white matter lesions was 
0.61 (good agreement). 
 
8.3.2 Neuroimaging features and delirium 
Delirium diagnosis was associated with the presence of global cerebral atrophy (100% 
of those diagnosed with delirium had atrophy compared with 91% of those in the non-
delirium group). There was no relationship between the diagnosis of delirium and the 
presence of a visible acute or chronic, ischaemic or haemorrhagic lesion, the presence 
of a hyperdense artery or the presence of WMLs.   
8.3.3 Multivariate analysis 
The assumptions for logistic regression including linearity (meaning that there is a 
linear relationship between continuous predictor variables and the logit of the 
outcome variable (in this instance delirium presence or absence)), independence of 
errors (meaning that each case of data is not related) and Multicollinearity (meaning 
that predictor variables are not highly correlated) were tested and met. In terms of 
multicollinearity, all of the tolerance values are greater than 0.1 and Variance 
Inflation Factor (VIF) values are all less than 10, which are within recommended 
limits (Field, 2009), and analysis of the eigenvalues does not suggest collinearity 
between variables. A logistic regression (using the enter method) was performed with 
delirium (binary outcome, yes/no) as the dependent variable and WMLs (linear scale 
where 0 = none, 1 = mild 2= moderate and 3= severe), atrophy (linear scale from 0-4 
as described for WMLs), presence of an acute stroke lesion, presence of a chronic 
stroke lesion, age, sex, NIHSS, and IQCODE as the predictor variables (table 8.2).  A 
total of 95 cases were analysed and the model accounted for between 38% and 55% of 
the variance in delirium status. Table 3 shows the odds ratio and 95% confidence 
intervals (CI) for each of the predictor variables. This shows that only sex (being 
female), NIHSS score at baseline and presence of atrophy were independent 
predictors of delirium incidence. The model is corrected for all of the variables 









Variable Odds ratio 95% CI p 
Age (years) 1.07 0.98-1.18 0.114 
Sex (female) 6.99 1.44-33.89 0.016 
NIHSS  1.28 1.09-1.51 0.003 
IQCODE score 6.23 0.36-107.84 0.208 
Brain atrophy 
(0-3) 
3.70 1.15-11.88 0.028 
White matter 
lesions (0-3) 
0.73 0.33-1.39 0.427 
Visible acute 
stroke lesion 
2.36 0.62-8.93 0.207 
Visible old 
stroke lesion 




























In this study of 95 participants, the relationship between post-stroke delirium and 
brain atrophy, WMLs and presence of acute and old stroke lesion visible on CT brain 
scans was investigated.  The presence of brain atrophy was associated with delirium at 
up to 12 months after stroke , and with each increase in atrophy score of one point (on 
the scale where 0 = none, 1 = mild 2= moderate and 3= severe) participants were 3.36 
times more likely to develop delirium.  However, the presence of WMLs and visible 
acute or chronic stroke lesions were not associated with delirium. The severity of the 
stroke (measured by NIHSS at baseline) predicted delirium, with those with a higher 
score being more likely to develop delirium. Female sex, but not age, was also 
associated with delirium. 
The finding that brain atrophy, but not WMLs, are associated with delirium after 
stroke is in keeping with findings of a previous study of delirium in the first week 
after stroke (Oldenbeuving, 2011).  It is well established that the extent and rate of 
total brain atrophy and ventricular enlargement are associated with development of 
dementia, independent of hippocampal atrophy (Appleman, 2010).  It is possible that 
those with pre-existing brain atrophy are more vulnerable to developing delirium, 
even if they do not have dementia, perhaps by virtue of the neuroanatomical changes 
found in atrophic brains such as narrowed gyri, widened sulci and enlarged ventricles, 
which in turn reflect neuronal loss (Gunther, 2012). Neuronal loss, perhaps in certain 
critical regions (Field, 2012), may reduce the resilience of the brain to resist acute 
dysfunction resulting from the precipitants commonly implicated in delirium. 
 
Whilst I did not find a relationship between the presence of a visible stroke lesion and 
delirium, it is important to note that the baseline CT scans were all performed within 
24 hours of stroke onset. It is possible therefore, for ischaemic, but not haemorrhagic 
strokes, that a subsequent scan may have revealed a stroke lesion, not evident on the 
initial scan and consequently an association between presence of an acute ischaemic 
stroke lesion and delirium could be missed. Thirty-seven out of 95 scans had a visible 
stroke lesion present, 13 out of 26 of those diagnosed with delirium had a stroke 
lesion visible on admission scan and 24 out of 69 of those not diagnosed with 
delirium had a visible lesion on the admission scan. The NIHSS score, as a marker of 
stroke severity, was associated with delirium. Again this is in keeping with the 
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findings of previous work (McManus, 2009, Oldenbeuving, 2011), however I 
assessed participants more frequently and over a longer period than these previous 
studies meaning that prolonged episodes of delirium or incident delirium occurring 
after the first few days of stroke was less likely to be missed . The finding of an 
association between female sex and delirium has not previously been reported, indeed 
neither female nor male sex was associated with delirium in the two previous studies 
of neuroimaging and stroke, and further research will be required to unpick whether 
this is a true association. It is interesting to note that age per se was not found to be 
associated with delirium in the multivariate analysis. In general, brain atrophy is 
associated with advancing age (Samorajski, 1976), however formal testing of 
covariance did not find a significant relationship which would preclude both being 
included in the statistical model. This may be because other factors, such as pre-
existing dementia, were more important in determining which participants had an 
atrophied brain, rather than simply age in this cohort. However, several other well 
conducted studies which have not included brain atrophy in their analysis have tended 
to find an association between age and delirium after stroke (McManus, 2011, Henon 
et al., 1999, Edlund, 2006).  
The inter-rater reliability between a neuroradiologist and geriatric medicine registrar 
was moderate for atrophy and good for WMLs. Few previous studies of inter-rater 
reliability for rating atrophy on CT scans have been conducted, although one study 
looking at the reliability between 4 neuroradiologist found fair agreement (kappa 0.24 
(Leonardi, 1993)). This suggests that with appropriate training and the use of a 
validated tool, it is reasonable for a clinician to rate CT scans for atrophy, as inter-
rater reliability is at least as good as that found between a group of experts.    
This study has several strengths: I used data from routinely obtained clinical CT brain 
scans, which are available for all of the participants meaning that findings are more 
generalizable to the in-patient stroke population than if, for example, I had used 
research MRI scans for the study. It is not currently clear how well CT performs 
versus MRI in terms of detecting WMLs and atrophy on scans from stroke patients, 
although preliminary data suggests that there is good agreement between the scan data 
certainly in terms of detecting moderate to severe changes (Wattjes M.P, 2009, 
Wahlund, 2001).  I recruited a sample of stroke participants with a median NIHSS 
score of 5 (range 1-28, IQR 4-8) which has been shown by a recent audit of UK 
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hospital admissions to be clinically representative in terms of stroke severity (the 
median NIHSS score for >11 000 admissions was 5, IQR 2-10)(Sentinal stroke 
national audit programme).   I used a well validated assessment method to rate the CT 
parameters (Wardlaw JM et al., 2015), and used several well-validated methods to 
assess participants for the features of delirium, and assessments were carried out with 
sufficient regularity (and with the additional chart assessment tool and discussions 
with ward staff and family members), that it is unlikely that an episode of delirium 
was overlooked even though participants were not assessed face to face every day. It 
must be acknowledged, however, that a very mild or very brief episode which was 
neither detected by family members and clinical staff nor recalled by the patient could 
be overlooked. Particular attention was paid to the features of hypoactive delirium 
(for example reduced level of arousal) which may be overlooked by clinicians and 
family members if not specifically sought. Participants were followed-up for twelve 
months at intervals, as it is established that delirium may occur over a prolonged 
period following a stroke (McManus, 2009), previous studies have not assessed the 
whole cohort in this detailed way over a prolonged time period.  
There are a number of limitations to this study: The study was relatively small (95 
participants), however, in the field of delirium research few neuroimaging studies  
have been performed and even fewer have looked at neuroimaging and delirium after 
stroke (only two to my knowledge as previously discussed) . A systematic review in 
2008 found that in the 12 included studies 5 to 69 participants with delirium were 
included and 11 to 197 controls (Soiza et al., 2008).  Only 5% of participants in this 
study had a haemorrhagic stroke, whereas a recent audit found that around 10% of 
admissions to UK stroke units are due to haemorrhagic stroke (Sentinal stroke 
national audit programme), meaning that ischaemic stroke may be overrepresented in 
the study. There are a number of possible barriers to recruiting those who have 
suffered a haemorrhagic stroke, for example those with haemorrhagic strokes have a 
four-fold increase in the risk of death compared to those with ischaemic stroke (taking 
all ischaemic stroke types together) in the first few days after stroke, and on 
admission those with haemorrhagic stroke have higher stroke severity scores 
(Anderson, 2009). I controlled for undiagnosed dementia in the study using the 
IQCODE, which has been validated for use in this way (Jorm, 1995b), however it is 
important to acknowledge that the IQCODE relies on the informant recognising 
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changes in memory, prior to the stroke. To this end it is possible that some cases of 
pre-existing undiagnosed dementia may have been missed. As discussed in previous 
chapters, there was attrition of participants, particularly from the group who 
developed delirium. This may have had a bearing on the findings, as those with the 
most severe strokes (which are more likely to be visible lesions on CT scan) are more 
likely to have died early in their admission, meaning that delirium is perhaps less 
likely to have been diagnosed due to the short time frame of their admission. Finally, 
binary logistic regression analysis was performed on the data. Whilst this is an 
accepted method of analysing multivariate data with a binary outcome, it must be 
acknowledged that two of the predictor variables are ordinal (atrophy and WMLs), 
that is the values are ranked, in this case as none, mild, moderate and severe, but the 
real distance between each rank is unknown. In logistic regression, ordinal variables 
have to be treated either as nominal unordered categories or have to be numerical. In 
the former case information is lost as to the order of categories, and so I chose to label 
the categories numerically (0= none, 1= mild, 2= moderate and 3= severe). This 
assumes that one unit change, for example from 0 to 1 is approximately the same as 
one unit change from 2 to 3, an assumption which is difficult to verify in the context 
of brain atrophy. 
 
In summary, I found that delirium at up to 12 months post-stroke was associated with 
cerebral atrophy on baseline CT brain.  Baseline CT features may be useful, in 
conjunction with clinical measures, in aiding clinicians to predict who is particularly 
at risk of delirium. This may be particularly useful to predict those likely to develop 
hypoactive (or “quiet”) delirium which is often under-recognised. Strategies to reduce 
the risk of delirium in the most vulnerable can then be considered and targeted 
appropriately. Moreover the results provide an intriguing insight into the potential 
pathophysiological mechanisms underpinning delirium after stroke, which require 






Chapter 9: Linear Computed Tomography (CT) 





Brain atrophy identified on CT, in non-stroke patients, is known to be associated with 
delirium (Koponen, 1989). This association also held true in the cohort of stroke 
patients presented in this thesis (chapter 8).  A recent study using MRI brain scans in 
non-stroke  Intensive Care Unit (ICU) survivors suggested that atrophy in specific 
regions of the brain (for example superior frontal atrophy) may be associated with 
delirium duration, which in turn is associated with long-term cognitive impairment 
(Gunther, 2012). This is intriguing, and it is not clear if atrophy in specific regions of 
the brain is associated with delirium or indeed cognitive impairment after stroke. As 
discussed in chapter 8, MRI scanning is not suitable for a significant proportion of 
stroke patients and a reproducible method of assessing regional brain atrophy on CT 
scans may be beneficial for future studies of these associations. 
 
The use of quantitative linear measurements of CT scans to assess the presence and 
degree of brain atrophy has been investigated as a tool to detect (n=129) (Jobst, 1992) 
and diagnose (n=307) (Zhang, 2008) Alzheimer’s Disease (AD). This involves taking 
measurements of pre-defined features on CT scans using either callipers for hard 
copies of scans or computer graphical functions for electronic scans. Using these 
methods, atrophy of the medial temporal lobe has been shown to be associated with 
AD determined histopathologically, although the study controlled only for age, but 
not for other confounders such as previous strokes (Jobst, 1992). A second study 
found that  temporal horn and supracellar cistern measurement made a useful 
contribution to making a diagnosis of AD, when combined with other clinical factors 
(such as apolipoprotein E4 genotype) (Zhang, 2008), however this methodology has 
not been widely adopted subsequently. The associations of quantitative CT 
measurements of brain atrophy with delirium, in general, but also in particular after 
stroke have not previously been investigated.  
 
It is possible that quantitative analysis of CT scans may be more objective than  so 
called ‘qualitative’ analysis (qualitative in this context meaning, for example, the use 
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of short-ordered atrophy rating scales, whereby atrophy is rated as none, mild , 
moderate or severe, by a trained observer) in clinical research and possibly also in 
clinical practice. Inter-observer reliability for qualitative atrophy rating scales has 
been shown to be only fair, even amongst expert neuroradiologists (Leonardi, 1993), 
and consequently subjective estimation of brain atrophy may not be sufficiently 
reliable if the presence or absence of atrophy is to contribute to research findings and 
clinical decision making.  
 
 







1. To investigate the intrarater and inter-rater reliability of linear measurements 
of CT brain scans 
2. To investigate the relationship between brain atrophy determined by a 
qualitative rating scale and brain atrophy determined by quantitative linear 
measurements of  CT brain scans in patients presenting after stroke. 
3. To investigate the relationship between quantitative linear measurements of 





95 participants were recruited to the main longitudinal study and underwent baseline 
CT brain imaging as part of routine clinical care as previously described. Subjects 
were scanned in a Toshiba 64-slice or 128-slice scanner. Brain scans were stored in 
the clinical Picture Archiving and Communication System (PACS). The study 
protocol, including how delirium was diagnosed and how scans were analysed using a 







9.3.1 Data extraction  
 
I (AJB) was trained by a Research Fellow (Dr Karen Ferguson) with extensive 
experience in both qualitative and quantitative brain imaging analysis. I was given 
verbal and written instructions on how to identify, align and measure CT parameters 
and was observed analysing several practice scans, prior to commencing the study. I 
then took linear measurements directly from electronic images stored on the PACS 
system for the participants in this study, blind to all other data about the participant. 
Images were aligned to the AC-PC line and adjusted for symmetry. The graphics 
function of PACS was then used to perform the measurements. Measurements were 
based on a scheme, published by Zhang and colleagues (Zhang, 2008). The 
measurements taken are shown in figure 9.1. Measurements A, B, C, H, I, O, P and N 
are measured on the slice where the feature is most clearly visualised, measurement E, 
F and J are measured on the slice that shows most prominently the heads of the 
caudate nuclei, G is measured on the slice displaying most of the body of the lateral 
ventricle and M is measured from the top slices without displaying the lateral 
ventricle. Measurements took approximately 20 minutes to complete for each scan. 
With the exception of those measurements relating to skull size (A, B and C), a larger 
measurement would be indicative of a greater degree of brain atrophy.  
From these measurements, the following indices and ratios were calculated: 
Evans ratio (E/C), bicaudate ratio (F/A), Huckman number (E+F), cella media index 
(G/A), third ventricular ratio (H/A), ventricle index (J/E), frontal subarachnoid ratio 
(I/B), four cortical sulcal ratio (M/A), cistern ambiens ratio (N/A) temporal horn ratio 
(O/A) and supracellar cistern ratio (P/A). Those ratio’s which involve measurements 
A, B or C (measurements of the skull vault) are included as they correct for skull size 














Figure 9.1 Linear measurements taken on axial CT slices Reproduced with permission 












A- Maximal transverse intracranial width 
B- Maximal longitudinal intracranial 
width 
C- Maximal width of frontal skull 
H- Maximal width of the third ventricle 
I- Maximal width of frontal 
subarachnoid space 
P- Temporal horn diameter 
 
O- Suprasellar cistern width 
N- Width of cistern ambiens 
E- Maximal frontal horn width 
F- Minimal intercaudate distance 
J- Distance between the choroid 
plexuses 
G- Minimal ventricular body width 
M- Sum of widths of four widest sulci 






Intrarater reliability was tested by comparing repeated measurements from 10 subjects 
(subjects 1, 10, 20, 30, 40, 50, 60, 70, 80 and 90 were selected). The interval between 
the measurements was 4 weeks.  
 
 
Interrater reliability was tested by comparing repeated measurements for 20 subjects 
(including the 10 used for the intrarater reliability test) using a second rater (Dr Karen 
Ferguson, Department of Geriatric Medicine, University of Edinburgh, UK), blind to 




9.3.3 Statistical analysis 
 
The relationship between linear measurements of atrophy and atrophy ratings (none, 
mild, moderate or severe, as previously described) was investigated using Spearman’s 
correlations (one-tailed). The intrarater and interrater reliability was investigated 
using Spearman’s correlations and intraclass correlation coefficients (ICC, using a 
fixed effects two way mixed model, with absolute agreement). The ICC was 
interpreted as follows: >0.75=excellent agreement, 0.4-0.75=fair to good agreement, 
<0.4= poor agreement (Altman, 1991). Despite some measurements showing poor 
agreement between raters, all were included in the initial analysis of relationships 
between linear measures and atrophy rating scores and between linear measures and 
delirium, because this study is exploratory in nature. 
 
The relationship between the linear CT measurements and delirium at any time point 
in the 12 months after stroke (binary outcome, yes or no) was initially investigated 
using point biserial correlations. Principle Component Analysis (PCA) was then 
considered for analysis of the data, because of potential collinearity when considering 
a multivariate regression analysis. However, the data were not suitable for PCA 
because of the sample size (n=95, the Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy=0.41, KMO should be >0.5 to proceed (Field, 2009) ).  Thus the 
assumptions required for multivariate logistic regression were tested. The assumption 
of linearity of the logit was met, with all continuous variables being linearly related to 
the log of the outcome variable (delirium). Multicollinearity was then tested for; 
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tolerance values were all greater than 0.1 and variance inflation factor values were all 
below 10 and the variance proportions do not cluster to one eigenvalue, all of which 
indicates that collinearity is not a concern (Field, 2009). Multivariate analysis was 
then performed using binary logistic regression using the enter method, with age, sex, 
NIHSS, IQCODE (variables selected a priori) and the linear measurements which 
showed a significant correlation with delirium (taken to be a p value of <0.01) in the 
univariate analysis being included in the model. This approach was taken, rather than 
using specific linear measurements selected a priori, because there is no previous data 






The brain scans for 95 participants were included in the study. Baseline characteristics 
of the participants are outlined in chapter 5. The linear measurements are outlined in 
table 9.1. The values for median measurements for all parameters are similar to those 


























Table 9.1 Linear measurements taken from baseline CT brain scans 
 
Linear measurement Alphabetical 
annotation 
Median (mm) IQR (mm) 
Maximal transverse 
intracranial width  
A 138.3 134.1-141.6 
Maximal longitudinal 
intracranial width  
B 157.1 151.4-161.6 
Maximal width of frontal 
skull  
C 106.2 101.5-111.9 
Maximal frontal horn 
width  
E 38.6 35.2-41.5 
Minimal intercaudate 
distance  
F 19.4 16.9-23.7 
Minimal ventricular body 
width  
G 27.0 23.8-31.9 
Maximal width of the 
third ventricle  
H 8.1 7.2-10.0 
Maximal width of frontal 
subarachnoid space  
I 4.0 3.5-5.1 
Distance between the 
choroid plexuses 
J 53.6 47.7-58.9 
Sum of the widths of the 
four widest sulci 
M 20.2 17.8-23.3 
Width of the cistern 
ambiens 
N 4.3 3.9-5.2 
Temporal horn diameter 
 
O 4.4 3.7-5.4 
Supracellar cistern width 
  
P 25.8 24.2-28.1 
Evans ratio  
 
E/C 0.4 0.3-0.4 
Bicaudate ratio  
 
F/A 0.14 0.12-0.17 
Huckman number 
 
E+F 59.3 52.9-64.9 
Cella media index  
 
G/A 0.2 0.17-0.23 
Third ventricular ratio  
 
H/A 0.06 0.05-0.07 
Ventricle index  
 
J/E 1.4 1.2-1.5 
Frontal subarachnoid ratio  I/B 0.03 0.02-0.03 
Four cortical sulci ratio  
 
M/A 0.15 0.13-0.17 
Cistern ambiens ratio  
 
N/A 0.03 0.03-0.04 
Temporal horn ratio  
 
O/A 0.03 0.03-0.04 
Supracellar cistern ratio  
 







9.4.1 Intra-rater reliability  
 
As can be seen from table 9.2, intrarater agreement was excellent for the majority of 
measurements with the exception of the maximal width of frontal skull, C (fair to 
good agreement), width of the cistern ambiens, N (fair to good agreement) and the 
temporal horn diameter, O (poor agreement). 
 
 
9.4.2 Inter-rater reliability 
 
As can be seen from table 9.3, interrater reliability was excellent for maximal skull 
width and frontal skull width, minimal intercaudate distance, maximal width of the 
third ventricle and the sum of the widths of the four widest sulci. There was fair to 
good agreement for the maximal frontal horn width, minimal ventricular body width, 
minimal width of the frontal subarachnoid space and the temporal horn diameter, and 
the remainder of the measurements showed poor interrater reliability. 
 
 
9.4.3 Correlations between linear measurements and global atrophy 
rating score  
 
All of the linear measurements showed a statistically significant correlation with the 
atrophy rating score (table 9.4), with the exception of measurements A, B, C, J and P. 
Correspondingly, all derived indices and ratios showed a significant correlation with 
the atrophy rating score, with the exception of I/B and P/A.  
 
 
9.4.4 Correlations between linear measurements and diagnosis of 
delirium at any point during the study (univariate analysis) 
 
As it was specified a priori that a p value of ≤0.01 would be considered significant, 
only the maximal longitudinal intracranial width and the cisterns ambiens ratio 
























intracranial width  
A 0.823 0.003 0.931 
Maximal 
longitudinal 
intracranial width  
B 0.927 <0.001 0.915 
Maximal width 
of frontal skull  
C 0.539 0.108 0.685 
Maximal frontal 
horn width 








G 0.770 0.009 0.953 
Maximal width 
of the third 
ventricle  
H 0.600 0.067 0.882 
Maximal width 
of the frontal 
subarachnoid 
space  




J 0.915 <0.001 0.780 
Sum of the 
widths of the four 
widest sulci 
M 0.661 0.038 0.828 
Width of cistern 
ambiens  
N 0.467 0.174 0.660 
Temporal horn 
diameter 
O 0.273 0.446 0.227 
Supracellar 
cistern width  
P 0.758 0.011 0.771 
+Poor agreement 




























B 0.655 0.002 0.376 
Maximal width of 
frontal skull (C) 
C 0.740 <0.001 0.859 
Maximal frontal 
horn width (E) 








G 0.486 0.03 0.653 
Maximal width of 
the third ventricle 
(H) 
H 0.703 0.001 0.847 








J 0.247 0.295 0.039+ 
Sum of the 
widths of the four 
widest sulci (M) 
M 0.678 0.001 0.813 
Width of cistern 
ambiens (N) 
N 0.038 0.872 0.142 
Temporal horn 
diameter (O) 
O 0.610 0.004 0.579 
Supracellar 
cistern width (P) 










Table 9.4 Spearman’s rho correlations between linear measurements and global 
atrophy rating scores (none, mild, moderate or severe) 
 
Linear measurement  Alphabetical 
annotation 
Spearman’s rho p 
Maximal transverse 
intracranial width 
A 0.116 0.13 
Maximal longitudinal 
intracranial width 
B 0.130 0.105 
Maximal width of frontal 
skull 
C 0.130 0.104 
Maximal frontal horn width E 0.563 <0.001 
Minimal intercaudate distance F 0.600 <0.001 
Minimal ventricular body 
width  
G 0.522 <0.001 
Maximal width of the third 
ventricle  
H 0.530 <0.001 
Maximal width of frontal 
subarachnoid space  
I 0.194 0.030 
Distance between the choroid 
plexuses  
J 0.097 0.176 
Sum of the widths of the four 
widest sulci  
M 0.192 0.031 
Width of the cistern ambiens  N 0.212 0.020 
Temporal horn diameter  O 0.416 <0.001 
Supracellar cistern width  P 0.084 0.208 
Evans ratio  E/C 0.504 <0.001 
Bicaudate ratio  F/A 0.606 <0.001 
Huckman number  E+F 0.609 <0.001 
Cella media index  G/A 0.518 <0.001 
Third ventricular ratio  H/A 0.528 <0.001 
Ventricle index  J/E -0.390 <0.001 
Frontal subarachnoid ratio  I/B 0.144 0.083 
Four cortical sulci ratio  M/A 0.173 0.047 
Cistern ambiens ratio  N/A 0.191 0.032 
Temporal horn ratio O/A 0.377 <0.001 













Table 9.5 Univariate analysis of the relationship between linear measurements on CT 
brain scans and diagnosis of delirium at any point after stroke (binary outcome, yes or 
no) n=95. 
 
Linear measurement  Alphabetical 
annotation 
rpb p 
Maximal transverse intracranial width  
 
A -0.157 0.128 
Maximal longitudinal intracranial 
width  
B -0.300 0.003 
Maximal width of frontal skull  
 
C -0.131 0.206 
Maximal frontal horn width 
  
E 0.132 0.204 
Minimal intercaudate distance  
 
F 0.113 0.278 
Minimal ventricular body width 
  
G -0.017 0.872 
Maximal width of the third ventricle  
 
H 0.197 0.057 
Maximal width of frontal 
subarachnoid space  
I 0.229 0.026 
Distance between the choroid 
plexuses  
 
J -0.113 0.277 
Sum of the widths of the four widest 
sulci  
M 0.101 0.328 
Width of the cistern ambiens  
 
N 0.208 0.043 
Temporal horn diameter  
 
O 0.181 0.080 
Supracellar cistern width  
 
P -0.017 0.869 
Evans ratio  
 
E/C 0.214 0.038 
Bicaudate ratio  
 
F/A 0.146 0.159 
Huckman number  
 
E+F 0.031 0.765 
Cella media index 
 
G/A -0.016 0.877 
Third ventricular ratio  
 
H/A 0.203 0.049 
Ventricle index  
 
J/E -0.228 0.027 
Frontal subarachnoid ratio  
 
I/B 0.240 0.020 
Four cortical sulci ratio  
 
M/A 0.135 0.193 
Cistern ambiens ratio  
 
N/A 0.323 0.001 
Temporal horn ratio  
 
O/A 0.190 0.067 
Supracellar cistern ratio  
 
P/A 0.013 0.898 
 




9.4.5 Multivariate analysis  
 
A logistic regression analysis was performed (table 9.6) with delirium as the 
dependant variable and age, sex, NIHSS, IQCODE (positive or negative) and the 
linear measurements which showed a significant correlation with delirium in the 
univariate analysis (with a p value of <0.01) as predictor variables. A total of 95 cases 
were analysed (omnibus chi-square = 40.63, df = 6, p < 0.0005). The model accounted 
for between 35.1% and 51.2% of the variance in the delirium status. Table 9.6 gives 
the Odds Ratios, 95% confidence internals and associated probability values for each 
of the predictor variables. This shows that only NIHSS score and the cistern ambiens 


























Table 9.6 Multivariate analysis: Binary logistic regression model. Predictors of 
delirium at any time point after stroke (n=95) 
 
Predictor variable Odds Ratio CI p 
Maximal longitudinal intracranial 
width (B) 
0.90 0.80-1.00 0.190 
Cistern ambiens ratio (N/A) 1.41 1.48-4.96 0.028 
Age (years) 1.09 1.00-1.19 0.075 
Sex (being female) 0.65 0.14-3.13 0.536 
IQCODE (positive or negative) 1.83 0.13-25.74 0.653 






























In this study, linear measurements in general showed excellent correlation with 
atrophy rating scores, with the exception of those measurements which are fixed and 
so would not alter in an atrophied brain (for example, skull dimensions, measurements 
A,B and C). In multivariate analysis, when age, sex, IQCODE and NIHSS scores are 
controlled for, only the cistern ambiens ratio was associated with delirium. NIHSS 
score (as a measure of stroke severity) also significantly predicted delirium when all 
other factors were controlled for. 
 
Intrarater reliability was good or excellent for all linear measurements, with the 
exception of the temporal horn diameter, which showed poor agreement. This may be 
due to the small overall size of the temporal horn, meaning that any small differences 
in measurements causes a large percentage difference between measurements. 
Furthermore, small changes in the level at which the CT slice is being measured 
would also have a large effect on the measurement. In future studies, it would be 
prudent to exclude those measures which showed poor reliability from the 
methodology.  
 
Interrater reliability was good or excellent for nine out of thirteen measurements. The 
measurements that showed poor interrater reliability were; maximal longitudinal 
intracranial width (B), distance between the choroid plexuses (J), width of cistern 
ambiens (N) and supracellar cistern width (P). These measurements all have the 
potential to vary quite significantly depending upon the slice selected to measure and 
it is possible that this, at least in part, accounts for the poor reliability. Furthermore 
the distance between the choroid plexuses relies on a subjective judgement of where 
the outer edge of the plexus begins, and this can be particularly difficult to judge if 
there is no calcification to demarcate the edges. 
 
Both intrarater reliability and interrater reliability can be calculated using statistical 
methods. The most appropriate test to use depends largely on the type of assessment 
being compared and whether raters are selected randomly from a population of 
potential raters or are fixed raters. For categorical variables, whereby the aim is to 
compare the ability of the raters to classify subjects into one of several groups, the 
measure of agreement most frequently used is kappa. Kappa is calculated by taking 
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the agreement that would be expected by chance and expressing the actual agreement 
found in the study as a proportion of the possible scope for doing better than chance. 
Thus when agreement is perfect, the kappa value will be 1 and when there is no 
agreement, the value is 0. As a guideline, Altman (Altman, 1991) suggests that a 
value of between 0.21-0.40 is fair agreement, 0.41-0.6 is moderate agreement, 0.61-
0.8 is good agreement and 0.81-1.00 is excellent agreement. Weighted kappa statistics 
are useful when the degree of disagreement between raters is important. For example 
if looking at the brain atrophy rating scores presented in chapter 8 it is helpful to take 
account of whether raters disagreed by one category (for example one rated atrophy as 
mild and one as moderate) or by more than one category (one rated the scan as mild 
atrophy and one as severe, for example). In order to calculate weighted kappa scores 
the degree of difference is given a weighting score. The kappa statistic cannot be used 
if the outcome variable is continuous, as the raters are not classifying subjects into 
groups. For continuous variables (such as the linear measurements investigated in this 
study), intraclass correlations coefficients (ICC) are a suitable alternative (Shrout and 
Fleiss, 1979). Intraclass correlations coefficients represent the proportion of variance 
in a set of scores that is attributable to the true score variance. The ICC is calculated 
by using ANOVA to test whether the 2 sets of scores are significantly different to 
each other, and the ANOVA results are then put into a fixed effects model to calculate 
the ICC. Thus an ICC of 0.95 implies that 5% of the variance seen in the observed 
scores is due to observer error, whereas a score of 0.10 would imply that 90 % of the 
variance seen between observed scores is due to observer error. Bland- Altman plots 
are a third statistical method often used to compare measurements in studies. Bland-
Altman plots are used to compare two different methods of measurement, for example 
they could be used to compare salivary cortisol levels measured by two different sets 
of laboratory equipment. They can also be used to analyse the repeatability of a single 
measurement and to compare measurements between two observers, although they 




The finding that the cistern ambiens ratio is the only measurement that predicts 
delirium is intriguing. However, it must be noted that the cistern ambiens ratio 
showed poor interrater agreement, and also that in multivariate analysis, the 95% 
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confidence intervals for this measurement were wide, and there was only a small 
change in cistern ambiens size per unit change in delirium status. Thus this finding 
should not be over-interpreted, particularly in the context of this small exploratory 
study.  Zhang and colleagues (Zhang, 2008), who  first described the methodology 
used here for linear measurements, looked at those with Alzheimer’s disease (AD) 
compared with controls and found that those with AD had a greater temporal horn 
ratio and supracellar cistern ratio when compared to controls. This finding is in 
keeping with medial temporal lobe atrophy, one of the known pathological changes 
found in AD. The ambient cistern is part of the subarachnoid cisterns, and widening 
of the cistern results from atrophy of the structures which border it (Chakeres, 1986), 
in particular the cerebellum, midbrain and pons. Furthermore,  the cistern ambiens 
laterally extends to become the transverse fissure, which is one of the 
perihippocampal fissures (Chakeres, 1986). Atrophy of the perihippocampal fissures 
has been shown to be associated with ageing and AD (Li, 2006). Interestingly, neither 
the cistern ambiens measurement nor the cistern ambiens ratio correlated significantly 
with the atrophy rating scores in univariate analysis. This may be explained, at least in 
part, by the fact that although the rater takes account of the whole brain when rating 
for atrophy, atrophy of the cistern ambiens is likely to be much more subtle than 
enlarged ventricles, for example. This would mean that the cistern ambiens rating 
would contribute little to the overall rating given to the brain scan.  
 
The maximal longitudinal intracranial width was also associated with delirium in 
univariate analysis, although this relationship did not hold true when other factors 
such as age and stroke severity were controlled for in the multivariate analysis. 
Furthermore, it is not the absolute measurement of the cistern ambiens that was 
associated with delirium in this study, but rather the ratio of the cistern to the 
maximum transverse intracranial width. This means that both measurements that are 
associated with delirium in the univariate analysis include a measure of head size. 
Head size is fixed throughout adulthood, whilst brain size tends to decrease due to 
age-related atrophy and intracranial area (ICA) varies considerably between 
individuals and is an estimate of peak or maximal brain volume (Shenkin, 2009), 
which is attained at around 6 years of age (Gale CR, 2003). This is important as it has 
previously been demonstrated that whole brain volume correlates positively with 
current intelligence (Shenkin, 2009) and also that ICA correlates positively with 
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general cognitive ability (MacLullich, 2002). This means that the associations found 
with delirium here may simply reflect a participant’s cognitive reserve, as a function 
of their general cognitive ability.  
 
It is perhaps surprising that other linear measurements do not seem to be associated 
with delirium, considering that the overall atrophy rating was. One may perhaps have 
expected measurements such as the ventricular body width to show an association 
with delirium. It may simply be that the absolute differences in measurements 
between those with and without delirium are subtle, and so no clear association 
emerges, whereas with the atrophy rating scale these subtleties are accounted for by 
the rater. Finally, and perhaps most importantly, it should be noted that this is a small 
pilot study, with only those who have recently had a stroke included, meaning that the 
findings should be interpreted with caution. Larger studies which are appropriately 
powered to investigate the associations between linear measures on CT and delirium 




























Chapter 10: General Discussion 
 
The studies presented in this thesis aimed to investigate: 1).The relationship between 
delirium after stroke and cortisol, 2). The relationship between delirium, cortisol and 
cognitive changes in the year after stroke, and 3). Baseline changes on brain CT scans 
and their relationship to delirium. The studies specifically aimed to investigate 
whether delirium after stroke is associated with elevated cortisol levels, the trajectory 
of cognitive function after stroke, and the relationship between cognition, delirium 
and cortisol levels. Finally, the associations between baseline features seen on 
admission CT brain scans (specifically white matter lesions, brain atrophy and the 
presence of an acute and/or chronic stroke lesion) and development of delirium were 
investigated, and an objective method of assessing brain atrophy on CT brain scans 
after stroke was piloted.  
 
This concluding chapter will summarise the main findings of this thesis, will discuss 




10.1 Main findings 
 
As was expected, following my systematic review of the previous literature (chapter 
2), there was an elevation in cortisol levels in the first 7 days after stroke, in a 
proportion of participants. This was more marked in the participants who developed 
delirium, however when other confounders were controlled for, such as age and stroke 
severity, cortisol was not found to be independently associated with delirium. There 
was also a trend towards loss of diurnal variation in cortisol levels in the delirium 
group, but again this was not statistically significant once other confounders had been 
controlled for. The overall cognitive trajectory for all participants showed a degree of 
improvement over the 12 month follow-up period.  Those in the delirium group 
tended to have poorer cognitive function at the outset, and although there was a trend 
towards improvement in cognition, particularly for those who had a mild or moderate 
severity delirium, this is confounded by attrition of those with more severe cognitive 
impairment. Delirium was associated with a lower MoCA score overall, however 
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incident delirium did not have a significant effect on the trajectory of the MoCA over 
the 12 month follow-up period. An association was found between baseline global 
cognition after stroke (measured by the MoCA score at the time of recruitment) and 
the loss of the normal diurnal pattern of cortisol levels. Brain atrophy, seen on 
admission CT brain scans, was associated with the development of delirium after 
stroke, however other changes, such as white matter lesions and the presence of a 
visible acute stroke lesion, were not. Finally, linear measurements of brain regions, as 
an objective measurement of brain atrophy, had good inter-rater reliability, but 
correlated only fairly with qualitative assessments of brain atrophy, and linear 
measurements were not associated with delirium in multivariate analysis.   
 
The studies presented in this thesis are all observational cohort studies. This means 
that it is not possible to infer the direction of causation for the findings. For example, 
it may be the case that those with brain atrophy were predisposed to developing 
delirium after stroke because of undiagnosed (and perhaps subtle) cognitive decline, 
which was not picked up by the IQCODE, rather than brain atrophy per se being the 
causative factor. Confounders were controlled for in multivariate analysis where 
possible, however the number of confounders that it is possible to control for is 
limited by the number of participants in the study (Field, 2009), and is also limited to 
factors that it is possible to quantify. Although I was not able to demonstrate a 
statistically significant relationship between cortisol and delirium in this thesis, it 
remains possible that cortisol is amongst the underlying mechanisms that lead to 
delirium, but that the effect size is smaller than the ‘moderate effect’ that the study 
was powered for. It may be that other factors that I did not measure in these studies, 
such as inflammation, play an important role in the pathogenesis of delirium 
(Maldonado, 2013), and that this may occur alongside any effects of HPA axis 
dysregulation.  
 
Perhaps the most unexpected finding in this thesis has been that the global cognitive 
trajectory for the whole cohort improved over the course of the 12 months. The 
magnitude of the improvement for the whole cohort, after controlling for the presence 
of delirium, was small and probably not clinically significant (an increase of 1.09 
points on the MoCA scale across the year), however, when participants who 
developed delirium were stratified by delirium severity, some groups showed a clear, 
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clinically significant, improvement. For example, for those who developed a mild 
delirium (n=8), the median MoCA score at baseline was 18, and at 12 months the 
median score for this group (n=7) was 25.5. There was a trend towards improvement 
in the group of participants who never developed delirium (median baseline MoCA 
24, Median MoCA at 12 months 26), although again this is probably not clinically 
significant. As no pre-morbid cognitive testing was available, it can only be said that 
any improvement occurred from the time of recruitment, and it was not possible to 
say whether there had been any overall improvement or deterioration at 12 months 
compared to pre-stroke cognitive function. However, for those who survived to 12 
months, this may have important implications for follow-up and discharge planning. It 
must be noted that these results should be treated with extreme caution, as attrition of 
those with the poorest cognitive function has skewed the results at follow-up (this has 
been termed “survival bias.” (Weuve et al., 2015)), and there may also be a learning 
effect for the cognitive tests, resulting in artificially higher results at 12 months. 
Furthermore, although depression was not specifically tested for in the studies, it is 
known that depression is common after stroke, affecting around 30% in the year after 
stroke, falling to around 25% between 1 and 5 years post-stroke, meaning that some 
of the improvement may have been explained by resolving depression (Hackett and 
Pickles, 2014). Even accounting for these factors, a proportion of participants 
undoubtedly showed improvement in global cognitive function over the 12 month 
follow-up period. Resolution of the acute effects of a stroke and of delirium probably 
accounts for much of the improvement seen and it is interesting to note that the 
improvement continued between 1 month and 4 months, and to a lesser extent, 
between 4 months and 12 months, which was not hypothesised, based on previous 
literature. As previously discussed much of the previous literature investigating 
cognition after stroke has not accounted for the effect of delirium on cognitive 
function. This is important as I have found that each episode of delirium in this study 
was associated with a 5 point decrease in the MoCA score overall, although delirium 








10.2 Strengths and limitations 
 
10.2.1 Strengths  
 
The studies presented in this thesis have several strengths. A service user group 
helped to ensure that the study was acceptable to participants, and their valuable 
insights also helped to retain participants for the duration of the study (89 % 
completed the study in total). This relatively high follow-up rate was achieved largely 
because I made home visits to participants, ensuring that the study was as acceptable 
as possible to a frail cohort, many of whom were left with a disability after stroke.      
 The methods used for assessing delirium were frequent, detailed, and attempted to 
determine the presence, duration and severity of delirium in a methodical way, 
incorporating both subjective and objective methods of assessment, as well as detailed 
assessment of level of alertness. This very detailed and structured method of 
assessment has not been used in studies of delirium after stroke before, although a 
similar methodology has been used in a study of delirium after hip fracture (Hall et 
al., 2015). Furthermore, delirium assessments were also performed at follow-up visits 
and, where possible, episodes of delirium between assessment points at 4 months and 
12 months were ascertained from informants, clinical notes and General Practitioners. 
Again, this detailed method which attempts to capture the natural history of delirium 
after stroke, has not previously been attempted, although again a similar methodology 
has been employed in a study of delirium after hip fracture (Neerland et al., 2016).  
In contrast with previous studies of delirium after stroke, patients who had a reduced 
level of consciousness were included in the study. This is essential, as drowsiness is 
commonly seen in those with delirium (Chester et al., 2012).  Care was taken to 
ensure that delirium was only diagnosed strictly by DSM-IV criteria, if there was a 
change in the patient’s condition, from what may be thought of as their new baseline 
after stroke. In this way it was possible to include those with severe TACS, and the 
results are therefore more generalizable to the acute stroke unit population. Delirium 
after stroke is particularly challenging to study in those with neurological deficits such 
as aphasia and inattention, as the core criteria for diagnosis of delirium rely on 
assessment of organized thinking and of attention (McManus et al., 2007). However, 
using the very careful detailed assessments described in this thesis, it was possible to 
apply the DSM-IV criteria to all participants, although none of those included had a 
very dense aphasia. The study protocol was planned such that those with a very dense 
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aphasia would be excluded from the study if there was no evidence of improvement 
over the first 2 weeks after stroke, but in practice it was not necessary to exclude any 





There are some important limitations to the studies described in this thesis. One of the 
major limitations is the numbers of participants recruited. Extreme care was taken in 
the planning and execution of the study, including the formation of a service user 
group, to try and maximise recruitment given the constraints of a single centre study 
and a relatively frail target population. Every effort was made to recruit all eligible 
participants, but inevitably, this meant approaching frail, elderly and extremely 
unwell people, many of whom did not have the capacity to provide informed consent. 
As outlined in previous chapters, this made timeous recruitment challenging, and also 
led to large numbers of proxies being approached to provide consent (with large 
numbers of proxies going on to refuse consent). Proxies may have found it 
particularly difficult to give consent for a study which had a 1 year follow-up period, 
which may have seemed onerous, and may also have been reluctant to provide 
consent for a study which was not providing obvious potential benefit for participants, 
in the way that inclusion to a randomised controlled trial may be perceived to have 
potential benefits. The potential benefits of careful follow-up of cognitive function, as 
well as the benefits of early detection of delirium in the acute phase, were fully 
explained, however many proxies felt that their relative was too unwell to take part in 
any study requiring multiple follow-up visits.  These challenges, many of which apply 
to all longitudinal studies of delirium, are difficult to overcome, although integrating 
delirium assessment into routine clinical care may be one method of reducing the 
perceived burden of studies. The small study size also meant that subgroup analysis 
was difficult, with some groups having only a few members by the 12 month follow-
up. This means that some of the sub-studies must be seen as exploratory. Recruitment 
and follow-up in the acute phase after stroke was all done by a single assessor. This 
has some benefits, in that there is likely to be good internal consistency for delirium 
assessments, however it did mean that the number of assessments had to be limited. It 
is therefore possible that a brief episode of delirium could have been overlooked, 
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although casenote analysis and informant and staff interviews were performed in a 
semi-structured way in order to minimise omission.   
 
10.3 Contribution to existing knowledge 
 
This thesis presents the largest study to date to investigate the associations between 
cortisol after stroke and delirium. Furthermore, it provides one of the most detailed 
assessments for delirium after stroke to have been used in the literature, and also 
includes the longest follow-up period of any of the studies of cortisol and delirium 
after stroke. The study of CT brain scans has provided additional and complementary 
detail to the previous studies which have found an association between brain atrophy 
and delirium after stroke (Oldenbeuving, 2011, Henon et al., 1999). Finally it has 
added to our knowledge of the trajectory of global cognition after stroke, and in 
particular has highlighted the importance of assessing for delirium when testing 
cognition after stroke, and also the importance of re-assessment- particularly if 
decisions about discharge placement have been based on cognitive function 
 
It seems unlikely to me that any single pathophysiological factor is entirely 
responsible for the development of delirium. Whilst cortisol may well have a role to 
play, other factors such as the underlying vulnerability of the brain, direct insults to 
the brain, and peripheral (and central) inflammation all probably play their part to a 
greater or lesser extent (Maldonado, 2013). This complexity means that it is extremely 
challenging to establish which of these factors is the most important in any patient 
population. Furthermore, those most at risk of delirium tend to either be elderly, with 
multiple co-morbidities, or be extremely unwell, perhaps requiring Intensive Care 
treatment. This adds another layer of complexity as illness, polypharmacy and 
environmental factors all may play a part in the development and maintenance of 
delirium. Unravelling which few factors are the most important and, crucially, 
determining which of these are safely modifiable is the challenge now facing the field 
of delirium research. Potential directions for future work will be discussed in detail in 
the following section (section 10.4) 
 
.   




10.4 Future work  
 
There is a clear need to further unpick the underlying pathophysiology of delirium 
after stroke, as the impact of delirium on outcomes after stroke is so devastating for 
patients, and understanding the pathophysiology offers potential for therapeutic 
targets. The evidence presented in this thesis does not provide a strong enough case 
for trials of treatments aimed solely at lowering cortisol levels, or dampening the HPA 
axis response, to be considered. A larger prospective study to investigate the role of 
cortisol in delirium after stroke (perhaps in combination with other factors such as 
markers of inflammation) may be fruitful, given the trend towards higher cortisol in 
the delirium group in this study, but this would require a much larger population 
based study, allowing participants to be recruited prior to stroke, to have cognitive 
testing and cortisol levels measured, and then to follow those that do have a stroke 
into the hospital setting (if we set α at 0.05 a sample size of 220 would be required to 
provide 80% power to detect a difference in cortisol levels between the two groups, 
and a sample size of 300 would be needed to provide 90% power). This would be 
difficult and costly to do, as a large initial sample would be required, in order that the 
study have sufficient power to detect any differences in cortisol between those with 
and those without delirium. However, the benefits of identifying key underlying 
pathophysiological processes are great, offering the potential to reduce not only the 
burden of delirium incidence for stroke patients, but also potentially reducing the 
burden of cognitive decline after stroke, which is a key priority for both stroke 
survivors and their carers (Pollock et al., 2014).  
Despite the lack of clarity surrounding the pathophysiology of delirium after stroke, 
given its high prevalence and association with adverse outcomes, it may be more 
fruitful to pursue a pragmatic multi-component intervention study, similar to that used 
in the Hospital Elder Life Program (Inouye et al., 2000), in the stroke unit. Some 
aspects of this may be challenging in stroke patients, for example nutritional needs are 
often being met by nasogastric feeding, however many of its components would be 
feasible. I personally feel that these types of intervention studies may in fact prove 
more useful, with tangible and timely benefits to patients, than studies attempting to 




The neuroimaging studies presented in this thesis, alongside other similar work, 
provide intriguing possibilities in terms of determining the brain structural risk factors 
for delirium in more detail. A deeper understanding of whether there are specific 
pathological changes which predispose individuals to developing delirium (and 
indeed dementia) may allow these factors to be targeted as preventative measures. 
The neuroimaging studies presented in this thesis have demonstrated the feasibility of 
obtaining CT brain images for the whole of the target population (there were no 
participants who were unable to have a CT brain scan performed) and also the 
feasibility of subsequent clinical correlation to assess for evidence of delirium. 
Computed Tomography remains an attractive modality for investigating neuroimaging 
changes in delirium because of its acceptability to patients, even those who are 
acutely unwell. As CT technology improves, scans are becoming more fine grained in 
the detail they can provide. It may soon be possible, for example, to delineate the 
hippocampus on CT images, in much the same way that it is possible to do on MRI 
scans currently. This presents exciting opportunities in the field of delirium research, 
particularly after stroke, as it offers the possibility of scanning those who are very 
unwell (and thus unable to tolerate MRI) and to map out any acute structural changes 
that may take place during an episode of delirium, in crucial regions such as the 
hippocampus. This real-time scanning during delirium has not been attempted in 
stroke patients, and although challenging, has the potential to dramatically improve 
our understanding of the structural brain changes which take place during an episode 
of delirium. Ideally one would also have pre and post delirium scans for comparison, 




In conclusion, the findings from this thesis are relevant to important areas of delirium 
research, including the diagnosis of delirium after stroke, the pathophysiological 
mechanisms of delirium after stroke and potential avenues for further investigation of 
the predisposing factors which lead to the development of delirium.  I would now like 
to utilise the knowledge and skills gained from these studies to undertake a 
randomized controlled trial of a multicomponent intervention for delirium prevention 
after stroke. The study would require detailed delirium assessments for all participants 
and, as all participants would have had a CT brain scan, it would also be possible to 
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include detailed baseline CT analysis, and possibly follow-up CT brain scanning. The 
multicomponent intervention would need to be tailored to the stroke population, but 
would be based on those successfully used in studies based in general medical wards 
such as that outlined in the Hospital Elder Life Program (Inouye et al., 2000) . The 
primary outcome from the study would be delirium incidence, with secondary 
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Appendix 1: Search strategy for systematic 
literature review of glucocorticoids and stroke 
(chapter 2)  
 
 
Part A: Stroke search strings (Cochrane Stroke Group) 
1. cerebrovascular disorders/ 
2. exp basal ganglia cerebrovascular disease/ 
3. exp brain ischemia/ 
4. exp carotid artery diseases/ 
5. cerebrovascular accident/ 
6. exp brain infarction/ 
7. exp cerebrovascular trauma/ 
8. exp hypoxia-ischemia, brain/ 
9. exp intracranial arterial diseases/ 
10. intracranial arteriovenous malformations/ 
11. exp “Intracranial Embolism and Thrombosis”/ 
12. exp intracranial hemorrhages/ 
13. vasospasm, intracranial/ 
14. vertebral artery dissection/ 
15. aneurysm, ruptured/ 
16. brain injuries/ 
17. brain injury, chronic/ 
18. exp carotid arteries/ 
19. endarterectomy, carotid/ or endarterectomy/ 
20. *heart septal defects, atrial/ 
21. *atrial fibrillation/ 
22. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral 
vasc$ or cva$ or apoplex$ or isch?emi$ attack$ or 
tia$1 or neurologic$ deficit$ or SAH or AVM).tw. 
23. ((brain$ or cerebr$ or cerebell$ or cortical or vertebrobasilar or hemispher$ or 
intracran$ or intracerebral or infratentorial or 
supratentorial or MCA or anterior circulation or posterior circulation or basal ganglia) 
adj10 (isch?emi$ or infarct$ or thrombo$ or 
emboli$ or occlus$ or hypox$ or vasospasm or obstruction or vasculopathy)).tw. 
24. ((lacunar or cortical) adj5 infarct$).tw. 
25. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or 
intraventricular or infratentorial or supratentorial 
or basal gangli$ or subarachnoid or putaminal or putamen or posterior fossa) adj10 
(haemorrhage$ or hemorrhage$ or haematoma$ 
or hematoma$ or bleed$)).tw. 
26. ((brain or cerebral or intracranial or communicating or giant or basilar or vertebral 
artery or berry or saccular or ruptured) adj10 
aneurysm$).tw. 
27. (vertebral artery dissection or cerebral art$ disease$).tw. 
28. ((brain or intracranial or basal ganglia or lenticulostriate) adj10 (vascular adj5 
(disease$ or disorder or accident or injur$ or trauma$ 
or insult or event))).tw. 
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29. ((isch?emic or apoplectic) adj5 (event or events or insult or attack$)).tw. 
30. ((cerebral vein or cerebral venous or sinus or sagittal) adj5 thrombo$).tw. 
31. (CVDST or CVT).tw. 
32. ((intracranial or cerebral art$ or basilar art$ or vertebral art$ or vertebrobasilar or 
vertebral basilar) adj5 (stenosis or isch?emia or 
insufficiency or arteriosclero$ or atherosclero$ or occlus$)).tw. 
33. ((venous or arteriovenous or brain vasc$) adj5 malformation$).tw. 
34. ((brain or cerebral) adj5 (angioma$ or hemangioma$ or haemangioma$)).tw. 
35. carotid$.tw. 
36. (patent foramen ovale or PFO).tw. 
37. ((atrial or atrium or auricular) adj fibrillation).tw. 
38. asymptomatic cervical bruit.tw. 
39. exp aphasia/ or anomia/ or hemiplegia/ or hemianopsia/ or exp paresis/ or 
deglutition disorders/ or dysarthria/ or pseudobulbar 
palsy/ or muscle spasticity/ 
40. (aphasi$ or apraxi$ or dysphasi$ or dysphagi$ or deglutition disorder$ or 
swallow$ disorder$ or dysarthri$ or hemipleg$ or hemipar$ 
or paresis or paretic or hemianop$ or hemineglect or spasticity or anomi$ or 
dysnomi$ or acquired brain injur$ or hemiball$).tw. 
41. ((unilateral or visual or hemispatial or attentional or spatial) adj10 neglect).tw. 
42. or/1-41 
 
Part B: Cortisol search strings 
43. Hydrocortisone/ 
44. cortisol.tw. 
45. s-cortisol.tw.  




50. glucocorticoid*.tw.  
51. epicortisol.tw. 







Appendix 2: Results of the STROBE quality assessment 
for articles included in systematic literature review of 





# Criteria Number (%) of 
papers meeting 
criteria 
1 Title and abstract 18 (38) 
Introduction   
2 Background/rationale 48(100) 
3 Objectives 41 (85) 
Methods   
4 Study Design 47 (98) 
5 Setting 41 (81) 
6 Participants 43 (90) 
7 Variables 44 (92) 
8 Data sources/measurement 48 (100) 
9 Bias 36 (75) 
10 Study size 1 (2) 
11 Quantitative Variables 42 (88) 
12 Statistical methods 42 (88) 
Results   
13 Participants 40 (83) 
14 Descriptive data 40 (83) 
15 Outcome data 46 (96) 
16 Main results 41 (85) 
17 Other analyses 42 (88) 
Discussion   
18 Key results 47 (98) 
19 Limitations 23 (48) 
20 Interpretation 46 (96) 
21 Generalizability 36 (75) 
Other information   
























Firstly thank you for allowing me to attend your group to speak with you 
about my research study. 
There had been increasing interest in recent years in involving service users in 
research design for a number of reasons outlined below: 
 People who use services are able to offer different perspectives 
 People who use services can help to ensure that issues identified and 
prioritised are important to them and therefore to health care, public 
health and social care services as a whole. 
 Public involvement can help to ensure that money and resources aren’t 
wasted on research that has little or no relevance. 
 Service users can help to ensure that research doesn’t just measure 
outcomes that are identified and considered important by professionals 
 Service users have been found to be a good way of disseminating 
important research results into the public domain 
   
 
The main aim of this discussion is so to find out how you, as service users and 
stroke survivors, view the study and in particular the information I am 
providing for potential participants in the study, but also the way the study is 
conducted. This is really important, as you have a unique insight into how 
potential participants will be feeling about research after they have had a 






Study title: Delirium and long-term cognitive impairment after stroke: the role 
of the HPA axis 
 
 
Description of the study: People who have had a stroke sometimes have 
problems with thinking and alertness. This is called delirium. A hormone 
called cortisol is thought to be important in this process.  Cortisol levels can 
be measured from a small sample of saliva. This study will find out whether 
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cortisol is related to problems with thinking in the first weeks after a stroke. 
We also want to find out whether cortisol levels are abnormal in the longer 




Recruitment: We will be recruiting people from the stroke unit, in the first few 
days after their stroke and will plan to follow them up for one year. We are 
planning to include those who are not able to give consent for themselves, buy 
asking their nearest relative for consent. Details of when follow up will be 

































Appendix 4: Patient and proxy information sheets and 
consent forms 
 
Patient information sheet  
 
 
Study Title: Delirium and long-term cognitive impairment after stroke 
 
You are being asked to consider taking part in a research study. Before you decide whether or not to 
take part it is important that you understand what it will involve and why the research is being done. 
 
This information sheet tells you about the purpose and conduct of the study and what will happen if 
you take part 
 
Please ask us if there is anything that is not clear or if you would like to know more.  Take time to 
decide whether or not you wish to take part. 
 
What is the purpose of the study? 
 
People who have had a stroke sometimes have problems with thinking and alertness. This is called 
delirium. A hormone called cortisol is thought to be important in this process.  Cortisol levels can be 
measured from a small sample of saliva. This study will find out whether cortisol is related to problems 
with thinking in the first weeks after a stroke. We also want to find out whether cortisol levels are 




Why have I been chosen? 
 
You have been asked to take part because you have recently had a stroke, are in hospital and over the 
age of 60. 
 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. You will be given as long as you feel you require 
to make this decision, up to 24 hours, and will always be given enough time to discuss this with your 
family should you wish. If you do decide to take part you will be given this information sheet to keep 
and the Chief Investigator will ask you to sign a consent form. You can decide to stop your involvement 
at any time. A decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part?  
What do I have to do?  
 
 
Whilst you are in hospital: 
 





The researcher will help you collect a small sample of saliva. This will be done by placing a small cotton 
bud under your tongue for a couple of minutes. This will be done twice on the first day that you take 
part (in the morning and early evening). It will be repeated on a further 6 occasions whilst you are in 
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hospital. If your hospital stay is short, we may ask to visit you at home in the first month after 
discharge. You will be asked not to drink, eat or smoke for 20 minutes before the sample is taken. The 
hormone cortisol will be measured in the saliva. The saliva samples will then be analysed for the 





On the first day you will then be asked some questions to test your memory and alertness. These 
questions will take about 20 minutes. We will also ask your Next of Kin to complete a questionnaire 
designed to check how your memory was before the stroke. Then, a shorter set of questions will be 
asked at each subsequent visit whilst you are in hospital. We will use a tape recorder to record some of 
your responses. This is to ensure that you are given an accurate score for the tests. The recording will 
be deleted as soon as we have scored the tests. 
 
 
Information from your notes 





When you were admitted to hospital, you had a brain scan. We would like to look at this scan in detail, 




The National Health Service Central Register contains basic details about everyone born in Scotland and 
anyone else who is (or has been) on the list of a general practitioner in Scotland. We would like to use 
information held by the NHS and records maintained by the National Health Service Central Register for 
Scotland to keep in touch with you and follow your health status in the longer term. 
 
Follow-up at home: 
 
You will be visited in your home 4 months after your stroke, and then again at one year after your 
stroke. At these visits we will take salivary samples as described previously. We will also test your 
memory in a little more detail. These tests will take approximately 1 hour in total. If you prefer not to 
be seen at home, we can arrange for you to be seen in hospital.  
 
 
Will any genetic tests be done? 
 
No. Genetic testing is not a part of this study 
 
Involvement of the General Practitioner/Family doctor (GP)  
 
Your own general practitioner will be informed about your participation in the study.  If you are still in 
hospital when the interview is conducted, we will write in your medical records that you are taking part.  
 
 
What are the possible disadvantages and risks of taking part? 
 
There are minimal risks involved in the study, because we are not testing new treatments.  
 
 




With your permission, we give your doctors and nurses the results of the memory tests, because they 
may find this information helpful.  
 
 
What happens when the research study stops? 
 
No further involvement is required. We will ask your permission to store your saliva samples in the 
Clinical Research Facility, Royal Infirmary so that we can consider them for use in future research 
studies that we may carry out. Any future use of samples would not identify you by name and would 








What if there is a problem? 
 
Complaints: 
If you have a concern about any aspect of the study, you should ask to speak with Dr Barugh, 
Professor MacLullich or Professor Mead who will do their best to answer your questions. If you 
remain unhappy and wish to complain formally, you can do this through the complaints procedure in 
the hospital. Contact details are outlined at the end of this information sheet 
 
Harm: 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds for a 
legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated during the course of 
this study, the normal hospital complaints mechanisms will be available to you. 
 
 
What will happen to the results of the research study? 
 
The results of the study will be published in medical journals and presented at professional 
conferences. You will not be identified in any publication or presentation. If the results show that 
delirium and longer term memory problems are related to high levels of cortisol, we will do further 
research to find out whether treatment to reduce cortisol levels prevents delirium and longer term 
cognitive impairment after stroke.  
 
 
Who is organising and funding the research? 
 
The study is being organised by a team of doctors and researchers working in the Royal Infirmary of 
Edinburgh and is funded by the Dunhill Medical Trust. 
 
 
Will my taking part in this study be kept confidential? 
 
Yes. All information which is collected about you during the course of the research will be kept 
strictly confidential. The information will be stored securely and any identifying information will be 
removed. Our procedures for handling, processing, storage and destruction of data comply with the 
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Data Protection Act 1998. The information will be retained for three years and then disposed of 
securely. You have the right to check the accuracy of data held about you and correct any errors. 
 
The sponsors of the research (University of Edinburgh and NHS Lothian) and regulatory authorities 
will have access, as necessary, to view the data for monitoring the quality of research. All will have a 
duty of confidentiality to you as a research participant and nothing that could reveal your identity 
will be disclosed outside the research site. 
 
 
Who has reviewed the study? 
 




You will be given a copy of this information sheet and the consent form to keep. 
 
 











































Dr Amanda Barugh,  
Research Fellow and Honorary Specialty 
Registrar in Medicine of the Elderly, 
Room s1643, 
Royal Infirmary of Edinburgh, 





If you wish to make a complaint 
about the study please contact NHS 
Lothian: 
 
NHS Lothian Complaints Team, 
2nd Floor, 
Waverley Gate, 
2-4 Waterloo Gate 
Edinburgh, 
EH1 3EG 




Relative/proxy information sheet   
 
 
Study Title: Delirium and long-term cognitive impairment after stroke 
 
You are being asked to consider whether you would give consent for your relative to take part in a 
research study because your relative is unable to give consent themselves. You should base your 
decision on what you believe your relative would decide to do, if they were able to make the decision 
alone. Before you decide whether or not to give consent it is important that you understand what it will 
involve and why the research is being done. 
 
This information sheet tells you about the purpose and conduct of the study and what will happen if 
your relative takes part. 
 
Please ask us if there is anything that is not clear or if you would like to know more.  Take time to 
decide whether or not you wish to give consent on your relative’s behalf. 
 
 
What is the purpose of the study? 
 
People who have had a stroke sometimes have problems with thinking and alertness. This is called 
delirium. A hormone called cortisol is thought to be important in this process and cortisol levels can be 
measured from a small sample of saliva. This study is to try and find out if cortisol is related to 
problems with thinking in the first weeks after a stroke, and to find out if problems with cortisol 
regulation are seen longer term following stroke. We also hope to determine whether high cortisol 
levels in turn lead to longer term problems with memory and thinking. 
 
 
Why has my relative been chosen? 
 
Your relative has been asked to take part because they have recently had a stroke, are in hospital and 
over the age of 60. 
 
 
Do I have to agree? 
 
It is up to you to decide whether or not to give consent. You will be given as long as you feel you 
require to make this decision, up to 24 hours, and will be given time to discuss this in detail with your 
relative. If you do decide to give consent you will be given this information sheet to keep and the Chief 
Investigator will ask you to sign a consent form. You or your relative can decide to stop involvement at 
any time. A decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care your relative receives. 
What will happen to my relative if they take part?  
What will they have to do? 
 
Whilst your relative is in hospital: 
 
The researcher will discuss the study with you and your relative in detail and give you the opportunity 




Your relative will be asked to provide a small saliva sample, which they will be helped to obtain by the 
researcher. This will be collected by placing a small cotton bud under their tongue for a couple of 
minutes. This will be done twice on the first day that they take part (in the morning and early evening) 
and this process will be repeated on 6 subsequent days over the following month, if they remain an in-
patient. If they are discharged more quickly, we may ask to undertake some of this in their own home 
with both your and your relative’s permission. Participants will be asked not to drink, eat or smoke for 
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20 minutes before the sample is taken. The saliva samples will then be analysed for the hormone 





On the first day your relative will be asked some questions to test their memory and alertness. These 
questions should take approximately 20 minutes. We will also ask you to complete a questionnaire 
designed to check how your relative’s memory was before the stroke. Then, your relative will be asked 
a shorter set of questions at each subsequent visit whilst they are in hospital. We will use a tape 
recorded to record some of your relative’s responses. This is to ensure they are given an accurate score 
for the tests. The recording will be deleted as soon as we have scored the tests. 
 
From case notes 
 
We will obtain information about how your relative is and the type of stroke they have had from their 




Your relative will have had a scan taken of their brain as part of usual medical care. We would like to 




The National Health Service Central Register contains basic details about everyone born in Scotland and 
anyone else who is (or has been) on the list of a general practitioner in Scotland. We would like to use 
information held by the NHS and records maintained by the National Health Service Central Register for 
Scotland to keep in touch with you and your relative and follow their health status in the longer term. 
 
Follow-up at home: 
 
Your relative will be visited in their home 4 months after their stroke and then again one year after 
their stroke. At these visits we will take further saliva samples in the same way as described previously 
and will perform more detailed memory tests. These visits will take approximately 1 hour in total. If 




Will any genetic tests be done? 
 
No. Genetic testing is not a part of this study 
 
Involvement of the General Practitioner/Family doctor (GP)  
 
Your relative’s own general practitioner will be informed about their participation in the study.  If they 
are still in hospital when the interview is conducted, we will write in their medical records that they are 
taking part.  
 
 
What are the possible disadvantages and risks of taking part? 
 
There are minimal risks involved in the study, because we are not testing new treatments. 
 
 




With your permission, we will inform the medical and nursing team responsible for clinical care about 
the results of the tests. This may add more detailed information than they have already, and it may 
help your relative for them to know this. 
 
 
What happens when the research study stops? 
 
No further involvement is required. We will ask your permission to store your relative’s saliva samples 
in the Clinical Research Facility, Royal Infirmary so that we can consider them for use in future research 
studies that we may carry out. Any future use of samples would not identify your relative by name and 










If you have a concern about any aspect of the study, you should ask to speak with Dr Barugh, 
Professor MacLullich or Professor Mead who will do their best to answer your questions. If you remain 
unhappy and wish to complain formally, you can do this through the complaints procedure in the 
hospital. Details are included at the end of this information sheet. 
Harm: 
If your relative is harmed by taking part in this research project, there are no special compensation 
arrangements.  If your relative is harmed due to someone’s negligence, then you may have grounds for 
a legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or how your relative was treated 
during the course of this study, the normal hospital complaints mechanisms will be available to you. 
 
 
What will happen to the results of the research study? 
 
The results of the study will be published in medical journals and presented at professional 
conferences. Your relative will not be identified in any publication or presentation. If the results show 
that delirium and longer term memory problems are related to high levels of cortisol, we will do further 
research to find out whether treatment to reduce cortisol levels prevents delirium and longer term 
cognitive impairment after stroke.  
 
 
Who is organising and funding the research? 
 
The study is being organised by a team of doctors and researchers working in the Royal Infirmary of 
Edinburgh and is funded by the Dunhill Medical Trust 
 
 
Will my relative taking part in this study be kept confidential? 
 
Yes. All information which is collected about your relative during the course of the research will be kept 
strictly confidential. The information will be stored securely and any identifying information will be 
removed. The information will be retained for one year and then disposed of securely. Our procedures 
for handling, processing, storage and destruction of data comply with the Data Protection Act 1998. 





The sponsors of the research (University of Edinburgh and NHS Lothian) and regulatory authorities will 
have access, as necessary, to view the data for monitoring the quality of research. All will have a duty 
of confidentiality to your relative as a research participant and nothing that could reveal their identity 
will be disclosed outside the research site. 
 
Who has reviewed the study? 
 








Contact details for Chief Investigator: 
 
Dr Amanda Barugh,   
Research Fellow and Honorary Specialty Registrar in Medicine of the Elderly, 
Room s1643, 
Royal Infirmary of Edinburgh, 






If you wish to make a complaint about the study please contact NHS Lothian: 
 
NHS Lothian Complaints Team, 
2nd Floor, 
Waverley Gate, 
2-4 Waterloo Gate 
Edinburgh, 
EH1 3EG 



















CONSENT FORM –Patient (version 1)  
 




Name of Researcher:  
Name of Participant: 
                                                                                                                                        Please tick box 
 
 
1. I confirm that I have read and understand the information sheet dated 03/07/2012  




2. I understand that my participation is voluntary and that I am free to withdraw at  
 any time, without giving any reason, without my medical care or legal rights  




3. I understand that sections of any of my medical notes, including brain scans, 
     may be looked at by responsible individuals from the University of Edinburgh or from     
 regulatory authorities where it is relevant to my taking part in research.   




4.   I consent to anonymised information from this study being stored for  




5. I agree to my general practitioner and members of my health care team being   i 




6. I agree that my saliva will be sampled for the purpose of measuring  
   cortisol and that saliva will be stored, in anonymised form, for analysis of future, 
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CONSENT FORM –Relative/Proxy (version 1) 
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Appendix 7: Histograms of salivary cortisol levels at day 3, 











































Appendix 8: Scatterplot of median cortisol levels during 
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